Cover Page for Protocol 
Sponsor name:  Novo Nordisk A/S 
NCT number [STUDY_ID_REMOVED] 
Sponsor trial ID: NN9924-4223 
Official title of study: PIONEER 2 – vs. SGLT-2 Inhibitor 
A 52-week, randomised, open label , active-controlled trial 
to investigate the efficacy a nd safety of oral semaglutide 
versus empagliflozin in subjects with type 2 diabetes 
mellitus inadequately c ontrolled on metformin 
Document date: 02 October 2018 
Link
LinkLink
Link
LinkList of contents
Protocol ....................................................... ............................................................... .........................
Appendix A - Calcitonin monitoring .............................. ............................................................... ...
Appendix B - Adverse events requiring additional data collection ................................................
Attachment I and II............................................ ............................................................... .................
Protocol Amendment 1 - Global................................... ............................................................... ......CONFIDENTIALDate: Novo Nordisk
Version:
Status:Oral Semaglutide
Trial ID: NN9924-4223Clinical Trial Report
Appendix 16.1.12FWREHU 2018

)LQDO
16.1.1 Protocol and protocol amendments
Redacted protocol 
Lncludes redaction of personal identifiable DQGFRPSDQ\
FRQILGHQWLDO information. 
. CONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 1 of 125
Protocol
Trial ID: NN9924-4223
PIONEER 2 – vs. SGLT-2 Inhibitor
Efficacy and Safety of Oral Semaglutide versus Empagliflozin
in Subjects with Type 2 Diabetes Mellitus
A 52-week Randomised, Open-label, Active-controlled Trial
Trial phase: 3a
Protocol originator
, 
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.CONFIDENTIAL
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 2 of 125
Table of Contents   Page
Table of Figures............................................................................................................... .................................6
Table of Tables................................................................................................................ ..................................6
List of abbreviations.......................................................................................................... ...............................7
1 Summary....................................................................................................................... ...........................10
2 Flow chart .................................................................................................................... ............................13
3 Background information and rationale for the trial............................................................................ 18
3.1 Background information...................................................................................................... ........18
3.1.1 Type 2 diabetes mellitus ............................................................................................18
3.1.2 Glucagon-like peptide-1 ............................................................................................18
3.1.3 Oral semaglutide........................................................................................................18
3.1.4 Nonclinical data .........................................................................................................1 9
3.1.4.1 Semaglutide.........................................................................................193.1.4.2 SNAC ..................................................................................................20
3.1.5 Clinical data for or al semaglutide..............................................................................21
3.1.5.1 Pharmacokinetics ................................................................................21
3.1.5.2 Efficacy ...............................................................................................22
3.1.5.3 Safety...................................................................................................22
3.1.6 Empagliflozin............................................................................................................. 23
3.2 Rationale for the trial ..................................................................................................... ..............23
4 Objectives and endpoints...................................................................................................... ..................24
4.1 Objectives .................................................................................................................. ..................24
4.1.1 Primary objective.......................................................................................................244.1.2 Secondary objectives .................................................................................................24
4.2 Endpoints ................................................................................................................... ..................24
4.2.1 Primary endpoint........................................................................................................24
4.2.2 Secondary endpoints..................................................................................................24
4.2.2.1 Confirmatory seconda ry endpoints .....................................................24
4.2.2.2 Supportive seconda ry endpoints..........................................................24
5 Trial design .................................................................................................................. ............................27
5.1 Type of trial ............................................................................................................... ..................27
5.2 Rationale for trial design.................................................................................................. ............27
5.3 Treatment of subjects....................................................................................................... ............28
5.3.1 Dosing instructions ....................................................................................................29
5.3.2 Background medication .............................................................................................29
5.4 Treatment after disconti nuation of tr ial product ..........................................................................29
5.5 Rationale for treatment ..................................................................................................... ...........30
6 Trial population.............................................................................................................. .........................31
6.1 Number of subjects .......................................................................................................... ............31
6.2 Inclusion criteria .......................................................................................................... ................31
6.3 Exclusion criteria .......................................................................................................... ...............31
6.4 Rescue criteria............................................................................................................. .................32
6.5 Criteria for premature discontinuation of trial product................................................................33CONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 3 of 125
6.6 Withdrawal from trial ....................................................................................................... ...........33
6.7 Subject replacement......................................................................................................... ............33
6.8 Rationale for trial population.............................................................................................. .........34
7 Milestones.................................................................................................................... .............................35
8 Methods and a ssessments ....................................................................................................... ................36
8.1 Visit procedures ............................................................................................................ ...............36
8.1.1 Screening, visit 1........................................................................................................ 36
8.1.2 Fasting visits ............................................................................................................ ..37
8.1.3 Randomisation and trial product administration........................................................38
8.1.4 End-of-treatment (visit 12) and Follow-up (visit 13).................................................38
8.1.5 Premature discontinuation of trial product and follow-up (V12A and V13A) ..........38
8.1.6 Withdrawals............................................................................................................... 39
8.1.7 Investigator assessments............................................................................................39
8.2 Subject related information-/assessments.................................................................................... 40
8.2.1 Demography...............................................................................................................4 0
8.2.2 Diabetes history and diabetes complications .............................................................40
8.2.3 Concomitant illness a nd medical history ...................................................................41
8.2.4 Concomitant medication............................................................................................41
8.2.5 Childbearing potential................................................................................................42
8.2.6 Tobacco use ............................................................................................................... 42
8.3 Efficacy assessments........................................................................................................ ............43
8.3.1 Laboratory assessmen ts for efficacy..........................................................................43
8.3.1.1 Fasting plasma glucose........................................................................43
8.3.2 Self-measured plasma glucose...................................................................................43
8.3.3 Body weight and height .............................................................................................44
8.3.4 Waist circumference ..................................................................................................458.3.5 Patient reported outcomes questionnaires..................................................................45
8.4 Safety assessments.......................................................................................................... .............46
8.4.1 Adverse events...........................................................................................................4 6
8.4.1.1 Medication error..................................................................................46
8.4.1.2 Adverse events requiring additional data collection ...........................47
8.4.2 Physical examination .................................................................................................48
8.4.3 Vital signs ............................................................................................................... ...48
8.4.4 Eye examination ........................................................................................................48
8.4.5 Electrocardiogram (12-lead) ......................................................................................49
8.4.6 Laboratory assessments for safety .............................................................................508.4.7 Pregnancy testing.......................................................................................................51
8.4.8 Anti-semaglutide antibodies ......................................................................................51
8.4.9 Hypoglycaemic episodes ...........................................................................................51
8.5 Laboratory assessments ...................................................................................................... .........54
8.6 Other assessments........................................................................................................... .............55
8.6.1 Lactate................................................................................................................... .....55
8.6.2 Pharmacokinetics.......................................................................................................55
8.6.2.1 Semaglutide and SNAC p lasma concentrations..................................55
8.6.3 Subject diary ............................................................................................................. .56
8.7 Subject compliance.......................................................................................................... ............56
9 Trial supplies ................................................................................................................ ...........................58CONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 4 of 125
9.1 Trial products.............................................................................................................. .................58
9.2 Labelling ................................................................................................................... ...................58
9.3 Storage ..................................................................................................................... ....................59
9.4 Drug accountability and destruction ......................................................................................... ...59
9.5 Auxiliary supplies.......................................................................................................... ..............60
10 Interactive voice/web response system ........................................................................................ ..........61
11 Randomisation procedure ...................................................................................................... ................62
12 Adverse events, technical comp laints and pregnancies .......................................................................63
12.1 Definitions ................................................................................................................ ...................63
12.1.1 Adverse event ............................................................................................................ 63
12.1.2 Serious adverse event.................................................................................................64
12.1.3 Non-serious adverse event .........................................................................................65
12.1.4 Medication errors.......................................................................................................6 5
12.1.5 Adverse events requiring additional data collection..................................................66
12.1.6 Technical complaints .................................................................................................67
12.2 Reporting of adverse events................................................................................................ .........68
12.3 Follow-up of adverse events ................................................................................................ ........71
12.4 Technical complaints and tec hnical complaint samples ..............................................................72
12.4.1 Reporting of technical complaints .............................................................................72
12.4.2 Collection, storage and shipment of technical complaint samples ............................72
12.5 Pregnancies ................................................................................................................ ..................73
12.5.1 Pregnancies in female subjects ..................................................................................73
12.6 Precautions and/or overdose ................................................................................................ ........74
12.7 Committees related to safety............................................................................................... .........75
12.7.1 Novo Nordisk sa fety committee ................................................................................75
12.7.2 Event adjudication committee....................................................................................75
13 Case report forms............................................................................................................ ........................79
13.1 Corrections to cas e report forms........................................................................................... .......79
13.2 Case report form flow...................................................................................................... ............79
14 Monitoring procedures ........................................................................................................ ...................81
15 Data management.............................................................................................................. ......................83
16 Computerised systems......................................................................................................... ....................84
17 Statistical considerations ................................................................................................... .....................85
17.1 Sample size calculation.................................................................................................... ............87
17.2 Definition of analysis sets................................................................................................ ............89
17.3 Primary endpoint........................................................................................................... ...............92
17.3.1 Primary analysis for the primary estimand ................................................................92
17.3.2 Primary analysis for th e secondary estimand.............................................................93
17.3.3 Sensitivity analyses....................................................................................................9 3
17.3.3.1 Pattern mixture models........................................................................95
17.3.3.2 Other sensitivity analyses....................................................................95
17.3.3.3 Assessment of sensitivity analyses......................................................96
17.4 Secondary endpoints........................................................................................................ ............96
17.4.1 Confirmatory sec ondary endpoints............................................................................96CONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 5 of 125
17.4.2 Supportive seconda ry endpoints ................................................................................97
17.4.2.1 Efficacy endpoints...............................................................................97
17.4.2.2 Safety endpoints ..................................................................................99
17.5 Interim analysis........................................................................................................... ...............103
17.6 Pharmacokinetic and/or pha rmacodynamic modelling..............................................................103
17.7 Patient reported outcomes.................................................................................................. ........104
18 Ethics ....................................................................................................................... ...............................105
18.1 Benefit-risk assessment of the trial....................................................................................... .....105
18.1.1 Risks and precautions ..............................................................................................105
18.1.1.1 Empagliflozin....................................................................................107
18.1.2 Benefits................................................................................................................. ...108
18.1.3 Risk and benefit conclusion.....................................................................................108
18.2 Informed consent ........................................................................................................... ............108
18.3 Data handling.............................................................................................................. ...............109
18.4 Information to sub jects during trial....................................................................................... .....109
18.5 Premature termination of the trial and/or trial site.....................................................................10 9
19 Protocol compliance.......................................................................................................... ....................111
19.1 Protocol deviations ........................................................................................................ ............111
19.2 Prevention of missing data................................................................................................. ........111
20 Audits and inspections ....................................................................................................... ...................112
21 Critical documents ........................................................................................................... .....................113
22 Responsibilities ............................................................................................................. .........................115
23 Reports and publications..................................................................................................... .................116
23.1 Communication of results................................................................................................... .......116
23.1.1 Authorship ............................................................................................................... 117
23.1.2 Site-specific publication(s) by investigator(s) .........................................................117
23.2 Investigator access to data and review of results .......................................................................117
24 Retention of clinical trial docume ntation and human  biosamples....................................................118
24.1 Retention of clinical trial documentation.................................................................................. .118
24.2 Retention of human biosamples.............................................................................................. ...118
25 Institutional Review Boards/Independent Ethics Committees and regulatory authorities............120
26 Indemnity statement .......................................................................................................... ...................121
27 References ................................................................................................................... ...........................122
Attachment I – Global list of key staff and relevant departments and suppliers
Attachment II – Country list of key staff and relevant departments
Appendix A – Monitoring of calcitonin
Appendix B – Adverse events requiring additional data collectionCONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 6 of 125
Table of Figures
Page
Figure 5–1 Trial design......................................................................................................... ....................27
Figure 12–1 Reporting of AEs.................................................................................................... ................70
Figure 17–1 Graphical illustration of the closed testing procedure ............................................................89
Figure 17–2 ADA classification of hypoglycaemia................................................................................. .102
Table of Tables
Page
Table 5–1 Treatment overview.................................................................................................... ............28
Table 9–1 Investigati onal medicinal products.................................................................................... .....58
Table 9–2 Storage conditions for investigational medicinal products.....................................................59
Table 12–1 Adverse events requiring completion of specific event forms and/or are subject to event 
adjudication ................................................................................................................... .........67
Table 12–2 Adverse events for adjudication ...................................................................................... .......76
Table 17–1 Assumptions used in the for sample size calculation .............................................................88
Table 17–2 Calculated powers for individual hypotheses .........................................................................8 8CONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 7 of 125
List of abbreviations
ADA American Diabetes Association
AE adverse eventALT alanine aminotransferaseANCOVA analysis of covariance AST aspartate aminotransferaseAUC area under the curveBG blood glucoseBMI body mass indexCLAE clinical laboratory adverse eventCoEQ control of eating questionnaireCK creatine kinaseCRF case report formCTR clinical trial reportDPP-4 dipeptidyl peptidase-4DUN dispensing unit numberECG electrocardiogrameCRF electronic case report formEAC event adjudication committeeEOT end-of-treatmentFAS full analysis setFDA U.S. Food and Drug AdministrationFDAAA Food and Drug Administration Amendment Act FPG fasting plasma glucoseFSFV first subject first visitGCP Good Clinical PracticeGLP-1 glucagon-like peptide-1GLP-1 RA glucagon-like peptide-1 receptor agonistHbA
1c glycosylated haemoglobinCONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 8 of 125
HDL high density lipoprotein
HOMA-Bhomeostatic model assessment index of beta-cell 
function
HOMA-IRhomeostatic model assessment index of insulin 
resistance
IB Investigator’s Brochure
ICH International Conference on HarmonisationICMJE International Committee of Medical Journal Editors IEC independent ethics committeeIRB institutional review boardIWRS interactive web response systemLDL low density lipoproteinLLoQ lower limit of quantification LSFV last subject first visitLSLV last subject last visitMAR missing at randomMedDRA Medical Dictionary for Regulatory ActivitiesMEN 2 multiple endocrine neoplasia type 2MI myocardial infarctionMMRM mixed model for repeated measurementsMTC medullary thyroid carcinomaNSTEMI non-ST-elevation acute myocardial infarctionNYHA New York Heart AssociationOAD oral antidiabetic drugPG plasma glucosePK pharmacokinetics PP per protocolPRO patient reported outcomeSAE serious adverse eventCONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 9 of 125
SAP statistical analysis plan
SAS safety analysis sets.c. subcutaneous(ly)SGLT-2 sodium-glucose co-transporter-2SIF safety information form
SMPG self-measured plasma glucose
SmPC summary of product characteristicsSNAC sodium N-[8-(2-hydroxybenzoyl)amino]caprylateSTEMI ST-elevation acute myocardial infarctionSUSAR suspected unexpected serious adverse reactionTEAE treatment-emergent adverse events TIA transient ischaemic attackTMM Trial Materials ManualUNL Upper Normal LimitUTN Universal Trial NumberVLDL very low density lipoproteinCONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 10 of 125
1 Summary
Objectives and endpoints:
Primary objective
To compare the effect of once-daily dosing of 14 mg oral semaglutide versus 25 mg empagliflozin, 
both in combination with metformin, on glycaemic control in subjects with type 2 diabetes mellitus.
Secondary objectives
To compare the effect of once-daily dosing of 14 mg oral semaglutide versus 25 mg empagliflozin, 
both in combination with metformin, on body weight in subjects with type 2 diabetes mellitus.
To compare the safety and tolerability of once-daily dosing of 14 mg oral semaglutide versus 25 mg 
empagliflozin, both in combination with metformin, in subjects with type 2 diabetes mellitus.
Primary endpoint
Change from baseline to week 26 in glycosylated haemoglobin (HbA 1c)
Key secondary endpoints
Change from baseline to week 52 in HbA 1c
Change from baseline to week 26 and week 52 in:
!Body weight (kg)
!Fasting plasma glucose
If a subject after week 26 and week 52 achieves (yes/no):
!HbA 1c< 7.0 % (53 mmol/mol) American Diabetes Association target
Number of treatment-emergent adverse events during exposure to trial product, assessed up to 
approximately 57 weeks.
Number of treatment-emergent severe or blood glucose-confirmed symptomatic hypoglycaemic 
episodes during exposure to trial product, assessed up to approximately 57 weeks.
Trial design:
This is a 52-week, randomised, open-label, active-controlled, parallel-group, multicentre, 
multinational trial with 2 arms comparing the efficacy and safety of oral semaglutide with 
empagliflozin in subjects with type 2 diabetes mellitus inadequately controlled on metformin. CONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 11 of 125
Subjects will be randomised 1:1 to receive one of the following treatments:
!14 mg oral semaglutide once-daily
!25 mg empagliflozin once-daily
The total trial duration for the individual subject will be approximately 59 weeks. The trial includes 
a 2-week screening period, followed by a 52-week randomised treatment period and a follow-up 
period of 5 weeks.
Trial population:
Number of subjects planned to be randomised: 816 subjects.
Inclusion criteria
1. Informed consent obtained before any trial-related activities. Trial-related activities are any 
procedures that are carried out as part of the trial, including activities to determine suitability for 
the trial.
2. Male or female, age above or equal to 18 years at the time of signing informed consent.
3. Diagnosed with type 2 diabetes mellitus ≥ 90 days prior to day of screening.
4. HbA 1cof 7.0-10.5 % (53-91 mmol/mol) (both inclusive).
5. Stable daily dose of metformin ( ≥ 1500 mg or maximum tolerated dose as documented in the 
subject medical record) ≥ 90 days prior to the day of screening.
Key exclusion criteria
1. Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing 
potential and not using an adequate contraceptive method (adequate contraceptive measure as 
required by local regulation or practice). 
For certain specific countries: Additional specific requirements apply.
2. Any disorder, which in the investigator’s opinion might jeopardise subject’s safety or 
compliance with the protocol.
3. Family or personal history of Multiple Endocrine Neoplasia Type 2 or Medullary Thyroid 
Carcinoma.
4. History of pancreatitis (acute or chronic).
5. History of major surgical procedures involving the stomach potentially affecting absorption of 
trial product (e.g. subtotal and total gastrectomy, sleeve gastrectomy, gastric bypass surgery).
6. Any of the following: myocardial infarction, stroke or hospitalisation for unstable angina or 
transient ischaemic attack within the past 180 days prior to the day of screening. 
7. Subjects presently classified as being in New York Heart Association Class IV.
8. Planned coronary, carotid or peripheral artery revascularisation known on the day of screening.
9. Subjects with ALT > 2.5 x upper normal limit.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 12 of 125
10. Renal impairment defined as Estimated Glomerular Filtration Rate < 60 mL/min/1.73 m2as per 
Chronic Kidney Disease Epidemiology Collaboration formula (CKD-EPI).
11. Treatment with any medication for the indication of diabetes or obesity other than stated in the 
inclusion criteria in a period of 90 days before the day of screening. An exception is short-term 
insulin treatment for acute illness for a total of ≤ 14 days.
12. Proliferative retinopathy or maculopathy requiring acute treatment. Verified by fundus 
photography or dilated fundoscopy performed within 90 days prior to randomisation.
13. History or presence of malignant neoplasms within the last 5 years (except basal and squamous 
cell skin cancer and carcinoma in situ ).
14. History of diabetic ketoacidosis.
Key assessments:
Efficacy
!HbA 1c
!Fasting plasma glucose
!Body weight
!PK sampling
Safety
!Adverse events
!Hypoglycaemic episodes
Trial product:
Investigational medicinal products:
!Test product: semaglutide 3 mg, 7 mg and 14 mg tablets
!Reference therapy: empagliflozin (Jardiance®) 10 mg and 25 mg tabletsCONFIDENTIAL
Protocol UTN: U1111-1176-6006 Date: 14 March 2016 Status: Final Novo Nordisk
Trial ID: NN9924-4223 EudraCT No.: 2015-005209-36 Version: 2.0 Page: 13 of 125
2 Flow chart
Trial Periods ScreeningaRandomi-
sation TreatmentEnd-of-
treatment 
(EoT)Follow-
upbEoT premature 
discontinuationcFollow-up 
premature 
discontinuationc
Visit (V), Phone (P) V1 V2 P3 V4 V5 V6 V7 V8 V9 V10 V11 V12 V13 V12A V13A
Timing of visit
(Weeks)Up to -2 
weeks0 2 4 8 14 20 26 32 38 45 52 57Day of
discontinuation
of trial
product5 weeks after
discontinuation
of trial product
(Days)±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 +3 +3 +3
SUBJECT RELATED
INFO/ASSESSMENTS
Informed consent x
In/exclusion criteria x x
Concomitant medication x x x x x x x x x x x x x x x
Demography x
Tobacco use x
Concomitant illness and 
medical historyx
Diagnosis of diabetes/
diabetes complicationsx
History of cardiovascular 
disease x
History of gallbladder 
diseasex
History of gastrointestinal 
diseasex
Protocol UTN: U1111-1176-6006 Date: 14 March 2016 Status: Final Novo Nordisk
Trial ID: NN9924-4223 EudraCT No.: 2015-005209-36 Version: 2.0 Page: 14 of 125
Trial Periods ScreeningaRandomi-
sation TreatmentEnd-of-
treatment 
(EoT)Follow-
upbEoT premature 
discontinuationcFollow-up 
premature 
discontinuationc
Visit (V), Phone (P) V1 V2 P3 V4 V5 V6 V7 V8 V9 V10 V11 V12 V13 V12A V13A
Timing of visit
(Weeks)Up to -2 
weeks0 2 4 8 14 20 26 32 38 45 52 57Day of
discontinuation
of trial
product5 weeks after
discontinuation
of trial product
(Days)±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 +3 +3 +3
Randomisation x
Criteria for premature 
discontinuation of trial 
productx x x x x x x x x
EFFICACY
HbA 1c x x x x x x x x x x x x
Fasting plasma glucose x x x x x x x x x
Fasting insulin and 
proinsulinx x x x
Fasting C-peptide x x x x
Fasting glucagon x x x x
7-point profile x x x x
Lipids x x x x x
CRP x x x x
Height x
Body weight x x x x x x x x x x x
Waist circumference x x x x x x
PRO questionnaires x x x x
Semaglutide PK samplingdx x x
Protocol UTN: U1111-1176-6006 Date: 14 March 2016 Status: Final Novo Nordisk
Trial ID: NN9924-4223 EudraCT No.: 2015-005209-36 Version: 2.0 Page: 15 of 125
Trial Periods ScreeningaRandomi-
sation TreatmentEnd-of-
treatment 
(EoT)Follow-
upbEoT premature 
discontinuationcFollow-up 
premature 
discontinuationc
Visit (V), Phone (P) V1 V2 P3 V4 V5 V6 V7 V8 V9 V10 V11 V12 V13 V12A V13A
Timing of visit
(Weeks)Up to -2 
weeks0 2 4 8 14 20 26 32 38 45 52 57Day of
discontinuation
of trial
product5 weeks after
discontinuation
of trial product
(Days)±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 +3 +3 +3
SNAC PK samplingex x x
SAFETY
Eye examinationfx
Physical examination x x x
ECG x x x x x x
Vital signs x x x x x x x x x x x x x
Pregnancy testgx x x x x x x x x x x x x x
Calcitonin x x x x x x x x
Biochemistryhx x x x x x x x x x x
Lactateix x x
Haematology x x x x x x x x x x
Antibodiesjx x x x x x x x x x
Adverse eventskx x x x x x x x x x x x x x
Hypoglycaemic episodes x x x x x x x x x x x x x x
Technical complaints x x x x x x x x x x x
TRIAL MATERIAL
IV/IWRS call x x x x x x x x x x x x
Drug accountability x x x x x x x x x x x
Dispensing visit x x x x x x x x x
Protocol UTN: U1111-1176-6006 Date: 14 March 2016 Status: Final Novo Nordisk
Trial ID: NN9924-4223 EudraCT No.: 2015-005209-36 Version: 2.0 Page: 16 of 125
Trial Periods ScreeningaRandomi-
sation TreatmentEnd-of-
treatment 
(EoT)Follow-
upbEoT premature 
discontinuationcFollow-up 
premature 
discontinuationc
Visit (V), Phone (P) V1 V2 P3 V4 V5 V6 V7 V8 V9 V10 V11 V12 V13 V12A V13A
Timing of visit
(Weeks)Up to -2 
weeks0 2 4 8 14 20 26 32 38 45 52 57Day of
discontinuation
of trial
product5 weeks after
discontinuation
of trial product
(Days)±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 +3 +3 +3
REMINDERS
Training in dosing 
instructionsx x x x x x x x x x x
Attend visit fastinglx x x x x x x x x
Handout and instruct in 
BG meter usex
Handout ID card x
Dispense and/ or collect 
diaryx x x x x x x x x x x x x x
Protocol UTN: U1111-1176-6006 Date: 14 March 2016 Status: Final Novo Nordisk
Trial ID: NN9924-4223 EudraCT No.: 2015-005209-36 Version: 2.0 Page: 17 of 125
Footer Description
xaSubject can be randomised as soon as all inclusion and exclusion criteria are confirmed. The screening assessment must not exce ed 2
weeks prior to randomisation (V2).
xbSubjects, who have discontinued trial product prematurely, are not required to attend V13 (Follow-up).
xcV12A and V13A are only applicable for subjects who have discontinued trial product prematurely.
xdSample should be taken for all subjects 25 (+/- 5) minutes post dosing.
No PK sampling should be done for visits occurring after V13A (subjects who have discontinued trial product prematurely).
xeSamples should be taken for all subjects 25 (+/- 5) minutes and 40 (+/- 5) minutes post dosing.
No PK sampling should be done for visits occurring after V13A (subjects who have discontinued trial product prematurely).
xfDilated fundoscopy/fundus photography performed within 90 days prior to randomisation is acceptable if results are available fo r
evaluation at V2, unless worsening of visual function since last examination.
xgFor women of child-bearing potential: Urine pregnancy test should also be performed at any time during the trial if a menstrual  period 
is missed, and/or according to local regulations/law.
xhAt V1, only ALT, creatinine and eGFR will be assessed as part of Biochemistry.
xiSamples should be taken for all subjects pre-dose and 25 (+/- 5) and 40 (+/- 5) minutes post-dosing.
xjSamples should be taken for all subjects. At randomisation, the antibody sampling must be done pre-dose. No antibody sampling 
should be done for visits occurring after V13A (subjects who have discontinued trial product prematurely).
xkAdverse events reporting includes adverse events from the first trial-related activity after the subject has signed the informed  consent at
V1. Pre-existing conditions identified as a result of the screening procedures should be reported as medical history.
xlFasting for blood sampling is defined as no food or liquid within the last 8 hours prior to blood sampling, however water is al lowed up 
until 2 hours prior to blood sampling. Trial product must be taken after blood sampling. Other oral medication can be taken 30 mi nutes 
after trial product (for subjects randomised to oral semaglutide only). Injectable medications can be administered after blood sampling. 
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 18 of 125
3 Background information and rationale for the trial
The trial will be conducted in compliance with this protocol, International Conference on 
Harmonisation (ICH) good clinical practice (GCP)1and applicable regulatory requirements, and in 
accordance with the Declaration of Helsinki2. 
In this document, the term investigator refers to the individual responsible for the overall conduct of 
the clinical trial at a trial site.
3.1 Background information
3.1.1 Type 2 diabetes mellitus 
Type 2 diabetes mellitus (T2DM) is a progressive metabolic disease primarily characterised by 
abnormal glucose metabolism. The pathogenesis is heterogeneous involving environmental, 
lifestyle and genetic factors leading to chronic hyperglycaemia caused by peripheral tissue insulin 
resistance, impaired insulin secretion due to abnormal beta-cell function and abnormal glucose 
metabolism in the liver3.
Optimal glycaemic control is the treatment goal in subjects with T2DM in order to prevent long-term complications associated with chronic hyperglycaemia
4. Despite the availability of several 
anti-diabetic drugs, a significant proportion of subjects with T2DM do not achieve the recommended targets for glycaemic control
5, 6.
3.1.2 Glucagon-like peptide-1
Glucagon-like peptide-1 (GLP-1) is an incretin  hormone with a glucose-dependent stimulatory 
effect on insulin and inhibitory effect on glucagon secretion from the pancreatic islets7, 8.
Subjects with T2DM have a decreased incretin effect9-12. However, the insulinotropic action of 
GLP-1 and thus, the ability to lower blood glucose (BG) levels, is preserved when GLP-1 is 
administered at supraphysiological levels13. In addition, supraphysiol ogical levels of GLP-1 induce 
reduction in body weight14. GLP-1 is a physiological regulator of appetite and food intake and GLP-
1 receptors are present in several areas of the brain involved in appetite regulation15, 16. 
Physiologically, GLP-1 also has a pronounced inhibitory effect on gastric emptying; however this 
effect seems to diminish upon chronic exposure14-16. These mechanisms of action make GLP-1 
receptor agonists (GLP-1 RAs) an attractive pharmacological treatment for T2DM17-19.
3.1.3 Oral semaglutide  
Semaglutide is a long-acting GLP-1 RA structurally similar to liraglutide (Victoza®), a once-daily 
GLP-1 RA developed by Novo Nordisk and approved worldwide for the treatment of T2DM. 
Compared to human native GLP-1, which has a short half-life, the semaglutide molecule has three 
minor but important modifications ensuring protraction of its action: amino acid substitutions at CONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 19 of 125
position 8 (alanine to alfa-aminoisobutyric acid, a synthetic amino acid) and position 34 (lysine to 
arginine) and acylation of the peptide backbone with a spacer and C-18 fatty di-acid chain to lysine 
in position 2620. The fatty di-acid side chain and the spacer mediate strong binding to albumin, 
thereby reducing renal clearance. The amino acid substitution at position 8 makes semaglutide less susceptible to degradation by dipeptidyl peptidase-4 (DPP-4). The change in position 34 from a 
lysine to an arginine is included to have only one lysine in the sequence whereto a spacer can be 
attached.
Semaglutide is in development for oral once-daily treatment of T2DM. As the bioavailability of 
GLP-1 RAs is low when administered orally, semaglutide has been co-formulated with the 
absorption -enhancing excipient sodium N-[8-(2-hydroxybenzoyl)amino]caprylate (SNAC) to 
increase the bioavailability of semaglutide. The absorption-enhancing properties of SNAC co-
formulation is based on the  concept developed by .
SNAC facilitates the absorption of semaglutide in a strictly time and size dependent manner, 
primarily via the transcellular route. The available data for semaglutide co-formulated with SNAC 
support that the absorption takes place in the stomach in a localised, buffered environment in close 
proximity of the tablet erosion. The absorption process is hampered if dosed with food, liquid or in 
the presence of significant stomach content. 
The absorption enhancement requires co-formulation between semaglutide and SNAC. Throughout 
this document “oral semaglutide” will refer to the drug product, that is, semaglutide co-formulated 
with 300 mg SNAC. 
3.1.4 Nonclinical data
3.1.4.1 Semaglutide
The nonclinical programme for semaglutide was designed according to the ICH M3 guideline
21to 
support the clinical development. The standard nonclinical data package required to support phase 3 
clinical trials has been completed. In addition, 2-year carcinogenicity studies and a pre- and 
postnatal development toxicity study have been completed. Semaglutide was generally well 
tolerated in animals (mice, rats and cynomolgus monkeys). Two potential safety issues have been 
identified and these are detailed below.
Thyroid C-cell tumours in rodents
Treatment-related non-genotoxic proliferative changes in the thyroid C-cells of mice and rats were 
observed in 2-year carcinogenicity studies with semaglutide; thyroid hyperplasia was preceded by 
an increase in serum calcitonin. C-cell changes have not been observed in long-term studies in non-
human primate. The observed pattern of effects in mice and rats and lack of these effects in the non-
human primate and in man suggest that the mechanism by which semaglutide acts on the thyroid C-
cells in rodents is the same as has been demonstrated for other GLP-1 RAs, including liraglutide. CONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 20 of 125
According to this mechanism, C-cell hyperplasia is mediated by the GLP-1 receptor and is not 
associated with RET (re-arranged during transfection) gene activation and rodents appear to be 
particularly sensitive, whereas humans are not. The relevance for human subjects is currently 
unknown, but considered to be low22.
Embryo−foetal development toxicity
Semaglutide caused embryo-foetal development toxicity in the rat through a GLP-1 receptor 
mediated effect on the inverted yolk sac placenta leading to impaired nutrient supply to the 
developing embryo. Primates do not have an inverted yolk sac placenta which makes this 
mechanism unlikely to be of relevance to humans and cynomolgus monkeys. In the developmental 
toxicity studies in cynomolgus monkey, a marked maternal body weight loss associated with the 
pharmacological effect of semaglutide coincided with increased early foetal loss; however, there 
was no indication of a teratogenic potential of semaglutide in this species.
A review of the results from the nonclinical studies can be found in the investigator’s brochure (IB) 
for semaglutide (subcutaneous administration), edition 1023and the IB for oral administration of 
semaglutide (NN9924), edition 624, or any updates of these documents.
3.1.4.2 SNAC
SNAC was developed as an absorption-enhancing excipient for the oral route of administration. The 
nonclinical programme to support clinical phase 3 development and marketing authorisation 
application submission has been conducted including a 26-week carcinogenicity study in transgenic 
rasH2 mice and a 2-year carcinogenicity study in Sprague-Dawley rats.
 
 
 
 
 
Measurements of lactate levels have 
been included at selected time points around peak concentrations of SNAC in two of the phase 3a 
trials in the PIONEER programme (NN9924-4233 and this trial) with the intention to document that 
SNAC does not impair cellular respiration in humans. In addition, events of lactic acidosis must be 
reported as an AE requiring additional data collection, please refer to Section 8.4.1.2 , Section 12.1.5
and appendix B .
The carcinogenicity studies demonstrated that SNAC was not carcinogenic to the transgenic rasH2 
mouse or the Sprague-Dawley rat. The doses tested covered total exposures of SNAC in plasma (in CONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 21 of 125
terms of area under the curve [AUC]) of 2-fold in the mouse and up to 44-fold in the rat when 
compared to the mean total exposure of SNAC in humans following a clinical dose of 300 mg 
SNAC/day.
A review of the SNAC results from the nonclinical studies can be found in the IB for oral 
administration of semaglutide (NN9924), edition 624, or any updates hereof.
3.1.5 Clinical data for oral semaglutide
A comprehensive clinical pharmacology programme including 12 trials has been completed, as well 
as a 26-week phase 2 dose-finding trial involving more than 600 subjects with T2DM.
For details on the individual trials, please see the IB for oral administration of semaglutide 
(NN9924) edition 624, or any updates hereof.
3.1.5.1 Pharmacokinetics
In the multiple-dose trial (NN9924-3991), oral semaglutide has demonstrated a long mean terminal 
half-life (t½) ranging from 153 to 161 hours (~1 week) and a median time to reach maximum 
observed concentration (t max) ranging from 1 to 2 hours in healthy subjects. 
In multiple-dose pharmacokinetics (PK) trials, the exposure to oral semaglutide increased with 
increasing dose. Overall, the pharmacokinetic properties of semaglutide appeared similar in healthy 
subjects and in subjects with T2DM.
Exposure of semaglutide exhibits a substantially greater dose-to-dose variation following oral 
administration compared to subcutaneous (s.c.) administration. However, when administered orally 
once-daily the PK properties of semaglutide, i.e. low clearance and long half-life, will limit the 
variation in exposure at steady state.
Data obtained following investigation of different dosing conditions for oral semaglutide have 
demonstrated that subjects should take the oral semaglutide tablet in the morning in a fasting state 
and at least 30 minutes before the first meal of the day. 
 
 
 
 
 
  CONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 22 of 125
 
 
 
In subjects with mild to severe hepatic impairment, the exposure to semaglutide appeared to be 
unaffected by the degree of hepatic impairment, whereas the exposure to SNAC (in terms of both 
AUC and C max) was increased for subjects with hepatic impairment as compared to subjects with 
normal hepatic function.
All tablets of oral semaglutide contain 300 mg of SNAC regardless of the semaglutide dose. SNAC 
is rapidly absorbed with a median t maxranging from 0.35-0.5 hours in healthy subjects and from 
0.52-1.43 hours in subjects with T2DM. It is extensively metabolised and no accumulation of 
SNAC has been observed in clinical trials.
3.1.5.2 Efficacy
The efficacy of oral semaglutide in adult subjects with T2DM was investigated in a 26-week phase 
2 dose-finding trial (NN9924-3790). In this trial, placebo or one of the following doses of oral 
semaglutide were administered once-daily: 2.5, 5, 10, 20 and 40 mg.
Results from the trial showed that oral semaglutide effectively lowered glycosylated haemoglobin 
(HbA 1c) and body weight. Placebo-adjusted reductions in HbA 1cwere dose-dependent and 
statistically significant for all oral semaglutide treatment arms at week 26 (range: -0.40% to -
1.59%). Placebo-adjusted reductions in body weight were dose-dependent and statistically 
significant for oral semaglutide treatment doses of 10 mg and above at week 26 (range: -3.61 kg 
to -6.98 kg). 
3.1.5.3 Safety
In the clinical trials completed so far, no unexpected safety findings have been identified for oral 
semaglutide administered up to 40 mg once-daily. Consistent with other GLP-1 RAs, commonly 
reported adverse events (AEs) included nausea and vomiting, most of them were mild to moderate 
in severity. In line with findings for other GLP-1 RAs, an increase in heart rate and serum levels of lipase and amylase has also been observed in subjects exposed to oral semaglutide.
In addition to the 13 completed clinical trials with oral semaglutide, SNAC has been investigated in 
the programme of orally administrated heparin in combination with SNAC (heparin/SNAC). The 
heparin/SNAC programme ( ) included 29 phase 1 trials (SNAC doses 
ranged from 0.172-10.5 g). In three of these trials, SNAC alone was investigated (to a maximum 
dose of 10.5 g). The trials covered formulation development, food effect, hepatic and renal 
impairment, age-effect and drug-drug interaction. The programme also included a total of three CONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 23 of 125
phase 2 and 3 trials in which the effects of orally delivered heparin solution (with > 1.5 g SNAC 
three times a day) was investigated. The overall safety profile of oral semaglutide and 
heparin/SNAC indicates that SNAC is safe and well-tolerated. 
For further details, please see the IB for oral administration of semaglutide (NN9924) edition 624, or 
any updates hereof.
3.1.6 Empagliflozin
The selected active comparator in this trial is empagliflozin, a selective inhibitor of the sodium-
glucose co-transporter-2 (SGLT-2), the predominant transporter responsible for glucose 
reabsorption from the glomerular filtrate back into the circulation. Inhibition of SGLT-2 reduces 
BG levels by blocking renal glucose reabsorption, thereby increasing urinary glucose excretion. The 
amount of glucose removed by the kidney through this glucuretic mechanism is dependent on the 
BG concentration and renal function. Empagliflozin was developed by Boehringer Ingelheim and 
Eli Lilly and approved in 2014 under the trade name Jardiance®to improve glycaemic control in 
adults with T2DM.
For further details, please see the current approved label for Jardiance®25, 26
For an assessment of benefits and risks of the trial, see Section 18.1.
3.2 Rationale for the trial
Many patients with T2DM are not in glycaemic control with the currently marketed oral anti-
diabetic drugs (OADs). Nevertheless, treatment with more efficacious injectable therapies such as 
GLP-1 RAs and insulin are rarely added during the early stages of the disease. Oral semaglutide is 
the first GLP-1 RA in development in a tablet formulation and it has the potential of becoming a 
new attractive treatment option early in the treatment cascade due to its effects on both 
hyperglycaemia and body weight. 
The purpose of the present trial is to compare oral semaglutide with empagliflozin, an established 
OAD within the drug class of SGLT-2 inhibitors, in terms of glycaemic control, weight loss and 
other efficacy and safety parameters in subjects with T2DM inadequately controlled on metformin.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 24 of 125
4 Objectives and endpoints
4.1 Objectives
4.1.1 Primary objective
To compare the effect of once-daily dosing of 14 mg oral semaglutide versus 25 mg empagliflozin, 
both in combination with metformin, on glycaemic control in subjects with type 2 diabetes mellitus.
4.1.2 Secondary objectives
To compare the effect of once-daily dosing of 14 mg oral semaglutide versus 25 mg empagliflozin, 
both in combination with metformin, on body weight in subjects with type 2 diabetes mellitus.
To compare the safety and tolerability of once-daily dosing of 14 mg oral semaglutide versus 25 mg 
empagliflozin, both in combination with metformin, in subjects with type 2 diabetes mellitus.
4.2 Endpoints
The confirmatory endpoints are evaluated as a change from baseline to week 26. There will not be 
an interim analysis at week 26, the evaluation will take place after completion of the trial.
4.2.1 Primary endpoint
Change from baseline to week 26 in HbA 1c
4.2.2 Secondary endpoints
4.2.2.1 Confirmatory secondary endpoints
Change from baseline to week 26 in body weight (kg)
4.2.2.2 Supportive secondary endpoints
Supportive secondary efficacy endpoints
Key supportive secondary endpoint prospectively selected for disclosure (e.g. clinicaltrials.gov and 
EudraCT) are marked with an asterisk (*).
Change from baseline to week 52 in: 
!HbA 1c*
!Body weight (kg)*CONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 25 of 125
Change from baseline to week 26 and week 52 in:
!Fasting plasma glucose (FPG)*
!Fasting C-peptide
!Fasting insulin and proinsulin
!Fasting glucagon
!Insulin resistance (homeostatic model assessment index of insulin resistance [HOMA-IR]) and 
beta-cell function (homeostatic model assessment index of beta-cell function [HOMA-B])
!7-point self-measured plasma glucose (SMPG) profile
– Mean 7 point profile
– Mean postprandial increment (over all meals)
!Body weight (%)
!Body mass index (BMI)  
!Waist circumference
!Fasting lipid profile (total cholesterol, low-density lipoprotein (LDL) cholesterol, very low 
density lipoprotein (VLDL) cholesterol, high-density lipoprotein (HDL) cholesterol, 
triglycerides, free fatty acids)
!C-reactive protein (CRP)
!Patient reported outcomes (PROs)
– Short Form (SF)-36v2TM (acute version) health survey
– Control of Eating questionnaire (CoEQ)
If a subject after week 26 and week 52 achieves (yes/no):
!HbA 1c< 7.0 % (53 mmol/mol) American Diabetes Association (ADA) target*
!HbA 1c≤6.5 % (48 mmol/mol) American Association of Clinical Endocrinologists (AACE) 
target
!HbA 1creduction ≥ 1 % (10.9 mmol/mol)
!Weight loss ≥3%
!Weight loss ≥5%  
!Weight loss ≥10 % 
!HbA 1c< 7.0 % (53 mmol/mol) without hypoglycaemia (treatment-emergent severe or 
BG-confirmed symptomatic hypoglycaemia) and no weight gain
!HbA 1creduction ≥1.0 % (10.9 mmol/mol) and weight loss ≥3%
Time to event:
!Time to rescue medicationCONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 26 of 125
Supportive secondary safety endpoints
!Number of treatment-emergent adverse events (TEAEs) during exposure to trial product, 
assessed up to approximately 57 weeks*
!Number of treatment-emergent severe or blood glucose-confirmed symptomatic hypoglycaemic 
episodes during exposure to trial product, assessed up to approximately 57 weeks*
!Treatment-emergent severe or blood glucose-c onfirmed symptomatic hypoglycaemic episodes 
during exposure to trial product, assessed up to approximately 57 weeks (yes/no)
Change from baseline to week 26 and week 52 in:
!Haematology
!Biochemistry
!Calcitonin
!Pulse
!Systolic blood pressure
!Diastolic blood pressure
!Electrocardiogram (ECG) category
!Physical examination (only week 52)
Change from pre-dose to post-dose (25 and 40 min ) at week 4, week 26 and week 52 in:
!Lactate
Any occurrence of anti-semaglutide antibodies (yes/no) up to approximately 57 weeks:
!Anti-semaglutide binding antibodies
!Anti-semaglutide neutralising antibodies 
!Anti-semaglutide binding antibodies cross reacting with native GLP-1  
!Anti-semaglutide neutralising antibodies cross reacting with native GLP-1 
Anti-semaglutide binding antibodies up to approximately 57 weeks:
!Anti-semaglutide binding antibody levels
Supportive secondary pharmacokinetic endpoints
!SNAC plasma concentrations 
!Semaglutide plasma concentrations for population PK analysesCONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 27 of 125
5 Trial design
5.1 Type of trial
This is a 52-week, randomised, open-label, active-controlled, parallel-group, multicentre, 
multinational trial with 2 arms comparing the efficacy and safety of oral semaglutide with 
empagliflozin in subjects with T2DM inadequately controlled on metformin. 
Subjects will be randomised 1:1 to receive one of the following treatments:
!14 mg oral semaglutide once-daily
!25 mg empagliflozin once-daily
The total trial duration for the individual subject will be approximately 59 weeks. The trial includes 
a 2-week screening period, followed by a 52-week randomised treatment period and a follow-up 
period of 5 weeks.
A schematic illustration of the trial design is shown in Figure 5–1
Figure 5–1 Trial design
5.2 Rationale for trial design
The trial has been designed as a parallel-group, 2-armed trial to secure a direct comparison between 
oral semaglutide and the active comparator empagliflozin. Subjects will be randomised 1:1 between 
the two treatment arms. Manufacture of placebo tablets resembling empagliflozin was not feasible. 
Therefore, the trial is open-labelled.
The treatment duration will be 52 weeks to ensure adequate time to compare the full effect and 
sustainability of both treatments on glycaemic control and body weight. 
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 28 of 125
The confirmatory endpoints will be defined after 26 weeks of treatment where the extent of missing 
data, use of rescue medication or premature treatment discontinuation is expected to be limited. 
This allows for a robust estimation of the effect of oral semaglutide on HbA 1cand body weight that 
is considered adequate and meaningful. There will not be an interim analysis at week 26. The 
subjects will sign up for 52 weeks when they sign the informed consent.
The follow-up period is 5 weeks to allow for wash-out of semaglutide and to prevent interference in 
the antibody assay.
5.3 Treatment of subjects
Treatment of subjects is summarised in Table 5–1
Table 5–1 Treatment overview
Trial periods Screening Treatment period 
1Treatment period 
2Treatment period 
3
First visit in each period V1 V2 V4 V5
Duration of each period 2 weeks 4 weeks 4 weeks 44 weeks
Treatment arm N
Oral semaglutide 408 Screening 3 mg 7 mg 14 mg
Empagliflozin 408 Screening 10 mg 10 mg 25 mg
Oral semaglutide treatment
Oral semaglutide is a long-acting GLP-1 RA to be administered orally once-daily. Subjects 
randomised to oral semaglutide will initiate treatment with 3 mg once-daily and follow a fixed 
4-week dose escalation regimen until reaching the maximum treatment dose of 14 mg once-daily, as 
illustrated in Table 5–1 . To mitigate the risk of gastrointestinal AEs, it is important to follow the 
fixed 4-week dose escalation intervals. The dose must not be changed during the course of the trial 
once the 14 mg dose of oral semaglutide has been reached.
Empagliflozin treatment
Subjects should be considered suitable for treatment with empagliflozin and the use of 
empagliflozin should be in accordance with the current, approved label25. Renal function and signs 
and symptoms of volume depletion should be monitored during therapy.
Treatment with empagliflozin will be initiated at 10 mg once-daily. The dose will be escalated after 
8 weeks to the recommended maximum dose of 25 mg in subjects tolerating empagliflozin who 
have an estimated glomerular filtration rate (eGFR) ≥ 60 mL/min/1.73 m2. However, in subjects 
whose eGFR falls persistently < 60 mL/min/1.73 m2(confirmed by retest at central laboratory), the 
dose of empagliflozin should be reduced to 10 mg once-daily. The dose can be re-escalated to 25 
mg once-daily in case the renal function improves (eGFR ≥ 60 mL/min/1.73 m2) during the trial. If CONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 29 of 125
the eGFR falls persistently < 45 mL/min/1.73 m2(confirmed by re-test at central laboratory), 
treatment with empagliflozin should be discontinued (see Section 6.5).
5.3.1 Dosing instructions
Oral semaglutide
Absorption of oral semaglutide is significantly affected by food and fluid in the stomach, hence 
dosing should be once-daily in the morning in a fasting state and at least 30 minutes before the first 
meal of the day. Oral semaglutide tablets can be taken with up to half a glass of water 
(approximately 120 mL/4 fluid oz). The tablets must be swallowed whole by the subject and must 
not be broken or chewed ( Table 9–2 ). Furthermore, other oral medication can be taken 30 minutes 
after administration of trial product.
Empagliflozin 
Tablets should be taken once-daily in the morning. The tablet should be swallowed whole with 
water and it can be taken with or without food. 
5.3.2 Background medication
After signing the informed consent, subjects must continue their anti-diabetic background 
medication (metformin) throughout the entire trial. The background medication must be maintained 
at the same dose level as given at trial entrance and with the same frequency during the entire 
treatment period unless rescue medication is needed (see Section 6.4) or a safety concern related to 
the background medication arises.
In addition, all background medication:
!is considered to be non-investigational medicinal product
!will not be provided by Novo Nordisk A/S, except if required by local regulations
!should be used in accordance with standard of care and current approved label in the individual 
country
!should not exceed the maximum approved dose in the individual country
5.4 Treatment after discontinuation of trial product
When discontinuing trial product, either at the scheduled end-of-treatment visit (see Section 8.1.4 ) 
or if trial product is discontinued prematurely (see Section 8.1.5 ), the subject should be switched to 
a suitable marketed product at the discretion of the investigator ( for Brazil only: or it will be made 
available according to local regulations ). After discontinuation of oral semaglutide, GLP-1 RAs are 
not allowed before completion of the follow-up visit 5 weeks after the last date on trial product (to 
avoid interference with the antibody assay for oral semaglutide). Throughout the protocol, last date 
on trial product is defined as date of the subject’s last dosage of trial product.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 30 of 125
As this trial is a phase 3a trial, oral semaglutide will not be available for prescription until after 
marketing authorisation.
5.5 Rationale for treatment
For oral semaglutide, the three dose levels (3, 7 and 14 mg), treatment initiation with the lowest 
dose and the 4-week dose escalation steps have been chosen based on data from the phase 2 
dose-finding trial. This regimen is expected to have the optimal benefit-risk profile for further 
development for treatment of T2DM in the PIONEER programme.
Empagliflozin has been chosen as active comparator since it is an established OAD within the drug 
class of SGLT-2 inhibitors and treatment will be initiated with 10 mg in accordance with the 
current, approved label. 
Both oral semaglutide and empagliflozin will be dose escalated to their highest respective 
maintenance doses to investigate and compare the maximum efficacy of the two drugs when added 
to metformin. 
The duration of randomised treatments is consider ed adequate to collect s ufficient data on efficacy 
and safety in accordance with the trial objectives.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 31 of 125
6 Trial population
6.1 Number of subjects 
Number of subjects planned to be screened: 1360
Number of subjects planned to be randomised:     816
Number of subjects expected to complete the trial on or off trial product:   735
6.2 Inclusion criteria
For an eligible subject, all inclusion criteria must be answered “yes”. 
1. Informed consent obtained before any trial-related activities. Trial-related activities are any 
procedures that are carried out as part of the trial, including activities to determine suitability for 
the trial.
2. Male or female, age above or equal to 18 years at the time of signing informed consent.
3. Diagnosed with type 2 diabetes mellitus ≥ 90 days prior to day of screening.
4. HbA 1cof 7.0-10.5 % (53-91 mmol/mol) (both inclusive).
5. Stable daily dose of metformin ( ≥ 1500 mg or maximum tolerated dose as documented in the 
subject medical record) ≥ 90 days prior to the day of screening.
6.3 Exclusion criteria
For an eligible subject, all exclusion criteria must be answered “no”. 
1. Known or suspected hypersensitivity to trial product(s) or related products. 
2. Previous participation in this trial. Participation is defined as signed informed consent.
3. Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing 
potential and not using an adequate contraceptive method (adequate contraceptive measure as 
required by local regulation or practice). 
For Brazil only: for women who expressly declare free of the risk of pregnancy, either by not 
engaging in sexual activity or by having sexual activity with no birth potential risk, use of contraceptive method will not be mandatory.
For Greece only: adequate contraceptive measures are defined as combined hormonal 
contraception (containing oestrogen and progesterone), which suppress ovulation (oral, intravaginal, percutaneous), progesterone-only hormonal contraception which suppress 
ovulation (oral, injectable, implantable), intrauterine device, hormone-releasing intrauterine 
system, bilateral tubal occlusion, partner with vasectomy, sexual abstinence.
4. Receipt of any investigational medicinal product within 90 days before screening.
For Brazil only: Participation in other trials within one year prior to screening visit (V1) unless 
there is a direct benefit to the research subject at the investigator's discretion.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 32 of 125
5. Any disorder, which in the investigator’s opinion might jeopardise subject’s safety or 
compliance with the protocol.
6. Family or personal history of Multiple Endocrine Neoplasia Type 2 (MEN 2) or Medullary 
Thyroid Carcinoma (MTC).
7. History of pancreatitis (acute or chronic).
8. History of major surgical procedures involving the stomach potentially affecting absorption of 
trial product (e.g. subtotal and total gastrectomy, sleeve gastrectomy, gastric bypass surgery).
9. Any of the following: myocardial infarction, stroke or hospitalisation for unstable angina or 
transient ischaemic attack within the past 180 days prior to the day of screening. 
10. Subjects presently classified as being in New York Heart Association (NYHA) Class IV.
11. Planned coronary, carotid or peripheral artery revascularisation known on the day of screening.
12. Subjects with alanine aminotransferase (ALT) > 2.5 x upper normal limit (UNL).
13. Renal impairment defined as estimated Glomerular Filtration Rate (eGFR) < 60 mL/min/1.73 
m2as per Chronic Kidney Disease Epidemiology Collaboration formula (CKD-EPI).
14. Treatment with any medication for the indication of diabetes or obesity other than stated in the 
inclusion criteria in a period of 90 days before the day of screening. An exception is short-term 
insulin treatment for acute illness for a total of ≤14 days.
15. Proliferative retinopathy or maculopathy requiring acute treatment. Verified by fundus 
photography or dilated fundoscopy performed within 90 days prior to randomisation.
16. History or presence of malignant neoplasms within the last 5 years (except basal and squamous 
cell skin cancer and carcinoma in situ ).
17. History of diabetic ketoacidosis.
6.4 Rescue criteria
Subjects with persistent and unacceptable hyperglycemia should be offered treatment 
intensification. To allow time for dose escalation to maximum dose and to observe the expected 
effect of treatment on glycaemic parameters, rescue criteria will be applied from week 8 and 
onwards. If any of the FPG values (including fasting SMPG) exceed the limits outlined below and 
no intercurrent cause of the hyperglycaemia can be identified, a confirmatory FPG (at the central laboratory) should be obtained by calling the subject for a re-test. If the confirmatory FPG also 
exceeds the value described below, the subject should be offered rescue medication (i.e. 
intensification of anti-diabetic background medication and/or initiation of new anti-diabetic 
medication):
!14.4  mmol/L (260 mg/dL) from week 8 to the end of week 13
!13.3 mmol/L (240 mg/dL) from week 14 to the end of week 25
!11.1 mmol/L (200 mg/dL) from week 26 to the end of treatment
In addition, subject should be offered rescue medication if:
!HbA
1c(at central laboratory) >8.5% (69.4 mmol/mol) from week 26 to end of treatment.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 33 of 125
It is important for trial integrity that only subjects actually needing treatment intensification (as 
defined above) are started on rescue medication. Subjects that are started on rescue medication 
should continue to follow the protocol-specified visit schedule. Rescue medication should be 
prescribed at the investigator’s discretion as add-on to randomised treatment and according to 
ADA/European Association for the Study of Diabetes guidelines27and28(excluding GLP-1 RAs, 
DPP-4 inhibitors and amylin analogues in the oral semaglutide arm and excluding SGLT-2 inhibitors in the empagliflozin arm). Rescue medication and any changes hereto should be captured 
on the concomitant medication form in the electronic case report form (eCRF), see Section 8.2.4 . 
6.5 Criteria for premature discontinuation of trial product 
All efforts should be made to keep the subject on trial product. However, the subject may be 
prematurely discontinued from trial product at the discretion of the investigator due to a safety 
concern. The subject must be prematurely discontinued from trial product if the following applies:
!Safety concern related to trial product or unacceptable intolerability
!Included in the trial in violation of the inclusion and/or exclusion criteria
!Pregnancy
!Intention of becoming pregnant
!Simultaneous participation in another clinical trial of an approved or non-approved  
investigational medicinal product
!Calcitonin ≥ 100 ng/L
If a criterion for premature discontinuation of trial product is met, trial product should not be re-
initiated but subjects should continue with the scheduled site contacts.
See Section 8.1.5 for procedures to be performed for subjects discontinuing trial product 
prematurely.
6.6 Withdrawal from trial
The subject may withdraw consent at will at any time. The subject’s request to withdraw from the 
trial must always be respected. Only subjects who withdraw consent should be considered as 
withdrawn from trial.
See Section 8.1.6 for procedures to be performed for subjects withdrawing consent.  
6.7 Subject replacement
Subjects who withdraw consent or discontinue trial product prematurely will not be replaced. CONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 34 of 125
6.8 Rationale for trial population 
The trial population will include subjects with T2DM treated with stable doses of metformin for at 
least 90 days prior to screening as changes in the background medication shortly before trial 
participation may potentially impact the data interpretation. The HbA 1climits of 7.0-10.5 % 
(53-91 mmol/mol) have been chosen to include subjects needing intensification of their 
anti-diabetic medication. FPG and HbA 1cwill be monitored throughout the trial and rescue 
medication should be initiated in subjects with persistent, unacceptable hyperglycaemia. No BMI or 
blood pressure restrictions will be applied. Subjects with liver test abnormalities 
(ALT > 2.5 x UNL) will be excluded to avoid potential confounding of liver safety assessments. In 
addition, subjects with moderate, severe or end-stage renal impairment will be excluded due to 
restrictions in the labels of empagliflozin and metformin. As SGLT-2 inhibitors have been 
associated with euglycaemic diabetic ketoacidosis, subjects with a history of diabetic ketoacidosis 
will also be excluded from this trial. Overall, the eligibility criteria will allow for enrolment of a 
relatively broad trial population resembling the target population in common practice. CONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 35 of 125
7 Milestones
Planned duration of recruitment period FSFV-LSFV:       23 weeks
Planned FSFV: 10 Aug 2016
Planned LSLV: 13 Mar 2018
End of trial is defined as:       LSLV
Recruitment:
The screening and randomisation rate will be followed closely via the interactive web response 
system (IWRS) in order to estimate when to stop screening. All investigators will be notified 
immediately when the recruitment period ends, after which no further subjects may be screened and 
the IWRS will be closed for further screening.
Trial registration:
Information of the trial will be disclosed at clinicaltrials.gov and novonordisk-trials.com. According 
to the Novo Nordisk Code of Conduct for Clinical Trial Disclosure29it will also be disclosed 
according to other applicable requirements such as those of the International Committee of Medical 
Journal Editors (ICMJE)30, the Food and Drug Administration Amendment Act (FDAAA)31, 
European Commission Requirements32, 33and other relevant recommendations or regulations. If a 
subject requests to be included in the trial via the Novo Nordisk e-mail contact at these web sites, 
Novo Nordisk may disclose the investigator’s contact details to the subject. As a result of increasing 
requirements for transparency, some countries require public disclosure of investigator names and 
their affiliations.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 36 of 125
8 Methods and assessments
8.1 Visit procedures
The following sections describe the assessments and procedures. These are also included in the flow 
chart (see Section 2). Informed consent must be obtained before any trial related activity, see 
Section 18.2.
Refer to flowchart (Section 2) for number and timing of visits and specific assessments to be 
performed. 
Each subject will attend 12 site visits and 1 phone visit. It is the responsibility of the investigator to 
ensure that all site visits occur according to the flow chart (see Section 2).
Planned visits can be conducted and re-scheduled within the allowed visit window. If a visit is 
missed and it is not possible to re-schedule, every effort should be made to ensure information is 
collected at a telephone contact (within the visit window) and entered into the eCRF. Subjects will 
be invited for the next scheduled visit according to the visit schedule.
The investigator must keep a log of staff and a delegation of task(s) list at site. Investigator must 
sign the log of staff and the delegation of task(s) at site prior to the delegation of tasks.
The investigator must keep a subject screening log, a subject identification code list and a subject 
enrolment log. Only subjects who have signed the informed consent form should be included on the 
logs. The subject screening log and subject enrolment log may be combined in one log. 
8.1.1 Screening, visit 1
At screening, subjects will be provided with a card stating that they are participating in a trial and 
giving contact address(es) and telephone number(s) of relevant trial site staff. Subjects should be 
instructed to return the card to the investigator at the last trial visit or to destroy the card after the 
last visit.
A screening session must be made in the IWRS. Each subject will be assigned a unique 6-digit 
subject number which will remain the same throughout the trial.
Once all data relating to V1 have been obtained, these must be reviewed, dated and signed by the 
investigator and/or documented in medical records to assess that the subject is eligible to continue 
in the trial.
Screening failures: For screening failures the screening failure form in the eCRF must be 
completed with the reason for not continuing in the trial. Serious adverse events (SAEs) from CONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 37 of 125
screening failures must be transcribed by the investigator into the eCRF. Follow-up on SAEs must 
be carried out according to Section 12.
A screening failure session must be made in the IWRS. The case book must be signed.
Re-screening is NOT allowed if the subject has failed one of the inclusion or exclusion criteria; this 
includes re-sampling if the subject has failed one of the inclusion or exclusion criteria related to 
laboratory parameters. However, in case laboratory samples are lost (e.g. haemolysed or displaced), 
re-sampling is allowed.
8.1.2 Fasting visits
The subjects must attend several visits in a fasting state (see Section 2). 
Fasting for blood sampling is defined as no food or liquid within the last 8 hours prior to blood 
sampling, however water is allowed up until 2 hours prior to blood sampling.
Trial product must be taken after blood sampling (see Section 5.3.1 for dosing instructions). Other 
oral medication can be taken 30 minutes after trial product (for subjects randomised to oral 
semaglutide only). Injectable medications can be administered after blood sampling. Note that for 
all subjects, the required fasting period is longer at visits with PK sampling and lactate assessments 
(see Section 8.6).
In case a subject attends a fasting visit in a non-fasting state, all non-fasting measurements should 
be performed. The subject should return to the site in a fasting state to have the fasting blood 
samples done within the visit window for the relevant visit.
Fasting samples:
!FPG
!fasting C-peptide
!fasting insulin and proinsulin
!fasting glucagon
!fasting lipid profile (total cholesterol, LDL cholesterol, VLDL cholesterol, HDL cholesterol, 
triglycerides, free fatty acids)
!lactate
!SNAC PK
!semaglutide PKCONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 38 of 125
8.1.3 Randomisation and trial product administration
Eligible subjects will be randomised into one of two treatment arms. The randomisation session 
must be performed in the IWRS which will allocate the dispensing unit number (DUN) of trial 
product to be dispensed to the subject.
All V2 assessments must be performed before administration of first dose of trial product.
Trial product (see Section 9) will be dispensed to the subject by the site, hospital pharmacy or 
equivalent at each site visit during the trial from randomisation to last visit before the end-of-
treatment visit (see Section 2). The investigator must document that subjects are trained in the 
dosing instructions at every dispensing visit, please see Section 5.3.1 .
Date of first administration of trial product will be captured in the eCRF.
8.1.4 End-of-treatment (visit 12) and Follow-up (visit 13)
Subjects, who stay on trial product throughout the trial, must attend the end-of-treatment visit (V12) 
52 weeks after randomisation and the follow-up visit (V13) 5 weeks after the last date on trial 
product (+3 days visit window). A completion call must be performed in the IWRS after completion 
of V12 (see Section 10).
In case the subject cannot be reached (by clinic visit or phone contact) at the scheduled V13, the site 
should consult the contacts provided by the subject (e.g. close relatives), relevant physicians, 
medical records and locator agencies (if allowed according to local law) to collect health status. If 
no health status can be collected, the subject should be considered lost to follow-up and this should 
be specified in the end-of-trial form.
8.1.5 Premature discontinuation of trial product and follow-up (V12A and V13A)
Subjects, who discontinue trial product prematurely, should attend V12A scheduled to take place on 
the day of discontinuation of trial product (+ 3 days visit window). V13A should be scheduled 5 
weeks (+3 days visit window) after the last date on trial product. The primary reason for premature 
discontinuation of trial product must be specified in the end-of-trial form in the eCRF, and final 
drug accountability must be performed. A treatment discontinuation session must be made in the 
IWRS at V12A (see Section 10).
If premature discontinuation of trial product is decided during a scheduled visit, the visit will be 
converted into a V12A and trial procedures must be performed accordingly.
Subjects should continue with the originally scheduled site contacts after V13A and up to and 
including V12. If necessary, in order to retain the subject in the trial, site visits can be replaced by 
phone contacts after V13A. However, if a subject is unable or unwilling to attend all subsequent CONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 39 of 125
visit(s), the investigator should at least aim to have the subject attend V8 (week 26) and V12 (end-
of-treatment) as these visits should be performed for all subjects, if at all possible (except subjects 
who withdraw informed consent, see Section 8.1.6 ).
Subjects, who only agree to attend or provide health status at the planned V12, should not be 
considered withdrawn from the trial. In case the subject cannot be reached (by clinic visit or phone 
contact) at the scheduled V12, the site should consult the contacts provided by the subject (e.g. 
close relatives), relevant physicians, medical records and locator agencies (if allowed according to 
local law) to collect health status. If no health status can be collected, the subject should be 
considered lost to follow-up and this should be specified in the end-of-trial form.
In summary, subjects should stay in the trial irrespective of lack of adherence to randomised 
treatment, lack of adherence to visit schedule, missing assessments or trial product discontinuation 
for any reason. Only subjects who decline any further contact with the site in relation to the trial 
should be considered as withdrawn from the trial (for withdrawal procedures, see Section 8.1.6 ).
8.1.6 Withdrawals
If a subject considers withdrawing from the trial, the investigator must aim to undertake procedures 
for V12A as soon as possible and V13A should be scheduled 5 weeks (+3 days visit window) after 
the last date on trial product, if the subject agrees to it.
The end-of-trial form must be completed and final drug accountability must be performed even if 
the subject is not able to come to the trial site. A treatment discontinuation session must be made in 
the IWRS (see Section 10). The case book must be signed. 
Although a subject is not obliged to give his/her reason(s) for withdrawing consent, the investigator 
must make a reasonable effort to ascertain the reason(s), while fully respecting the subject’s rights. 
Where the reasons are obtained, the primary reason for withdrawing consent must be specified in 
the end-of-trial form in the eCRF.
8.1.7 Investigator assessments
Review of diaries, PROs, laboratory reports, ECGs and fundoscopy/fundus photography must be 
documented either on the documents or in the subject’s medical record.
If clarification of entries or discrepancies in the diary or PROs is needed, the subject must be 
questioned and a conclusion made in the subject’s medical record. Care must be taken not to bias 
the subject.
The documents must be retained at the site as source documentation.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 40 of 125
For ECGs, physical examinations and eye examinations, the evaluations must follow the categories:
!Normal
!Abnormal
– Was the result clinically significant? (yes/no)
The evaluation should be based on investigator’s judgement.
For laboratory report values outside the reference range, the investigator must specify whether the 
value is clinically significant or not clinically significant. All laboratory printouts must be signed 
and dated by the investigator prior to the following visit. The signed laboratory report is retained at 
the site as source documentation.
In case of abnormal clinically significant findings found as a result of screening procedures 
conducted at V1 or assessments revealing baseline conditions at V2, the investigator must state a 
comment in the subject’s medical record and record this in the medical history/concomitant illness 
form in the eCRF. 
The Investigator or his/her delegate must collect and review the PROs and diaries for completeness 
and to ensure that AEs are reported. 
8.2 Subject related information-/assessments
8.2.1 Demography
Demography will be recorded in the eCRF at screening and consists of:
!Date of birth (according to local regulation)
!Sex
!Ethnicity (according to local regulation)
!Race (according to local regulation)
8.2.2 Diabetes history and diabetes complications
Diabetes history and diabetes complications will be recorded on a disease specific form at screening 
and consists of:
!Date of diagnosis of type 2 diabetes
!Information regarding diabetes complications including date of onset
– Diabetic retinopathy
– Diabetic neuropathy
– Diabetic nephropathy
Please note that macroangiopathy (including peripheral arterial disease) should be reported on the 
disease specific form History of cardiovascular disease (see Section 8.2.3 ).CONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 41 of 125
8.2.3 Concomitant illness and medical history
A concomitant illness is any illness that is present at the start of the trial (V1) or found as a result 
of a screening procedure or other trial procedures performed before exposure to trial product.
Medical history is a medical event that the subject has experienced in the past. Only relevant 
medical history as judged by the investigator should be reported.
The information collected for concomitant illness and medical history should include diagnosis, 
date of onset and date of resolution or continuation, as applicable.
The following must be recorded in the eCRF on the disease specific forms only, i.e. not on the 
medical history/concomitant illness form:
!History of cardiovascular disease (e.g. ischaemic heart disease, myocardial infarction (MI), 
heart failure incl. NYHA class, hypertension, stroke, peripheral arterial disease)
!History of gallbladder disease (e.g. gallstone, cholecystitis, cholecystectomy)
!History of gastrointestinal disease (e.g. gastroesophageal reflux disease, ulcer disease, chronic 
gastritis)
Any change to a concomitant illness should be recorded during the trial. A clinically significant 
worsening of a concomitant illness must be reported as an AE (see Section 12).
It must be possible to verify the subject’s medical history in source documents such as subject’s 
medical record. If a subject is not from the investigator’s own practice, the investigator must make 
reasonable effort to obtain a copy of subject’s medical record from relevant party, e.g. primary 
physician. The investigator must document any attempt to obtain external medical information by 
noting the date(s) when information was requested and who has been contacted.
8.2.4 Concomitant medication
A concomitant medication is any medication, other than the trial products, which is taken during 
the trial, including the screening and follow-up periods.
Details of any concomitant medication must be recorded at the first visit. Changes in concomitant 
medication must be recorded at each visit as they occur. 
The information collected for each concomitant medication includes
!trade name or generic name
!indication
!start date and stop date or continuation
!only applicable for anti-diabetic medication; start date of current dose and total daily doseCONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 42 of 125
If a change is due to an AE, then this must be reported according to Section 12. If the change 
influences the subject’s eligibility to continue in the trial, the monitor must be informed.
8.2.5 Childbearing potential
It must be recorded in the eCRF whether female subjects are of childbearing potential. 
Pregnancy testing must be performed on female subjects of childbearing potential as described in 
Section 8.4.7 (pregnancy testing). Female subjects of childbearing potential must be instructed to 
use an adequate contraceptive method throughout the trial and until 5 weeks after end of treatment.
Female of non-childbearing potential is defined as:
!Female who has undergone a hysterectomy, bilateral oophorectomy or bilateral tubal ligation 
!Postmenopausal defined as no menses for 12 months without an alternative medical cause
!Other medical reasons preventing childbearing potential
For Argentina only: Birth control methods will be reimbursed by Novo Nordisk Pharma Argentina 
S.A.
For Brazil only: for women who expressly declare free of the risk of pregnancy, either by not 
engaging in sexual activity or by having sexual activity with no birth potential risk, use of 
contraceptive method will not be mandatory.
For Greece only: Adequate contraceptive measures are defined as combined hormonal 
contraception (containing oestrogen and progesterone), which suppress ovulation (oral, 
intravaginal, percutaneous), progesterone-only hormonal contraception which suppress ovulation 
(oral, injectable, implantable), intrauterine device, hormone-releasing intrauterine system, bilateral 
tubal occlusion, partner with vasectomy, sexual abstinence.
8.2.6 Tobacco use
Details of tobacco use must be recorded at V1. Smoking is defined as smoking at least one cigarette 
or equivalent daily. 
Smoking status:
!Never smoked
!Previous smoker, smoking stop date
!Current smokerCONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 43 of 125
8.3 Efficacy assessments
8.3.1 Laboratory assessments for efficacy
For overall laboratory process see Section 8.5.
Blood samples will be drawn according to flow chart (see Section 2) and will be analysed at the 
central laboratory to determine levels of the following efficacy laboratory parameters:
Glucose metabolism:
!HbA 1c
!FPG (see Section 8.3.1.1 )
!Fasting insulin and proinsulin
!Fasting glucagon
!Fasting C-peptide
Fasting lipid profile: 
!Total cholesterol
!LDL cholesterol
!HDL cholesterol
!VLDL-cholesterol
!Free fatty acids
!Triglycerides
Other parameters:
!CRP
8.3.1.1 Fasting plasma glucose 
FPG is measured at central laboratory in order to evaluate glycaemic control. The subject must 
attend these visits fasting (see Section 8.1.2 ).
A central FPG result ≤ 3.9 mmol/L (70 mg/dL) in relation to planned fasting visits should not be 
reported as a hypoglycaemic episode  but as a clinical laboratory adverse event (CLAE) at the 
discretion of the investigator (see Section 12.1.1 ).
8.3.2 Self-measured plasma glucose
At V1, subjects will be provided with a BG meter including auxiliaries as well as instructions for 
use. The subjects will be instructed in how to use the device, and the instruction will be repeated as 
necessary during the trial. In case a hypoglycaemic episode is suspected, the provided BG meter 
should be used for SMPG measurement.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 44 of 125
The BG meters use test strips calibrated to plasma values. Therefore, all measurements performed 
with capillary blood are automatically calibrated to plasma equivalent glucose values, which will be 
shown on the display. 
Only the BG meters provided by Novo Nordisk A/S should be used for the measurements required 
in the protocol.
Subjects should be instructed in how to record the results of the SMPG values in the diaries. The 
record of each SMPG value should include date, time and value. All data from the diary must be 
transcribed into the eCRF during or following the contact. If obtained via phone and a discrepancy 
is later detected between the diary and the SMPG data obtained at the phone contact, the values in 
the eCRF must be corrected.
Occasional review by the investigator of the values stored in the memory of the BG meter and 
correct reporting of these in the diary is advised in order to ensure adequacy of the data reported in 
the trial database.
The subject will be instructed to perform a 7-point SMPG profile three times during the trial period 
(see Section 2) using the BG meter provided for the trial. The 7-point SMPG profile should be 
performed on a day where the subject does not anticipate unusual strenuous exercise. The 7-point 
SMPG profile should preferably be taken within a week prior to the visit.
The record of each SMPG measurement should include the following seven time points:
!before breakfast
!90 minutes after start of breakfast
!before lunch
!90 minutes after start of lunch
!before dinner
!90 minutes after start of dinner
!at bedtime
8.3.3 Body weight and height
Body weight must be measured and recorded in the eCRF in kilogram or pound (kg or lb), with one 
decimal (with an empty bladder, without shoes and only wearing light clothing). The body weight 
should be assessed on the same calibrated weighing scale equipment throughout the trial, if 
possible.
Height is measured without shoes in centimetres or inches and recorded in the eCRF to nearest 
½ cm or ¼ inch.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 45 of 125
8.3.4 Waist circumference
The waist circumference is defined as the minimal abdominal circumference located midway 
between the lower rib margin and the iliac crest.
The measurement of waist circumference must be performed and recorded in the eCRF. Waist 
circumference is measured in the horizontal plane and rounded up or down to the nearest ½ cm or ¼ 
inches using a non-stretchable measuring tape. The same measuring tape should be used throughout 
the trial.
The circumference should be measured when the subject is in a standing position, with an empty 
bladder and wearing light clothing. The subject should be standing, feet together with arms down 
their side and waist accessible. The tape should touch the skin but not compress soft tissue and 
twists in the tape should be avoided. The subject should be asked to breathe normally and the 
measurement should be taken when the subject is breathing out gently.
8.3.5 Patient reported outcomes questionnaires
PRO will be assessed using the questionnaires:
!SF-36v2™ (acute version) health survey34-36
!CoEQ37-40
The SF-36v2™ questionnaire is a commonly used instrument to evaluate PROs, also in the T2DM 
area. The CoEQ has not been developed to be used in clinical trials. However, it has previously 
been included in clinical trials on an item per item basis, among others in a T2DM population.
The questionnaires must be completed by the subject as specified in the flow chart, see Section 2, 
preferably before any other trial-related activities  for that visit. It takes approximately ten minutes 
to complete the two questionnaires. Subjects should be given the opportunity to complete the 
questionnaires by themselves without interruption. The completed questionnaires must be reviewed 
for potential AEs and missing data while the subject is still at the site. All results from the PRO 
questionnaires must be transferred into the eCRF.
All the questionnaires will be translated to local languages, and also be linguistically validated 
before being handed out to the subjects participating in the trial.
SF-36 acute version
SF-36v2™ acute version measures the individual overall health related quality of life on 8 domains; 
Physical functioning, Role physical, Bodily pain, General health, Vitality, Social functioning, Role 
emotional and Mental health. The acute version’s questions are based on a recall period of one 
week. SF-36v2™ contains 36 items.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 46 of 125
Control of Eating Questionnaire
The CoEQ has its origins in the Food Craving Record. It comprises 21 items designed to assess the 
intensity and type of food cravings, as well as subjective sensations of appetite and mood. For this 
study a version with only 19 items will be included.
8.4 Safety assessments
8.4.1 Adverse events
Adverse events (AEs) must be reported at each visit in accordance with the procedures outlined in 
Section 12and appendix B . 
8.4.1.1 Medication error 
If a medication error is observed during the trial, the following information is required and a 
specific event form must be completed in the eCRF in addition to the AE form (see Section 8.4.1.2 , 
12.1.5 and appendix B ): 
!Trial product involved 
!Classification of medication error
!Whether the subject experienced any hypoglycaemic episode and/or AE(s) as a result of the 
medication error 
!Suspected primary reason for the medication error 
For definition of medication errors, see Section 12.1.4 and appendix B .CONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 47 of 125
8.4.1.2 Adverse events requiring additional data collection 
For the following AEs, additional data collection is required and specific event forms must be 
completed in the eCRF in addition to the AE form:
!Acute coronary syndrome (MI or hospitalisation for unstable angina)
!Cerebrovascular event (stroke or transient ischaemic attack)
!Heart failure
!Pancreatitis
!Neoplasm (excluding thyroid neoplasm)
!Thyroid disease (including thyroid neoplasm)
!Renal event
!Hypersensitivity reaction
!Acute gallstone disease
!Medication error
!Lactic acidosis
!Creatine kinase (CK) > 10x UNL
!Hepatic event defined as:
– ALT or aspartate aminotransferase (AST) > 5x UNL and total bilirubin ≤ 2x UNL
– ALT or AST > 3x UNL and total bilirubin > 2x UNL*
– Hepatic event leading to trial product discontinuation.
*Please note that in case of a hepatic event defined as ALT or AST >3 x UNL and total 
bilirubin > 2 x UNL, where no alternative aetiology exists (Hy's law), this must be reported as an 
SAE using the important medical event criterion if no other seriousness criteria are applicable.
See Section 12and appendix B for details about the additional information to report. 
Note that additional assessments will be required according to appendix B in case of: 
!suspicion of acute pancreatitis
!suspicion of hypersensitivity reaction
!increased levels of creatine kinase
!increased levels of aminotransferase
In case any of these events fulfil the criteria for a SAE, please report accordingly, see Section 12.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 48 of 125
8.4.2 Physical examination
A physical examination will be performed by the investigator according to local procedure (see 
Section 2and 8.1.7 ). A physical examination must include:
!General appearance
!Head, ears, eyes, nose, throat, neck
!Thyroid gland
!Respiratory system
!Cardiovascular system
!Gastrointestinal system including mouth
!Musculoskeletal system
!Central and peripheral nervous system
!Skin
!Lymph node palpation
8.4.3 Vital signs
Systolic and diastolic blood pressure
Systolic and diastolic blood pressure should be measured in a sitting position after the subject has 
been resting for at least 5 minutes and by using the standard clinical practice at the site. The data 
must be recorded in the eCRF. The actual value of the blood pressure measurement should be 
recorded in the eCRF (without rounding). The same equipment should be used throughout the trial.
Pulse
Pulse (beats per minute) must be recorded in the eCRF at site visits after resting for 5 minutes in a 
sitting position.
8.4.4 Eye examination 
Dilated fundoscopy/fundus photography will be performed as per flow chart (see Section 2) by the 
investigator or according to local practise. Results of the dilated fundoscopy/fundus photography 
will be interpreted by the investigator (see Section 8.1.7 ).
If dilated fundoscopy/fundus photography has been performed within 90 days prior to 
randomisation, the procedure does not need to be repeated, unless worsening of visual function 
since the last examination. The results must be available prior to randomisation.
If the dilated fundoscopy/fundus photography is performed before the subject has signed the 
informed consent form, it must be documented in the medical records that the reason for performing 
the procedure was not related to this trial.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 49 of 125
8.4.5 Electrocardiogram (12-lead)
12-lead ECG will be performed as per flowchart (see Section 2) and the assessment must be 
reviewed as described in Section 8.1.7 by the investigator. The ECGs will also undergo central 
assessment and the investigator must forward the ECGs to the central ECG reader as soon as 
possible.
If the central ECG evaluation of a baseline ECG is suggestive of a prior MI, the investigator will be 
notified. The investigator should consider if an update of the History of cardiovascular disease form 
is required.
If the central ECG evaluation of a post-baseline ECG is suggestive of new MI, the investigator will 
be notified and a confirmatory ECG should be performed. Unless already done, the investigator 
should report this as an AE or a SAE at investigator’s discretion and according to Section 12. 
Additional ECG recordings can be performed at the investigator’s site at investigator’s discretion at 
other visits than the planned ECG visits. All these ECGs will undergo central assessment. The 
reason for additional ECG assessments should be documented and an AE should be reported if 
applicable.
All findings suggestive of new MI detected by the central ECG reading will be adjudicated by the 
event adjudication committee (see Section 12.7.2 ).CONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 50 of 125
8.4.6 Laboratory assessments for safety
For overall laboratory process see Section 8.5.
Blood samples will be drawn according to flow chart (see Section 2) and will be analysed at the 
central laboratory to determine levels of the following safety laboratory parameters:
Haematology:
!Haemoglobin
!Haematocrit
!Leucocytes
!Thrombocytes
!Differential count (eosinophils, neutrophils, basophils, lymphocytes and monocytes)
Biochemistry: 
!ALT
!Albumin
!Alkaline phosphatase
!Amylase
!AST
!Bilirubin, total
!Calcium, total
!Creatinine 
!eGFR per CKD-EPI41
!CK
!Lipase
!Potassium
!Sodium
!Urea
!Lactate (see Section 8.6.1 )
Hormones:
!Calcitonin
In case any calcitonin value at any time during the trial is ≥ 10 ng/L, the algorithm in appendix A
must be followed.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 51 of 125
Other parameters:
!Anti-semaglutide antibodies (see Section 8.4.8 )
8.4.7 Pregnancy testing
Females of childbearing potential will have a urine dip-stick pregnancy test performed at site as 
specified in Section 2or as required by local law. For definition of female of non-childbearing 
potential and contraceptive methods, see Section 8.2.5 .
In case a menstrual period is missed or if pregnancy is suspected between the scheduled visits, a 
urine pregnancy test should be performed. Investigator should instruct the subject to contact the site 
in case the pregnancy test is positive. At V2, females of childbearing potential will be provided with 
a urine dip-stick pregnancy test.
8.4.8 Anti-semaglutide antibodies 
Blood samples will be drawn for measurement of antibodies against semaglutide at selected visits 
(see Section 2). Positive anti-semaglutide binding antibody samples will be further characterised for 
cross reactivity to native GLP-1. Samples which are positive for anti-semaglutide binding 
antibodies will be further characterised for in vitro neutralising effect towards semaglutide. In 
addition, samples which are positive for antibodies cross-reacting with native GLP-1 will be further 
analysed for in vitro neutralising effect towards native GLP-1.
Furthermore, samples drawn at randomisation may be used for calculations of the neutralising effect 
in the in vitro neutralising antibody assays. The in vitro neutralising assays will be performed by 
Novo Nordisk.
At randomisation, the antibody sampling must be done pre-dose. 
Antibody samples will be stored as described in Section 24.2.
8.4.9 Hypoglycaemic episodes
Plasma glucose (PG) should always be measured and recorded when a hypoglycaemic episode is 
suspected. 
All PG values:
!≤ 3.9 mmol/L (70 mg/dL) or 
!> 3.9 mmol/L (70 mg/dL) occurring in conjunction with hypoglycaemic symptoms 
should be reported in the diary according to the instructions below throughout the trial from V1 to 
end of trial.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 52 of 125
Upon onset of a hypoglycaemic episode, the sub ject is recommended to measure PG every 
15 minutes until the SMPG value is > 3.9 mmol/L (70 mg/dL) and/or symptoms have been resolved 
in accordance to current guidelines42.
A SMPG value ≤ 3.9 mmol/L (70 mg/dL) or hypoglycaemic symptoms  must trigger a 
hypoglycaemic episode form to be completed by the subject. Repeated SMPG measurements and/or 
symptoms will per default be considered as one hypoglycaemic epis ode until a succeeding SMPG 
value is > 3.9 mmol/L (70 mg/dL) and/or symptoms have been resolved. One hypoglycaemic 
episode form is to cover these measurements and/or symptoms.
In case of several low SMPG values within the hypoglycaemic episode, the lowest value is the one 
that will be reported as the SMPG value for th e hypoglycaemic episode but  the start time of the 
episode will remain as the time for the first SMPG value and/or symptom.
The record should include the following information: 
!Start date and time of the hypoglycaemic episode.
!Stop date and time of the hypoglycaemic episode (stop time is the first time the PG value is 
> 3.9 mmol/L (70 mg/dL) and/or symptoms have been resolved).
If a stop date and time is not reported, a h ypoglycaemic episode will cover a period of 
60 minutes.
!The PG level before treating the episode (if available) and any follow up measurements. 
The lowest value measured during the hypoglycaemic episode will be reported as the PG value for the episode, the remaining values will be kept as source data in the diary.
!Whether the episode was symptomatic (Yes/No).
A hypoglycaemic episode starting without symptoms should be updated to symptomatic if the 
subject experiences symptoms later during the episode. 
!Whether the subject was able to treat him/herself.
If the severity of a hypoglycaemic episode a ggravates, only one hypoglycaemic episode should 
be reported reflecting the most  severe degr ee of hy pogly caemia.
!Date and time of last trial product administration, and for selected anti-diabetic medications 
administered prior to the episode, date and time as well as dose must also be collected.
!Date and time of last main meal (not including snacks) prior to the episode.
!Whether the episode occurred in relation to physical activity.
!Change in any concomitant illness.
!Any sign of fever and/or other acute disease.
!Whether the subject was asleep when the episode occurred.
– If yes, whether the symptoms of the episode woke up the subject.
The answer to the question: "Was the subject able to treat him/herself?" must be answered "No" for 
an episode requiring assistance of another person to actively administer carbohydrate, glucagon, or CONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 53 of 125
take other corrective actions. PG concentrations may not be available during an event, but 
neurological recovery following the return of PG to normal is considered sufficient evidence that 
the event was induced by a low PG concentration42.
Oral carbohydrates must not be given if the subject is unconscious.
If the question "Was the subject able to treat him/herself?" is answered "No", the following 
information should be recorded by the subject:
!Who assisted in the treatment of the hypoglycaemic episode (i.e. medical person or non-medical 
person)?
!Where the treatment was administered (in clinic/emergency room/ hospital or other. If the 
subject was treated in clinic/emergency room/hospital, whether they were transported in an 
ambulance or not)
!Type of treatment provided by another person (i.e. oral carbohydrates, glucagon, IV glucose or 
other)
!Were symptoms alleviated after administration of treatment?
!Factors contributing to the episode (i.e. physical activity, missed meal, diet change, medication 
error (i.e. overdose, mix-up between products, incorrect use of device), other factors not listed or unknown)
!Did the subject experience seizure?
!Was the subject unconscious/comatose?
!Did the subject experience any of the following symptoms
43(layman term used in the diary is 
specified in brackets if different from the protocol term)?
– Autonomic: sweating, trembling, hunger or palpitations (rapid or irregular heart beat)
– Neuroglycopenic: confusion, drowsiness, speech difficulty, visual disturbances, odd 
behaviour, impaired balance or incoordination (reduced ability to coordinate movement)
– General malaise: headache or malaise (feeling discomfort/unease)
!Other symptoms?
The Investigator must review the diary for low SMPG values not reported as hypoglycaemic 
episodes (see Section 2for relevant visits). The subject must be questioned whether any of the low 
values were severe i.e. whether the subject was able to self-treat or not. If the subject was not able 
to self-treat, it has to be reported as a se vere hypoglycaemic episode on a hypogly caemic episode 
form.
Low SMPG values for non-severe hypoglycaemic episodes not having a hypoglycaemic episode 
form completed within 7 days since the SMPG measurement should be reported on a 
hypoglycaemic episode form with as much information as possible. Novo Nordisk will not query 
for additional data except for the start date, SMPG value and whether the subject was able to self-
treat due to decreased validity of such data44, 45.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 54 of 125
The subject must be re-trained in how to report hypoglycaemic episodes if the investigator identifies 
low SMPG values not reported as hypoglycaemic episodes.
If the hypoglycaemic episode fulfils  the criteria for an SAE, then an AE form and a safety 
information form (SIF) must also be filled in, see Section 12.
8.5 Laboratory assessments
The laboratory analyses will mainly be performed by a central laboratory. Anti-semaglutide 
antibodies, in vitroneutralising effect, IgE anti-semaglutide antibodies and PK samples will be 
analysed by a special laboratory and Novo Nordisk A/S (see Sections 8.4.8and 8.6.2 ). For some of 
the analyses related to suspicion of acute pancreatitis and hypersensitivity reactions, a local 
laboratory must be used (see appendix B ).
The handling, transportation and storage of biological samples are described in the laboratory 
manual (for central and special laboratory details see Attachment I ).
Samples will be coded in order to keep subject identity anonymous.
Laboratory samples not drawn on the day of the actual visit should preferably be drawn on another 
day within the visit window stated in the flow chart (see Section 2). Please note that a laboratory 
sample pertaining to a specific visit must always be reported to that visit.
For some of the samples drawn during the trial, subjects will be asked to attend the site visits fasting 
(fasting for blood sampling is defined in Section 8.1.2 ).
The central laboratory will provide laboratory results to the investigator on an on-going basis. 
However, anti-semaglutide antibody and semaglutide plasma concentration results will not be available to the investigator during the trial. These results will be provided to the investigator upon request after the completion of the clinical trial report (CTR).
The laboratory provides results to the trial sites in the units preferred by the trial sites while the 
results that are transferred to the trial database will always be in SI units.
The laboratory equipment may provide analyses not requested in the protocol but produced 
automatically in connection with the requested analyses according to specifications in the laboratory standard operating procedures. Such data will not be transferred to the trial database, but abnormal values will be reported to the investigator. The investigator must review all laboratory results for concomitant illnesses and AEs and report these according to Section 8.2.4and Section 12.
For Brazil only: all laboratory samples will be communicated to the investigators.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 55 of 125
Laboratory samples will be destroyed at the latest at the completion of the CTR, or according to 
local regulations, except samples obtained for antibody analysis.
8.6 Other assessments
8.6.1 Lactate
Assessment of lactate levels will be included in this trial as a biomarker for impaired cellular 
respiration (see Section 3.1.4.2 ). At selected visits (see Section 2), three samples should be drawn 
for lactate assessment at the following time points in relation to dosing of trial product: 
!pre-dose*
!25 (+/- 5) minutes post dosing
!40 (+/- 5) minutes post dosing
*Trial product can be taken from the dosepack dispensed at the previous visit or at the current visit.
Correct pre-analytical handling of these samples is extremely important to ensure valid 
results. 
The subject must be fasting for the assessment and remain fasting until the last sample has been 
taken, that is, at least 40 minutes after dosing. Also, the subject should have rested for at least 30minutes in a sitting position prior to sampling. During sampling, use of tourniquet should be 
avoided (if possible). If blood pressure measurement has been performed prior to sampling, blood should preferably be drawn from the opposite arm. 
The blood samples must be kept on ice and centrifuged within 15 minutes of collection. Further 
handling and transportation of the samples are described in the laboratory manual supplied by the 
central laboratory (see attachment I ). 
8.6.2 Pharmacokinetics
8.6.2.1 Semaglutide and SNAC plasma concentrations
Blood samples will be drawn for assessment of plasma concentration of semaglutide and SNAC at 
selected visits (see Section 2). The semaglutide concentrations will be used for population PK 
analysis.
At each of these visits, samples for semaglutide analysis will be drawn 25 minutes post dosing
(+/-5 minutes), and samples for SNAC analysis will be drawn 25 and 40 min post dosing
(+/-5 minutes). CONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 56 of 125
The date and time of the latest trial product administration prior to the PK sampling must be 
recorded and transcribed into the eCRF.
The exact date and time for sampling the blood for PK analysis must be recorded on the lab 
requisition form.
Blood samples for PK assessments must be collected, handled and shipped according to the 
description in the laboratory manual supplied by the central laboratory (see attachment I) .
The PK responsible laboratory will be provided with the randomisation list and only samples from 
subjects treated with oral semaglutide will be analysed for semaglutide and SNAC plasma concentrations. However, at V4, 10% of the samples from subjects receiving empagliflozin will also 
be analysed for semaglutide and SNAC plasma concentrations for compliance evaluation. If any of 
the samples show values higher than the lower limit of quantification (LLoQ), the full range of collected samples from that subject will be analysed.
Semaglutide PK and SNAK PK samples will be stored at the specialised laboratory until final CTR 
in case Novo Nordisk requests further analysis of the PK samples.
8.6.3 Subject diary
The diaries should be handed out at the visits described in the flow chart Section 2. The recordings 
must be reviewed as described in Section 8.1.7 and transcribed to the eCRF at the following visit.
Entries in the diaries are only to be made by the subject, unless otherwise specified.
The investigator should instruct the subject in recording the following data in the diary:
!date of first trial product administration
!hypoglycaemic episodes
!changes in concomitant medication
!AEs
!SMPG 7-point profile
8.7 Subject compliance
Throughout the trial, the investigator will remind the subjects to follow the trial procedures and 
requirements to ensure subject compliance. 
Treatment compliance: Will be assessed by monitoring of drug accountability. Prior to visits 
where drug accountability is performed, the subject will be asked to return all used, partly used and
unused trial products. The investigator must assess the amount of trial products returned compared 
to what was dispensed at the last dispensing visit and, in case of discrepancies, question the subject.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 57 of 125
If a subject is found to be non-compliant, the investigator will remind the subject of the importance 
of following the instructions given including taking the trial products as prescribed and should 
document this discussion in the subject’s medical record.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 58 of 125
9 Trial supplies
Trial supplies comprise trial products and auxiliary supplies. Additional details regarding trial 
supplies can be found in the Trial Materials Manual (TMM). 
Trial products must not be dispensed to any person not included in the trial. 
9.1 Trial products
The following trial products are considered as investigational medicinal products and will be 
provided by Novo Nordisk A/S, Denmark:
Table 9–1 Investigational medicinal products
Trial product Strength Dosage formRoute of 
administrationContainer/
delivery device 
Semaglutide 3 mg tablet3 mg
Tablet Oral Blister carda Semaglutide 7 mg tablet7 mg
Semaglutide 14 mg tablet14 mg
Empagliflozin 10 mg tablet 10 mg Tablet Oral Blister cardb
Empagliflozin  25 mg tablet 25 mg
aOne dosepack contains one blister card with 7 tablets
bOne dosepack contains one blister card with 10 tablets
Metformin and rescue medication are considered non-investigational medicinal products and will 
not be supplied by Novo Nordisk. However, metformin will be reimbursed if required by the 
country’s regulatory authority or institutional review board (IRB)/independent ethics committee 
(IEC). 
 
9.2 Labelling
The trial products will be labelled in accordance with Annex 1346, local regulations and trial 
requirements.
Each trial site will be supplied with sufficient trial product for the trial on an on-going basis 
controlled by the IWRS. Trial products will be distributed to the trial sites according to enrolment 
and randomisation.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 59 of 125
9.3 Storage 
Storage conditions of the trial products are outlined in Table 9–2 .
Table 9–2 Storage conditions for investigational medicinal products
The investigator must ensure that trial product is kept under proper storage conditions, and record 
and evaluate the temperature. The investigator must inform Novo Nordisk immediately if any trial 
product has been stored outside specified conditions (e.g. outside temperature range). Additional 
details regarding handling of temperature deviations can be found in the TMM.
Trial product that has been stored improperly must not be dispensed to any subject before it has 
been evaluated and approved for further use by Novo Nordisk. The investigator must take 
appropriate action to ensure correct storage.
9.4 Drug accountability and destruction
Drug accountability of all trial products received at site is the responsibility of the investigator.
Subjects must be instructed to return all used, partly used and unused trial products including empty 
packaging material at each dispensing visit.
Returned trial product (used/partly used and/or unused) expired or damaged trial product can be 
stored at room temperature and must be stored separately from non-allocated trial product. Non-Trial productStorage conditions
(not-in-use)In-use conditions
Semaglutide 3 mg tablet Do not store above 30ºC (86ºF)
Do not refrigerateDo not freezeStore in the original packageTake the tablet 
immediately after 
dispensation from 
blister card
Take the tablets whole: 
Do not break or chewSemaglutide 7 mg tablet
Semaglutide 14 mg tablet
Empagliflozin 10 mg tablet EU: store below 25°C
US: store between 59°F – 77°F
Do not refrigerate
Do not freeze
Store in the original packageTake the tablet 
immediately after 
dispensation from
blister card
Empagliflozin  25 mg tabletCONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 60 of 125
allocated trial product including expired or damaged products must be accounted for at the latest at 
closure of trial site.
Drug accountability is performed by using the IWRS. Drug accountability must be done on tablet 
level.
Destruction of trial products can be performed on an on-going basis and will be done according to 
local procedures after accountability is finalised and reconciled by the monitor .Destruction of 
products must be documented in the IWRS.
9.5 Auxiliary supplies
The following will be provided by Novo Nordisk A/S in accordance with the TMM:
• BG meter and BG meter auxiliaries CONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 61 of 125
10 Interactive voice/web response system
A trial-specific IWRS will be set up which can be accessed at any time via the internet or telephone. 
Access to the IWRS must be restricted to and controlled by authorised persons. 
IWRS is used for: 
!Screening
!Screening failure
!Randomisation
!Medication arrival
!Dispensing
!Treatment discontinuation
!Completion
!Drug accountability
!Data change
IWRS user manuals will be provided to each trial site. DUNs will be allocated using the IWRS. It is 
important to dispense the exact allocated DUNs to a subject.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 62 of 125
11 Randomisation procedure
The trial is an open-label trial. A randomisation session will be carried out for all subjects using the
IWRS. 
At the randomisation visit (V2), subjects meeting all eligibility criteria will be randomised to one of 
two treatment arms as described in Section 5.1.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 63 of 125
12 Adverse events, technical complaints and pregnancies
12.1 Definitions
12.1.1 Adverse event 
An adverse event (AE) is any untoward medical occurrence in a subject administered a medicinal 
product, and which does not necessarily have a causal relationship with this treatment. 
An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory 
finding), symptom or disease temporally associated with the use of a product, whether or not 
considered related to the product. 
An AE includes:
!A clinically significant worsening of a concomitant illness.
!A CLAE: a clinical laboratory abnormality which is clinically significant, i.e. an abnormality 
that suggests a disease and/or organ toxicity and is of a severity that requires active 
management. Active management includes active treatment or further investigations, for 
example change of medicine dose or more frequent follow-up due to the abnormality.
The following should notbe reported as AEs:
!Pre-existing conditions, including those found as a result of screening or other trial procedures
performed before exposure to trial product (pre-existing conditions should be reported as 
medical history or concomitant illness).
!Pre-planned procedures unless the condition for which the procedure was planned has worsened 
from the first trial related activity after the subject has signed the informed consent.
!Non-serious hypoglycaemia is an AE, but is reported on a hypoglycaemic episode form instead 
of on an AE form, see Section 8.4.9 .
The following three definitions are used when assessing an AE:
!Severity 
–Mild - no or transient symptoms, no interference with the subject’s daily activities.
–Moderate - marked symptoms, moderate interference with the subject’s daily activities.
–Severe - considerable interference with the subject’s daily activities; unacceptable.
!Causality 
Relationship between an AE and the relevant trial product(s): 
–Probable - Good reason and sufficient documentation to assume a causal relationship.
–Possible - A causal relationship is conceivable and cannot be dismissed.
–Unlikely - The event is most likely related to aetiology other than the trial product.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 64 of 125
!Final outcome
–Recovered/resolved - The subject has fully recovered, or by medical or surgical treatment 
the condition has returned to the level observed at the first trial-related activity after the 
subject signed the informed consent.
–Recovering/resolving - The condition is improving and the subject is expected to recover 
from the event. This term is only applicable if the subject has completed the trial or has died 
from another AE.
–Recovered/resolved with sequelae - The subject has recovered from the condition, but 
with lasting effect due to a disease, injury, treatment or procedure. If a sequela meets an 
SAE criterion, the AE must be reported as an SAE.
–Not recovered/not resolved - The condition of the subject has not improved and the 
symptoms are unchanged, or the outcome is not known.
–Fatal - This term is only applicable if the subject died from a condition related to the 
reported AE. Outcomes of other reported AEs in a subject before he/she died should be 
assessed as “recovered/resolved”, “recovering/resolving”, “recovered/resolved with 
sequelae” or “not recovered/not resolved”. An AE with fatal outcome must be reported as 
an SAE.
–Unknown - This term is only applicable if the subject is lost to follow-up.
12.1.2 Serious adverse event
An SAE is an experience that at any dose results in any of the following:
!Death.
!A life-threateningaexperience.
!In-patient hospitalisationbor prolongation of existing hospitalisation.
!A persistent or significant disability or incapacityc.
!A congenital anomaly or birth defect.
!Important medical events that may not result in death, be life threateninga or require 
hospitalisationbmay be considered an SAE when - based on appropriate medical judgement -
they may jeopardise the subject and may require medical or surgical intervention to prevent one 
of the outcomes listed in the definition of SAEd. 
a. The term “life threatening” in the definition of SAE refers to an event in which the subject was 
at risk of death at the time of the event. It does not refer to an event which hypothetically might 
have caused death if it was more severe.
b. The term “hospitalisation” is used when a subject: 
– Is admitted to a hospital or in-patient, irrespective of the duration of physical stay, or 
– Stays at the hospital for treatment or observation for more than 24 hoursCONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 65 of 125
Medical judgement must always be exercised, and when in doubt, the hospital contact should be 
regarded as a hospitalisation. Hospitalisations for administrative, trial related and social 
purposes do not constitute AEs and should therefore not be reported as AEs or SAEs. Hospital 
admissions for surgical procedures, planned before trial inclusion, are not considered AEs or 
SAEs.
c. A substantial disruption of a subject’s ability to conduct normal life functions (e.g. following the 
event or clinical investigation the subject has significant, persistent or permanent change, 
impairment, damage or disruption in his/her body function or structure, physical activity and/or 
quality of life).
d. For example intensive treatment in an emergency room or at home of allergic bronchospasm, 
blood dyscrasia or convulsions that do not result in hospitalisation, or development of drug 
dependency or drug abuse.
The following AEs must always be reported as an SAE using the important medical event criteria if 
no other seriousness criteria are applicable:
!suspicion of transmission of infectious agents via the trial product
!risk of liver injury defined as ALT or AST > 3 x UNL and total bilirubin > 2 x UNL, where no 
alternative aetiology exists (Hy's law).
Additional assessments should be made for events meeting the criterion of Hy’s law as stated above
(see appendix B ). 
12.1.3 Non-serious adverse event
A non-serious AE is any AE which does not fulfil the definition of an SAE.
12.1.4 Medication errors
A medication error concerning trial products is defined as:
!Administration of wrong drug. 
Note: Use of wrong DUN is not considered a medication error unless it results in administration of wrong drug
!Wrong route of administration.
!Administration of an overdose with the intention to cause harm (e.g. suicide attempt), misuse or 
abuse of trial product
!Accidental administration of a higher dose than intended. A higher dose is a dose of at least one 
tablet more than the intended dose; however, the administered dose must deviate from the 
intended dose to an extent where clinical consequences for the trial subject were likely to 
happen as judged by the investigator, although they did not necessarily occur.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 66 of 125
Medication errors must be reported on an AE form and a specific event form, see Section 8.4.1.1 , 
12.1.5 and appendix B .
12.1.5 Adverse events requiring additional data collection
AEs requiring additional data collection are AEs where the additional data will benefit the 
evaluation of the product safety. A number of AEs that always require additional data collection 
have been pre-specified. See appendix B for details about these events and the additional 
information to report.
Some events in this trial will be adjudicated by an independent external committee as described in 
Section 12.7.2 .
Table 12–1 lists AEs that require completion of specific event forms in the eCRFs and/or are 
subject to event adjudication.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 67 of 125
Table 12–1 Adverse events requiring completion of specific event forms and/or are subject 
to event adjudication
Event Specific event form Event adjudication
Death No Yes
Acute coronary syndrome (MI or hospitalisation for 
unstable angina)Yes Yes
Cerebrovascular event (stroke or transient ischaemic 
attack [TIA])Yes Yes
Heart failure YesYes (only if requiring 
hospitalisation)
Pancreatitis Yes Yes (only if acute pancreatitis)
Neoplasm (excluding thyroid neoplasm) Yes Yes (only if malignant)
Thyroid disease (including thyroid neoplasm) YesYes (only if malignant thyroid 
neoplasm or C-cell hyperplasia)
Renal event Yes Yes (only if acute kidney injury)
Hypersensitivity reaction Yes No
Acute gallstone disease Yes No
Medication error Yes No
Lactic acidosis Yes Yes
CK > 10x UNL Yes No
Hepatic event defined as:
ALT or AST > 5x UNL and total bilirubin ≤ 2x UNL
ALT or AST > 3x UNL and total bilirubin > 2x UNL*
Hepatic event leading to trial product discontinuation.Yes No
*Please note that in case of a hepatic event defined as ALT or AST > 3 x UNL and total bilirubin > 2 x UNL, where no 
alternative aetiology exists (Hy's law), this must be reported as an SAE using the important medical event criterion if no 
other seriousness criteria are applicable.
For details about specific event forms, see Sections 8.4.1.2 , 12.2 and appendix B .
12.1.6 Technical complaints
A technical complaint is any written, electronic, or oral communication that alleges product 
(medicine or device) defects. The technical complaint may be associated with an AE, but does not 
concern the AE itself.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 68 of 125
Examples of technical complaints:
!The physical or chemical appearance of trial products (e.g. discoloration, particles or 
contamination)
!All packaging material including labelling
Only technical complaints related to adverse events will be reported in the clinical trial report.
12.2 Reporting of adverse events
All events meeting the definition of an AE must be collected and reported. This includes events 
occurring from the first trial-related activity after the subject has signed the informed consent until 
the end of the post-treatment follow-up period (V13) for subjects on trial product or until the end of 
trial (V12 or V13A, whichever comes last) for the subjects who have discontinued trial product 
prematurely. Events for withdrawn subjects will be collected and reported until last trial related 
contact with the subject. The events must be recorded in the applicable eCRF forms in a timely 
manner, see timelines below and Figure 12–1 .
During each contact with the trial site staff, the subject must be asked about AEs and technical 
complaints, for example by asking: “Have you experienced any problems since the last contact?”
All AEs, either observed by the investigator or subject, must be reported by the investigator and 
evaluated. 
All AEs must be recorded by the investigator on an AE form. The investigator should report the 
diagnosis, if available. If no diagnosis is available, the investigator should record each sign and 
symptom as individual AEs using separate AE forms.
For SAEs, a safety information form (SIF) must be completed in addition to the AE form. A SIF is 
a form to collect supplementary clinical information. If several symptoms or diagnoses occur as part 
of the same clinical picture, one SIF can be used to describe all the SAEs. 
AEs requiring additional data collection must be reported using both the AE form and the specific 
event form. A specific event form is a form tailored to collect specific information related to the 
individual event. See appendix B for details about the events and the additional information to 
report.
In case any of the above events fulfil the criteria for seriousness in Section 12.1, then the event 
should be reported as serious.
Some events will undergo event adjudication by the EAC, please refer to Section 12.7.2 . For AEs 
qualifying for event adjudication, the adjudication form will also have to be completed in the eCRF. 
The adjudication form is a checklist of clinical data to be provided from the site.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 69 of 125
For all non-serious AEs, the applicable forms should be signed when the event is resolved or at the 
end of the trial at the latest. 
Timelines for initial reporting of AEs:
The investigator must complete the following forms in the eCRF within the specified timelines:
!SAEs : The AE form within 24 hours and the SIF within 5 calendar days of the investigator's 
first knowledge of the SAE.
Both forms must be signed within 7 calendar days from the date the information was entered in 
the eCRF. 
For SAEs requiring reporting on a specific event form : In addition to the above, the specific 
event form within 14 calendar days from the investigator’s first knowledge of the AE.
Events for adjudication : adjudication form should be completed within 14 calendar days of the 
investigator’s first knowledge of the AE, see Section 12.7.2 . The investigator should preferably 
provide the medical documentation within 4 weeks of event identification according to 
instructions in the event adjudication site manual.
If the eCRF is unavailable, the concerned AE information must be reported on a paper AE form and 
sent to Novo Nordisk by fax, e-mail or courier within the same timelines as stated above. When the 
eCRF becomes available again, the investigator must enter the information on the form into the 
eCRF.
Contact details (fax, telephone, e-mail and address) are provided in the investigator trial master file.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 70 of 125
AE identifiedDoes the AE require 
a sp ecific even t 
form?Is the  AE  subject to 
adjudica tion and/or 
is  the outcome 
fatal?
AE  form < 24 hours
SIF < 5 calendar days
Specific event form  
For SAEs:
< 14 calendar days
Is the AE serious or 
non-serious?
AE form
Adjudication form
< 14 calendar da ys
Source data < 4 weeks
Non-seriousSerious
NoYes Yes
Queries and follow-up 
requests to be resolved 
< 14 calendar da ys
Timelines are for the completion of forms from the time of investigator’s awareness.
AEs requiring specific event forms are described in Section 12.1.4, 12.1.5 and appendix B.
AEs  for adjudi ca tion are de scribed i n Secti on 12.7.2
AE: Adverse event  SAE: Serious adverse event  SIF: Safety Information form 
No additional action
 No additional actionNo
Figure 12–1 Reporting of AEs
Novo Nordisk assessment of AE expectedness: 
Novo Nordisk assessment of expectedness is performed according to the following reference 
documents: IB for oral Semaglutide (NN9924)24and Jardiance® (empagliflozin) SmPC and 
prescribing information25, 26; current version and any updates thereto.
Reporting of trial product-related SUSARs by Novo Nordisk:
Novo Nordisk will notify the investigator of trial product-related suspected unexpected serious 
adverse reactions (SUSARs) in accordance with local requirements and ICH GCP1. In addition, the 
investigator will be informed of any trial-related SAEs that may warrant a change in any trial procedure.
In accordance with regulatory requirements, Novo Nordisk will inform the regulatory authorities, 
including European Medicines Agency, of trial product-related SUSARs. In addition, Novo Nordisk 
will inform the IRBs/IECs of trial product-related SUSARs in accordance with local requirement 
and ICH GCP
1, unless locally this is an obligation of the investigator.
Novo Nordisk products used as concomitant medication:
If an AE is considered to have a causal relationship with a Novo Nordisk marketed product used as 
concomitant medication in the trial, it is important that the suspected relationship is reported to 
Novo Nordisk, e.g. in the alternative aetiology section on the SIF. Novo Nordisk may need to report 
this AE to relevant regulatory authorities.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 71 of 125
12.3 Follow-up of adverse events
The investigator must record follow-up information by updating the medical records and the forms 
in the eCRF.
Follow-up information must be reported to Novo Nordisk according to the following:
!SAEs : All SAEs must be followed until the outcome of the event is “recovered/resolved”, 
“recovered/resolved with sequelae” or “fatal”, and until all queries have been resolved. Cases of 
chronic conditions, cancer or AEs ongoing at time of death (where death is due to another AE) 
may be closed with the outcome “recovering/resolving” or “not recovered/not resolved”. Cases 
can be closed with the outcome of “recovering/resolving” when the subject has completed the 
follow-up period and is expected by the investigator to recover.
The SAE follow-up information should only include new (e.g. corrections or additional) 
information and must be reported within 24 hours of the investigator’s first knowledge of the 
information. This is also the case for previously non-serious AEs which subsequently become 
SAEs.
!Non-serious AEs : Non-serious AEs must be followed until the outcome of the event is 
“recovering/resolving”, “recovered/resolved” or “recovered/resolved with sequelae” or until the 
end of the follow-up period stated in the protocol, whichever comes first, and until all queries 
related to these AEs have been resolved. Cases of chronic conditions, cancer or AEs ongoing at 
time of death (where death is due to another AE) may be closed with the outcome 
“recovering/resolving” or “not recovered/not resolved”. Cases can be closed with the outcome 
of “recovering/resolving” when the subject has completed the follow-up period and is expected 
by the investigator to recover.
The investigator must ensure that the recording of the worst case severity and seriousness of an 
event is kept throughout the trial. A worsening of an unresolved AE must be reported as follow up 
with re-assessment of severity and/or seriousness of the event.
Queries or follow-up requests from Novo Nordisk must be responded to within 14 calendar days
from the date of receipt of the request, unless otherwise specified in the follow-up request.
SAEs after end of trial: If the investigator becomes aware of an SAE with a suspected causal 
relationship to the investigational medicinal product occurring to a subject after the subject has 
ended the trial, the investigator should report this SAE within the same timelines as for SAEs 
during the trial.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 72 of 125
12.4 Technical complaints and technical complaint samples
12.4.1 Reporting of technical complaints
All technical complaints on any of the following products: 
!semaglutide 3 mg tablets
!semaglutide 7 mg tablets
!semaglutide 14 mg tablets
!empagliflozin 10 mg tablets
!empagliflozin 25 mg tablets
which occur from the time of first usage of the product until the time of the last usage of the 
product, must be collected and reported to Customer Complaint Center, Novo Nordisk.
Contact details (fax, e-mail and address) are provided in Attachment I to the protocol. The 
investigator must assess whether the technical complaint is related to any AEs or SAEs.
Technical complaints must be reported on a separate technical complaint form: 
!One technical complaint form must be completed for each affected DUN
!If DUN is not available, a technical complaint form for each batch number must be completed.
The investigator must complete the technical complaint form in the eCRF within the following 
timelines of the trial site obtaining knowledge of the technical complaint:
!Technical complaint assessed as related to an SAE within 24 hours
!All other technical complaints within 5 calendar days
If the eCRF is unavailable or when reporting a technical complaint that is not subject related, the 
information must be provided on a paper form by fax, e-mail or courier to Customer Complaint 
Center, Novo Nordisk, within the same timelines as stated above. When the eCRF becomes 
available again, the investigator must enter the information on the technical complaint form in the 
eCRF.
12.4.2 Collection, storage and shipment of technical complaint samples
The investigator must collect the technical complaint sample and notify the monitor within 5 
calendar days of obtaining the sample at trial site. The monitor must coordinate the shipment to 
Customer Complaint Center, Novo Nordisk (the address is provided in Attachment I ) and ensure 
that the sample is sent as soon as possible. A copy of the technical complaint form must be included 
in the shipment of the sample.If several samples are returned in one shipment, the individual 
sample and the corresponding technical complaint form must be clearly separated.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 73 of 125
The investigator must ensure that the technical complaint sample contains the batch number and, if 
available, the DUN. All parts of the DUN should be returned.
If the technical complaint sample is unobtainable, the investigator must specify on the technical 
complaint form why it is unobtainable. 
Storage of the technical complaint sample must be done in accordance with the conditions 
prescribed for the product. 
12.5 Pregnancies
12.5.1 Pregnancies in female subjects
Female subjects must be instructed to notify the investigator immediately if they become pregnant 
during the trial. The investigator must report any pregnancy in subjects who have received trial 
product(s).
The investigator must follow the pregnancy until the pregnancy outcome and the newborn infant is 
one month of age .
The investigator must report information about the pregnancy, pregnancy outcome, and health of 
the newborn infant(s), as well as AEs in connection with the pregnancy, and AEs in the foetus and 
newborn infant .
The following must be collected and reported by the investigator to Novo Nordisk - electronically 
(e.g. in PDF format), or by fax or courier :
1. Reporting of pregnancy information
Information about the pregnancy and pregnancy outcome/health of the newborn infant(s) has to 
be reported on Maternal Form 1A and 1B, respectively. 
When the pregnancy outcome is abnormal (i.e. congenital anomalies, foetal death including 
spontaneous abortion and/or any anomalies of the foetus observed at gross examination or 
during autopsy), and/or when a congenital anomaly is diagnosed within the first month, further 
information has to be reported for the female subject on Maternal Form 2. In addition, 
information from the male partner has to be reported on the Paternal Form, after an informed 
consent has been obtained from the male partner. 
Initial reporting and follow-up information must be reported within 14 calendar days of the 
investigator’s first knowledge of initial or follow-up information. CONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 74 of 125
2. Reporting of AE information
The investigator has to report AEs in connection with the pregnancy as well as in the foetus and 
newborn infant(s). The SAEs that must be reported include abnormal outcome, such as foetal 
death (including spontaneous abortion), and congenital anomalies (including those observed at 
gross examination or during autopsy of the foetus), as well as other pregnancy complications 
fulfilling the criteria of an SAE.
Forms and timelines for reporting AEs:
Non-serious AEs: 
– AE formawithin 14 calendar days of the investigator's first knowledge of the initial or 
follow-up information to the non-serious AE.
SAEs: 
– AE formawithin 24 hours of the investigator's first knowledge of the SAE.
– safety information form within 5 calendar days of the investigator's first knowledge of the 
SAE.
–SAE follow-up information to the AE form and/or safety information form within 24 
hours of the investigator's first knowledge of the follow-up information.
aIt must be clearly stated in the AE diagnosis field on the AE form if the event occurred in 
the subject, foetus or newborn infant. If the AE occurred in the foetus or newborn infant, the 
AE can only be reported on paper AE and safety information form.
Any queries or follow-up requests from Novo Nordisk to non-serious AEs, SAEs and pregnancy 
forms must be responded to by the investigator within 14 calendar days from the date of receipt of 
the request, unless otherwise specified in the follow-up request .
12.6 Precautions and/or overdose
There are no specific antidotes to semaglutide. Treatment of an overdose should be symptomatic.
There is a potential risk of hypoglycaemia during dosing with semaglutide. The typical signs and 
symptoms of a non-severe hypoglycaemia include: hunger, slight headache, nausea, light-
headedness, palpitations and sweating. Symptoms  of non-severe hypogl ycaemia should be treated 
by ingestion of carbohydrates. 
Severe hypoglycaemia resulting in  loss of consciousness should be treated according to best 
available medical practise. 
One case of accidental overdose of oral semaglutide was reported in the NN9924-3692 trial. The 
subject accidentally took the trial product  day and was thus treated with 20 mg of CONFIDENTIAL
PPI
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 75 of 125
oral semaglutide. The subject did not report any symptoms and treatment was continued without 
any change. 
One case of accidental overdose has been reported in subjects treated with s.c. semaglutide once 
weekly. The subject inadvertently injected  mg of semaglutide instead of 0.4 mg, which 
corresponds to a -fold higher dose than the maximum dose included in that trial. After  hours 
the subject felt nauseated, vomited and had a headache. The subject was instructed to drink 
sufficient amounts of fluids.  and the subject 
wished to continue in the trial. No symptoms  of hypoglycaemia or  any other symptoms or signs 
were noted.  
For further details please see the current edition of the IB for oral administration of semaglutide 
(NN9924), edition 624, and any updates hereof.
12.7 Committees related to safety
12.7.1 Novo Nordisk safety committee
Novo Nordisk will constitute an internal oral semaglutide safety committee to perform ongoing 
safety surveillance.
12.7.2 Event adjudication committee
An independent external event adjudication committee (EAC) is established to perform validation 
of selected AEs according to pre-defined diagnostic criteria. The validation is based on review of 
pre-defined clinical data related to the specific AE. Pre-defined clinical data consist of copies of 
source documents collected and delivered by the investigational sites.
The EAC is composed of permanent members covering required medical specialities. EAC 
members must disclose any potential conflicts of interest and must be independent of Novo 
Nordisk . 
The events are reviewed by the EAC in a blinded manner. The EAC will have no authorisations to 
impact on trial conduct, trial protocol or amendments.
The EAC works in accordance with written guidelines included in the EAC Charter describing in 
details the composition, tasks, responsibilities and work processes of the committee.
The events outlined in Table 12–2 have been selected for adjudication in order to obtain an external 
independent validation of the diagnosis. In addition, cardiovascular events are being adjudicated 
according to U.S. Food and Drug Administration (FDA) requirements47.CONFIDENTIAL
PPIPPI PPIPPI
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 76 of 125
The EAC will review copies in English (translated if necessary) of medical documentation received 
in the adjudication packages (e.g. x-ray, ECGs, ultrasound images, discharge summaries, pathology 
reports and death certificates). The investigator must provide medical documentation as soon as 
possible, when they receive the request from Novo Nordisk or the event adjudication vendor.
The AEs for adjudication are listed in Table 12–2 :
Table 12–2 Adverse events for adjudication
Events Description Adjudication outcome
Death !All-cause death !Cardiovascular death 
(including undetermined 
cause of death)
!Non-Cardiovascular death
Acute Coronary Syndrome Acute Coronary Syndrome conditions include: 
!ST-elevation acute myocardial infarction 
(STEMI)
!Non-ST elevation acute myocardial infarction 
(NSTEMI)
!Silent MI 
!Unstable angina pectoris!Acute MI (STEMI or 
NSTEMI), silent MI
!Unstable angina pectoris 
requiring hospitalisation
Cerebrovascular event !Episode of focal or global neurological 
dysfunction caused by brain, spinal cord, or 
retinal vascular injury as a result of 
haemorrhage or infarction
!Transient ischaemic attack is defined as a 
transient episode (< 24 hours) of focal neurological dysfunction caused by brain, spinal cord, or retinal ischaemia, without acute infarction!Ischaemic stroke
!Haemorrhagic stroke
!Undetermined stroke
!Transient ischaemic 
attack 
Heart failure requiring 
hospitalisation!Hospitalisation with a primary diagnosis of 
heart failure (new episode or worsening of 
existing heart failure)!Heart failure requiring 
hospitalisation
Acute pancreatitis The diagnosis of acute pancreatitis requires two of 
the following three features:
!Abdominal pain consistent with acute 
pancreatitis (acute onset of a persistent, severe, epigastric pain often radiating to the 
back)
!Serum lipase activity (and/or amylase activity) 
at least three times greater than the UNL
!Characteristic findings of acute pancreatitis on 
imagingAcute pancreatitis
!Mild
!Moderately severe
!Severe
Malignant neoplasm Malignant neoplasms are defined as
!neoplasms in which abnormal cells divide 
without control and can invade nearby tissues 
and/or spread to other parts of the body through 
the blood and lymph systems
Thyroid neoplasms are excluded in this event !Malignant neoplasmCONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 77 of 125
category
Thyroid disease, if malignant 
thyroid neoplasm or C-cell 
hyperplasiaMalignant thyroid neoplasms are defined as 
!thyroid neoplasms in which abnormal cells 
divide without control and can invade nearby 
tissues and/or spread to other parts of the body 
through the blood and lymph systems
!C-cell hyperplasia, defined as hyperplasia of the 
parafollicular C-cells of the thyroid gland!Malignant thyroid 
neoplasm
!C-cell hyperplasia
Acute kidney injury Acute kidney injury48is defined as any of the 
following (not graded):
!Increase in serum creatinine by ≥ 0.3 mg/dL 
(≥ 26.5 μmol/L) within 48 hours, or
!Increase in serum creatinine to ≥ 1.5 times 
baseline, which is known or presumed to have occurred within the prior 7 days, or
!Urine volume < 0.5 mL/kg/h for 6 hours!Acute kidney injury
Lactic acidosis !Lactic acidosis is characterized by increased 
blood lactate level in association with 
metabolic acidosis!Lactic acidosis
*Death is not a separate event, but an outcome
There are different processes for capturing events for adjudication:
!Direct reporting by investigator:
– All AEs need to be assessed by the investigator if any AE category is applicable. If the AE 
category selected is in scope for adjudication, the event specific adjudication form in the 
eCRF will be populated for sites to complete.
– AEs with fatal outcome.
!Screening: 
– All AEs will be screened by Novo Nordisk for potential missed events for adjudication and 
if needed, the investigator will be asked to provide additional information such as an 
alternative aetiology, underlying cause(s) and/or clinical details.
– All ECGs will be centrally read. If the central reading conclusion is suggestive of new MI, 
the ECG adjudication form will be populated for sites to complete for all post-baseline 
ECGs.
!EAC identified events:
– The EAC can decide to have an AE adjudicated even if not initially reported as an event for 
adjudication by the investigator.
Event adjudication will be performed for AEs in randomised subjects including AEs with an onset 
date during the screening period. Event adjudication will not be performed for AEs in screening 
failures.
AEs for adjudication must be reported according to Section 12.2. In addition, the specific
adjudication form should be completed within 14 calendar days of the investigator’s first CONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 78 of 125
knowledge of the AE and all relevant predefined documents provided within 4 weeks according to 
instructions in the event adjudication site manual.
The assessment made by the EAC will be included in the clinical trial report as well as the 
assessments made by the investigator. However, the adjudication made by an EAC, given its 
independent analysis of each event, will be attributed with greater importance of the two.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 79 of 125
13 Case report forms 
Novo Nordisk will provide a system for the eCRF. This system and support services to the system 
will be provided by an external supplier.
Ensure that all relevant questions are answered and that no empty data field exists. If a test or an 
assessment has not been done and will not be available, or if the question is irrelevant (e.g. is not 
applicable), indicate this according to the data entry instructions.
The following will be provided as paper case report forms (CRF):
!Pregnancy forms
The following will be provided as paper CRFs to be used when access to the eCRF is revoked or if 
the eCRF is unavailable:
!AE forms 
!SIFs
!Technical complaint forms (also to be used to report complaints that are not subject related (e.g. 
discovered at trial site before allocation)).
On the paper CRF forms print legibly, using a ballpoint pen. Ensure that all questions are answered 
and that no empty data blocks exist. Ensure that no information is recorded outside the data blocks. If a test/assessment has not been done and will not be available, indicate this by writing "ND" (not 
done) in the appropriate answer field in the CRF. If the question is irrelevant (e.g. is not applicable) 
indicate this by writing "NA" (not applicable) in the appropriate answer field. Further guidance can 
be obtained from the instructions in the CRF.
The investigator must ensure that all information is consistent with the source documentation. By 
electronically signing the case book in the eCRF, the investigator confirms that the information in 
the eCRF and related forms is complete and correct.
13.1 Corrections to case report forms 
Corrections to the eCRF data may be made by the investigator or the investigator's delegated staff.
An audit trail will be maintained in the eCRF application containing as a minimum: the old and the 
new data, identification of the person entering the data, date and time of the entry and reason for the 
correction. If corrections are made by the investigator's delegated staff after the date the investigator 
has signed the case book, the case book must be signed and dated again by the investigator .
13.2 Case report form flow 
The investigator must ensure that data is recorded in the eCRF as soon as possible, preferably 
within 5 days after the visit. Once data has been entered, it will be available to Novo Nordisk for 
data verification and validation purposes.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 80 of 125
At the end of the trial, the investigator must ensure that all remaining data have been entered into 
the eCRF no later than 3 days after last subject last visit (LSLV) at the site in order to ensure the 
planned lock of the database.
Site specific eCRF data (in an electronic readable format) will be provided to the trial site before 
access to the eCRF is revoked. This data must be retained at the trial site .When the final CTR is 
available, the data will be archived by Novo Nordisk.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 81 of 125
14 Monitoring procedures 
Monitoring will be conducted under a risk based approach.
During the course of the trial, the monitor will visit the trial site to ensure that the protocol is 
adhered to, that all issues have been recorded, to perform source data verification and to monitor 
drug accountability. The first monitoring visit will be performed as soon as possible after FSFV at 
the trial site and no later than 4 weeks after. The monitoring visit intervals will depend on the 
outcome of the remote monitoring of the eCRFs, the trial site's recruitment rate and the compliance 
of the trial site to the protocol and GCP, but will not exceed 12 weeks until LSLV at the trial site 
(for trial sites with active subjects (defined as subjects in screening, treatment or follow-up)).
The monitor must be given direct access to all source documents (original documents, data and 
records). Direct access includes permission to examine, analyse, verify and reproduce any record(s) 
and report(s) that are important to the evaluation of the trial. If the electronic medical record does 
not have a visible audit trail, the investigator must provide the monitor with signed and dated 
printouts. In addition the relevant trial site staff should be available for discussions at monitoring 
visits and between monitoring visits (e.g. by telephone).
All data must be verifiable in source documentation other than the eCRF.
For all data recorded the source document must be defined in a source document agreement at each 
trial site. There must only be one source defined at any time for any data element.
Source data generated by the trial site can be corrected by another person than the person entering 
the source data if accepted by local regulations; any correction must be explained, signed and dated 
by the person making the correction.
The original of the completed diaries and/or PROs must not be removed from the trial site, unless 
they form part of the eCRF and a copy is kept at the site.
The monitor will ensure that the eCRFs are completed and that paper CRFs are collected.
The following data will be source data verified for screening failures:
!Date for obtaining informed consent.
!Reason for screening failure
Monitors will review the subject’s medical records and other source data (e.g. the diaries and PROs) 
to ensure consistency and/or identify omissions compared to the eCRF. If discrepancies are found, 
the investigator must be questioned about these.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 82 of 125
A follow-up letter (paper or electronic) will be sent to the investigator following each monitoring 
visit. This should address any action to be taken.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 83 of 125
15 Data management
Data management is the responsibility of Novo Nordisk. Data management may be delegated under 
an agreement of transfer of responsibilities to a Contract Research Organisation. 
Appropriate measures, including encryption of data files containing person identifiable data, will be 
used to ensure confidentiality of subject data, when they are transmitted over open networks. 
Data from central laboratories will be transferred electronically. In cases where data is transferred 
via non-secure electronic networks, data will be encrypted during transfer.
The subject and any biological material obtained from the subject will be identified by subject 
number and trial ID. Appropriate measures such as encryption or leaving out certain identifiers will 
be enforced to protect the identity  of subjects in all presentations and publications as required by 
local, regional and national requirements.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 84 of 125
16 Computerised systems
Novo Nordisk will capture and process clinical data using computerised systems that are described 
in Novo Nordisk Standard Operating Procedures and IT architecture documentation. The use and 
control of these systems are documented.
Investigators working on the trial may use their own electronic systems to capture source data. CONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 85 of 125
17 Statistical considerations
General considerations
If necessary, a statistical analysis plan (SAP) may be written in addition to the protocol, including a 
more technical and detailed elaboration of the statistical analyses. The SAP will be finalised before 
database lock.
Data from all sites will be analysed and reported together. 
The latest available measurement, at or prior to the randomisation visit, will be used as the baseline 
measurement. If no measurement(s) have been obtained, at or prior to randomisation, the baseline 
value will be left missing.
Laboratory values below the LLoQ will be set to ½LLoQ. Number of values below LLoQ by 
treatment and visit will be summarised if deemed relevant.
The primary and confirmatory efficacy endpoints will be evaluated at week 26. This approach is 
expected to result in a lower proportion of missing data, use of rescue medication and premature 
treatment discontinuation, compared to the expected proportion of missing data, use of rescue 
medication and premature treatment discontinuation at week 52, and therefore considered a 
meaningful representation and confirmation of the effect of oral semaglutide.
Results from a statistical analysis will as a minimum be presented by the estimated treatment 
contrasts for oral semaglutide 14 mg vs. empagliflozin 25 mg with associated two-sided 95% 
confidence intervals and p-values corresponding to two-sided tests of no difference.
If no statistical analysis is specified, data will be presented using relevant summary statistics.
Primary and secondary estimands
Two estimands addressing different aspects of the trial objective will be defined; a primary de-facto 
(effectiveness) estimand and a secondary de-jure (efficacy) estimand: 
!Primary estimand
– de-facto treatment difference at week 26 for all randomised subjects regardless of adherence 
to randomised treatment and initiation of rescue medication 
The primary de-facto estimand assesses the expected glycaemic benefit in a future population that 
results from subjects initiating treatment with oral semaglutide including potential rescue 
medication(s) as compared to initiating treatment with empagliflozin including potential rescue 
medication(s). Generalisation of this estimand depends among other things on the extent to which 
the use of rescue medication in this trial reflects clinical practice and the adherence to trial product CONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 86 of 125
administration in this trial reflects the behaviour of the target population. Accordingly, data 
collected regardless of discontinuation of trial product or initiation of rescue medication(s) will be 
used to draw inference.
!Secondary estimand 
– de-jure treatment difference at week 26 for all randomised subjects if all subjects adhered to 
treatment and did not initiate rescue medication
The secondary de-jure estimand assesses the glycaemic benefit a future subject is expected to 
achieve if initiating and continuing treatment with oral semaglutide as compared to empagliflozin. It 
is considered a clinically relevant estimand as it provides information to treating clinicians about the
expected glycaemic efficacy of oral semaglutide compared to empagliflozin for purposes of treating 
individual subjects. Generalisation of this estimand depends among other things on the extent to 
which the adherence to trial product administration in this trial reflects the behaviour of the target 
population. Accordingly, only data collected prior to discontinuation of trial product or initiation of 
rescue medication will be used to draw inference. This will avoid confounding from rescue 
medication. 
Missing data considerations at week 26
When estimating the primary estimand, the proportion of missing data, i.e. data that do not exist 
even though subjects are intended to stay in the trial regardless of treatment status and initiation of 
rescue medication(s), is expected to be maximum 10% based on the oral semaglutide phase 2 trial 
(NN9924-3790). Thus, missing data will be due to withdrawal from trial or lost to follow-up.
When estimating the secondary estimand, the proportion of missing data is expected to be higher 
(20%) since data collected after discontinuation of trial product or initiation of rescue medication(s) 
will be set to missing. The 10% of missing data, which is due to discontinuation of trial product or 
initiation of rescue medication(s), is based on the empagliflozin assessment report49and the oral 
semaglutide phase 2 trial (NN9924-3790) indicates that a low starting dose with gradual dose escalation diminishes gastrointestinal AEs compared with more aggressive dosing regimens. The 
main reasons for missing data in the two treatment arms are expected to be early treatment 
discontinuation due to AEs (particular gastrointestinal AEs for the oral semaglutide arm) and 
initiation of rescue medication. A higher proportion of subjects is expected to discontinue treatment 
due to AEs in the oral semaglutide arm compared to empagliflozin whereas initiation of rescue 
medication is expected to be more frequent in the empagliflozin arm. So overall the frequency of 
missing data is expected to be similar across treatment arms.
Descriptive summaries and graphical representation of extent, reason(s) for and pattern of missing 
data will be presented by treatment arm.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 87 of 125
17.1 Sample size calculation
The primary endpoint is change from baseline to week 26 in HbA 1c. For HbA 1c, both non-inferiority 
and superiority of oral semaglutide versus empagliflozin are planned to be tested. The confirmatory 
secondary endpoint, change from baseline to week 26 in body weight, is planned to be tested for 
superiority of oral semaglutide versus empagliflozin. 
The sample size calculation is made to ensure a power of at least 90% for testing HbA 1csuperiority 
of oral semaglutide versus empagliflozin out of the three pre-specified confirmatory hypotheses 
shown in Figure 17–1 . The closed testing procedure described in Bretz et al 201150is used to 
control the overall type-I error at a nominal two-sided 5% level. 
The statistical testing strategy is based on the principle that glycaemic effect must be established in 
terms of HbA 1c non-inferiority before testing for added benefits in terms of HbA 1c superiority and/or 
body weight superiority.
The sample size is calculated using the calcPower function in the R package, gMCP51using 10000 
simulations. All of the three pre-specified confirmatory tests are assumed to be independent. Since 
some of the tests are positively correlated, the assumption of independence is viewed as 
conservative. 
The sample size assumptions for treatment effects (TE), adjusted treatment effects and the standard 
deviations (SD) are given in Table 17–1 . These assumptions are primarily based on the oral 
semaglutide phase 2 results (NN9924-3790), empagliflozin assessment report49and supported by 
results from the s.c. semaglutide phase 2 trial (NN9535-1821). 
To assess the effect of empagliflozin on glycaemic effect, a similar trial ([STUDY_ID_REMOVED]) where 
empagliflozin was used as add on to metformin was reviewed. Based on this trial, the chosen 
margin of 0.4 provides assurance that oral semaglutide has a clinically relevant effect greater than 
zero. With regards to the constancy assumption, controlled clinical trials have consistently 
established that empagliflozin is an effective anti-diabetic drug. Therefore, lack of trial sensitivity 
with empagliflozin as comparator is not anticipated to be an issue in this trial.
With regards to preserving an acceptable proportion of the effect of empagliflozin, the broader 
margin of 0.4, has been chosen instead of 0.3 because of the anticipated body weight advantage of oral semaglutide compared to empagliflozin. The trial has been powered to meet HbA
1csuperiority 
of oral semaglutide versus empagliflozin. With the anticipated added benefit on body weight, it is
considered acceptable to use a non-inferiority margin of 0.4.
Since the equalising effect of rescue medication will be included in the primary analysis as well as a 
conservative approach for handling of missing data will be performed, an adjustment in treatment 
effect will be implemented for the 10% of subjects who are expected to discontinue trial product or CONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 88 of 125
initiate rescue medication and for the 10% of subjects who are expected to have actual missing data. 
The treatment effects used in the sample size calculation will be adjusted according to a 75% 
smaller effect in these subjects. For the 10% of the subjects with missing data, the non-inferiority 
margin of 0.4% for HbA 1cis added to the imputed values, when testing for non-inferiority. The 
adjusted treatment effects for testing non-inferiority (HbA 1conly) and superiority are as described 
below:
!Non-inferiority
– 0.8×TE + 0.2×TE×0.25 + non-inferiority margin×0.1
!Superiority
– 0.8×TE + 0.2×TE×0.25
Table 17–1 Assumptions used in the for sample size calculation
Parameter Treatment effect 
(TE)Adjusted TE, 
non-inferiorityAdjusted TE, 
superiorityStandard 
deviationNon-inferiority 
margin
HbA 1c -0.3% -0.215% -0.255% 1.1% 0.4%
Body weight -1 kg -0.85 kg 4 kg
With the above assumptions, allocating 408 subjects to each of the two arms provides 90% power to 
confirm HbA 1csuperiority of oral semaglutide versus empagliflozin. In total 2×408 = 816 subjects 
are planned to be randomised. Calculated powers for individual hypotheses are presented in Table 
17–2. 
Table 17–2 Calculated powers for individual hypotheses
HbA 1cnon-inferiority HbA 1csuperiority Body weight superiority 
Power > 99% 90% 85%CONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 89 of 125
Figure 17–1 Graphical illustration of the closed testing procedure
The overall significance level of α = 0.05 (two-sided) is initially allocated to the HbA 1cnon-inferiority test of oral 
semaglutide vs. empagliflozin. The local significance level ( α-local) will be reallocated if a hypothesis is confirmed
according to the weight given by the directed edges between nodes (hypotheses). The sample size is based on the 
hypothesis in the dark box.
17.2 Definition of analysis sets
The following analysis sets will be defined:
Full analysis set (FAS): Includes all randomised subjects. Subjects in the FAS will contribute to 
the evaluation “as randomised”.
Safety analysis set (SAS): Includes all subjects exposed to at least one dose of trial product. 
Subjects in the SAS will contribute to the evaluation “as treated”.
Per protocol (PP) analysis set: Includes all subjects in the FAS who fulfils the following criteria
!have not violated any inclusion criteria
!have not fulfilled any exclusion criteria
!have a baseline HbA 1cmeasurement
!is exposed to trial product and have at least one HbA 1cmeasurement at or after week 14
Subjects in the PP analysis set will, as in the SAS, contribute to the analysis “as treated”.
Data selections and observation periods
Unless subjects withdraw their informed consent, data collection will continue for the full duration 
of the trial. The full duration of the trial is defined as up to and including
!the follow-up visit (V13) for subjects on trial product
!the latest occurring visit of the end-of-treatment visit (V12) or the follow-up premature 
discontinuation visit (V13A), for subjects who have discontinued trial product prematurely.       =0Body weight (kg)
Superiority
       =0HbA 1c(%)
Superiority       =0 . 0 5HbA 1c(%)
Non-inferiority
112⁄ 12⁄
1CONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 90 of 125
Subjects and data to be used in an analysis will be selected in a two-step manner.
!Firstly, subjects will be selected based on the specified analysis set
!Secondly, data points on the selected subjects from the first step will be selected based on the 
specified observation period
Definition of the observation periods:
In-trial: This observation period represents the time period where subjects are considered to be in 
the trial, regardless of discontinuation of trial product or initiation of rescue medication. The in-trial 
observation period starts at randomisation (as registered in the IWRS) and ends at the date of
!the last direct subject-site contact, which is scheduled to take place 5 week after planned last 
dose of trial product at the follow-up visit. 
!withdrawal for subjects who withdraw their informed consent.
!the last subject-investigator contact as defined by the investigator for subjects who are lost to 
follow-up.
!death for subjects who dies before any of the above.
On-treatment: This observation period represents the time period where subjects are considered 
treated with trial product. The observation period is a subset of the in-trial observation period. It 
starts at the date of first dose of trial product. Two slightly different end dates will be needed to 
cover all assessments appropriately. 
For adjudicated events, ECGs, anti-semaglu tide antibodies, and AE s including hypoglycaemic 
episodes, the observation period ends at the first date of any of the following:
!the follow-up visit (V13)
!the follow-up prematurely discontinuation visit (V13A)
!the last date on trial product +38 days 
!the end-date for the in-trial observation period
The follow-up visit is scheduled to take place 5 weeks after the last date on trial product 
corresponding to approximately five half-lives of oral semaglutide. The visit window for the follow-
up visit is +3 days.
For efficacy and other safety assessments (laboratory assessments, physical examination and vital 
signs) the observation period ends at the last date on trial product +3 days. This will be used in 
order to ensure specificity to reversible effects of treatment.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 91 of 125
On-treatment without rescue medication: This observation period is a subset of the on-treatment 
observation period, where subjects are considered treated with trial product, but have not initiated 
any rescue medications. The on-treatment without rescue medication observation period starts at 
first date on trial product and the observation period ends at the first date of any of the following:
!the last dose of trial product +3 days
!the date of initiation of rescue medication
The in-trial observation period will be the primary observation period when estimating the primary 
estimand. The on-treatment without rescue medication observation period will be the primary 
observation period when estimating the secondary estimand. The on-treatment observation period 
will be considered supportive for evaluating efficacy. Safety will be evaluated based on the in-trial 
and the on-treatment observation periods.
Data points collected outside an observation period will be treated as missing in the analysis. 
Baseline data will always be included in an observation period. For adjudicated events, the onset 
date will be the EAC adjudicated onset date. 
Before data are locked for statistical analysis, a review of all data will take place. Any decision to 
exclude either a subject or single observations from the statistical analysis is the joint responsibility 
of the members of the Novo Nordisk study group. Exclusion of data from analyses should be used 
restrictively, and normally no data should be excluded from the FAS. The subjects or observations 
to be excluded, and the reasons for their exclusion must be documented and signed by those 
responsible before database lock. The subjects and observations excluded from analysis sets, and 
the reason for this, will be described in the clinical trial report.
Confirmatory hypotheses  
For the primary HbA 1cendpoint and the confirmatory sec ondary body weight  endpoint the 
following confirmatory one-sided hypotheses are planned to be tested for oral semaglutide versus 
empagliflozin. Let the mean treatment difference be defined as μ = (oral semaglutide minus 
empagliflozin): 
!HbA 1cnon-inferiority, using a non-inferiority margin of 0.4%
–H 0: μ ≥ 0.4% against H a: μ < 0.4%
!HbA 1csuperiority
–H 0: μ ≥ 0.0% against H a: μ < 0.0%
!HbA 1cbody weight superiority
–H 0: μ ≥ 0.0kg against H a: μ < 0.0kg
Operationally the hypotheses will be evaluated by two-sided tests. CONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 92 of 125
Multiplicity and criteria for confirming hypotheses
The type I error for testing the three confirmatory hypotheses related to the HbA 1cand body weight 
endpoints will be preserved in the strong sense at 5% (two-sided) using the weighted Bonferroni-
based closed testing procedure described in Bretz et al 201150and outlined in Figure 17–1
The first hypothesis to be tested is non-inferiority of HbA 1c. It will be tested at the overall 
significance level (5%) while allocating 0% local significance level to the remaining of the 
hypotheses. For this hypothesis, and in general, if a hypothesis is confirmed the significance level 
will be reallocated according to the weight and the direction of the edges going from the confirmed 
hypothesis to the next hypotheses as specified in Figure 17–1 . Each of the following hypotheses 
will be tested at their local significance level ( α-local). This process will be repeated until no further 
hypotheses can be confirmed.
Non-inferiority and/or superiority will be considered confirmed if the mean treatment difference is 
supporting the corresponding alternative hypothesis and the two-sided p-value from the primary 
analysis of the primary estimand is strictly below its local two-sided significance level as defined by 
the closed testing procedure in Figure 17–1 . This is equivalent to using a one-sided p-value 
(nominal α = 0.025) and a one-sided 2.5% overall significance level in the closed testing procedure.
17.3 Primary endpoint
The primary endpoint is change from baseline to week 26 in HbA 1c.
17.3.1 Primary analysis for the primary estimand 
The primary estimand will be estimated based on the FAS using week 26 measurements from the 
in-trial observation period. The primary statistical analysis will be a pattern mixture model using 
multiple imputation to handle missing data assuming that the missing data mechanism is missing at 
random (MAR) within the groups used for imputation. Imputation of missing data at week 26 will 
be done within 4 groups of subjects defined by randomised treatment arm, and whether subjects at 
week 26; (i) have discontinued treatment or initiated rescue medication or (ii) are still on treatment 
and have not initiated  rescue medication. It is hereby assumed that the likely values of what the 
missing data would have been if available are best described by information from subjects who at 
week 26 are similar in terms of randomised treatment arm and treatment adherence/rescuemedication status.
Missing values for each group will be imputed as follows:
An analysis of covariance (ANCOVA) with region as a categorical fixed effect and baseline HbA
1c
measurement as a covariate will be fitted to observed values of the change from baseline in HbA 1c
at week 26.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 93 of 125
The estimated parameters for location and dispersion will be used to impute 100 values for each 
subject with missing week 26 data based on region and baseline HbA 1c. Thus, 100 complete data 
sets will be generated including observed and imputed values.
Analysis used for confirming superiority versus empagliflozin at week 26:
For each of the 100 (now complete) imputed data sets, the change in HbA 1cfrom baseline to week 
26 will be analysed using an ANCOVA with treatment and region as categorical fixed effects, and 
baseline HbA 1cas covariate. The results obtained from analysing the datasets will be combined 
using Rubin’s rule52to draw inference. 
Analysis used for confirming non-inferiority versus empagliflozin at week 26: 
Prior to analysing the data using the same model and approach as used for confirming superiority 
(see above), a value of 0.4% (the non-inferiority margin) will be added to imputed values at week 
26 for the oral semaglutide treatment arms only53. For evaluating non-inferiority versus 
empagliflozin unadjusted two sided p-value for testing no difference from the non-inferiority margin will be presented.
17.3.2 Primary analysis for the secondary estimand
The secondary estimand will be estimated based on the FAS using post-baseline measurements up 
to and including week 26 from the on-treatment without rescue observation period. The primary 
analysis for the secondary estimand will be a Mixed Model for Repeated Measurements (MMRM). 
A restricted maximum likelihood will be used. The model will include all post baseline HbA
1c
measurements collected at scheduled visits up to and including week 26 as dependent variables. The independent effects included in the model will be treatment and region as categorical fixed effects 
and baseline HbA
1cas a covariate, all nested within visit. An unstructured covariance matrix for 
HbA 1cmeasurements within the same subject will be employed, assuming measurements from 
different subjects are independent.
The MMRM is a well-established method that accounts for the uncertainty pertaining to missing 
data. This analysis assumes that the missing data mechanism is MAR. Under this assumption the 
statistical behaviour of the missing data (given the observed responses and model fixed effects and 
covariates) is assumed to be same as the observed data. 
17.3.3 Sensitivity analyses
To investigate the sensitivity of the primary analysis results, complementary and separate analyses 
will be performed for the primary and secondary estimand. In line with European Medicines 
Agency recommendations54and with a report from the US National Research Council55, these 
analyses will primarily evaluate the sensitivity of the results due to the impact of missing data. CONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 94 of 125
Since conservatism, i.e. avoiding bias in favour of oral semaglutide, depends on the context, 
separate sensitivity analyses will be made for non-inferiority and superiority testing.
The evaluation of the robustness of the primary analysis results will primarily be based on a pattern 
mixture model approach using multiple imputation. An overview of the sensitivity analyses for each 
of the estimands are specified below followed by a more detailed description of the three different 
pattern mixture models used. Finally, three additional sensitivity analyses for the primary analysis 
will be described that are not based on the pattern mixture model approach (see Section 17.3.3.2 ).
Sensitivity analyses for the primary estimand
The estimation of the primary estimand will be repeated using the following sensitivity analyses:
!A comparator multiple imputation analysis based on FAS using the in-trial observation period 
(superiority).
!A comparator multiple imputation analysis differentiating between reasons for discontinuing 
treatment prematurely based on FAS using the in-trial observation period (superiority).
!A tipping-point multiple imputation analysis based on FAS using the in-trial observation period 
(non-inferiority and superiority).
!A MMRM analysis (the primary analysis for the secondary estimand) based on FAS using the 
in-trial observation period (non-inferiority and superiority).
Sensitivity analyses for the secondary estimand
The estimation of the secondary estimand will be repeated using the following sensitivity analyses:
!A comparator multiple imputation analysis based on FAS using the on-treatment without rescue 
medication observation period (superiority).
!A comparator multiple imputation analysis based on FAS using the on-treatment observation 
period (superiority). This sensitivity analysis aims to compare oral semaglutide versus 
empagliflozin for subjects who adhere to treatment regardless of whether or not rescue 
medication has been initiated.
!A comparator multiple imputation analysis differentiating between reasons for discontinuing 
treatment prematurely based on FAS using the on-treatment without rescue medication 
observation period (superiority).
!A tipping-point multiple imputation analysis based on FAS using the on-treatment without 
rescue medication observation period (non-inferiority and superiority).CONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 95 of 125
17.3.3.1 Pattern mixture models
Common for the three pattern mixture model sensitivity analyses is that they all aim to stress-test 
the primary HbA 1cresults by changing the assumptions for part or all missing data in the oral 
semaglutide treatment arm, while maintaining the missing data assumption for the empagliflozin 
arm. 
!Comparator multiple imputation analysis: In this sensitivity analysis missing data at week 26 
for all subjects will be imputed to resemble the distribution of the week 26 values observed in 
the empagliflozin treatment arm. In effect, this imputation approach removes the treatment 
difference between oral semaglutide and empagliflozin for all subjects randomised to oral 
semaglutide, given that oral semaglutide is better than empagliflozin. Due to the potential lack 
of sensitivity for testing non-inferiority this sensitivity analysis will only be used to evaluate the 
robustness of HbA 1csuperiority conclusions.
!Comparator multiple imputation analysis differentiating between reasons for discontinuing 
treatment prematurely: In this sensitivity analysis missing data at week 26 for subjects who 
discontinue oral semaglutide treatment due to treatment related AE(s) will be imputed to 
resemble the distribution of the week 26 values observed in the empagliflozin treatment arm. 
Treatment related AEs are defined as AEs classified as possible or probable related to trial 
product as reported by the investigator. In effect this imputation approach removes the treatment 
difference between oral semaglutide and empagliflozin for this selected group of subjects 
randomised to oral semaglutide. This sensitivity analysis is less conservative as compared to the 
first sensitivity analysis. Due to the potential lack of sensitivity for testing non-inferiority this 
sensitivity analysis will only be used to evaluate the robustness of HbA 1csuperiority 
conclusions.
!Tipping-point multiple imputation analysis: In this sensitivity analysis, missing data will first be 
imputed according to the primary analysis. Secondly, for the oral semaglutide treatment arm a 
penalty will be added to the imputed values at week 26. The approach is to gradually increase 
this penalty until the HbA 1cconclusion from the primary analysis is changed. The specific value 
of the penalty that changes the conclusion will be used to evaluate the robustness of the primary 
analysis result. This sensitivity analysis will be used for evaluating the robustness of the HbA 1c
non-inferiority and superiority conclusions.
17.3.3.2 Other sensitivity analyses
The following additional sensitivity analyses will be specified
!Per-protocol analysis: This sensitivity will be based on the per-protocol analysis set. Data from 
the on-treatment without rescue medication observation period will be analysed using the 
primary analysis approach for the primary estimand. This sensitivity analysis will be used to 
evaluate the robustness of the HbA 1cnon-inferiority conclusions.
!Complete case analysis: This sensitivity analysis will be based on the on-treatment without 
rescue medication observation period and include subjects in the FAS who have a valid HbA 1cCONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 96 of 125
measurement at week 26. The change from baseline to week 26 in HbA 1cwill be analysed by a 
linear normal model (ANCOVA) with treatment and region as categorical fixed effects and 
baseline HbA 1cas a covariate. This sensitivity analysis will be used to evaluate the robustness of 
the HbA 1cnon-inferiority conclusions.  
!Last observation carried forward analysis: This sensitivity analysis will be based on the FAS 
using the on-treatment without rescue medication observation period. The change from baseline 
to week 26 in HbA 1cwill be analysed by a linear normal model (ANCOVA) with treatment and 
region as categorical fixed effects and baseline HbA 1cas a covariate. This sensitivity analysis 
will be used for evaluating the robustness of the HbA 1cnon-inferiority and superiority 
conclusions.
17.3.3.3 Assessment of sensitivity analyses
The results from the sensitivity analyses will be collectively used to interpret the robustness of the 
trial results for HbA 1c. Due to the large number of sensitivity analyses and their inherent 
conservative nature, it will not be a requirement that all confirmatory hypotheses are consistently 
confirmed across the sensitivity analyses. Thus, no absolute success criteria will be pre-defined for 
each sensitivity analysis. The sensitivity results in totality will be used to substantiate the credibility 
of the trial results.  
17.4 Secondary endpoints
17.4.1 Confirmatory secondary endpoints
Change from baseline to week 26 in body weight (kg) will be a confirmatory secondary endpoint. 
The primary and secondary estimands will be estimated using the same approaches as described for 
the primary HbA 1cendpoint. Body weight will only be tested for superiority. Baseline body weight 
will be used as a covariate instead of baseline HbA 1cin both the multiple imputation and analysis 
model.
Superiority will be considered confirmed if the mean treatment difference is supporting the 
corresponding hypothesis and the two-sided p-value from the analysis of the primary estimand is 
strictly below its local two-sided significance level resulting from the closed testing procedure in
Figure 17–1 . Sensitivity analyses similar to the ones pre-specified for testing superiority for the 
primary HbA 1cendpoint will be made to evaluate the robustness of the body weight results.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 97 of 125
17.4.2 Supportive secondary endpoints
17.4.2.1 Efficacy endpoints
The below supportive secondary efficacy endpoints will be evaluated for
!the primary estimand based on FAS using the in-trial observation period
!the secondary estimand based on FAS using the on-treatment without rescue medication 
observation period
No sensitivity analyses are planned for these. 
Continuous efficacy endpoints
Change from baseline to week 52 in:
!HbA 1c
!Body weight (kg)
Change from baseline to week 26 and week 52 in:
!Body weight (%)
!FPG
!Fasting C-peptide
!Fasting insulin and proinsulin
!Fasting glucagon
!Insulin resistance (homeostatic model assessment index of insulin resistance [HOMA-IR]) and 
beta-cell function (homeostatic assessment index of beta-cell function [HOMA-B])
!BMI
!Waist circumference
!Fasting lipid profiles (total cholesterol, LDL cholesterol, VLDL cholesterol, HDL cholesterol, 
triglycerides, free fatty acids)
!C-reactive protein (CRP)
BMI will be calculated based on body weight and height based on the formulae:
BMI kg/m2= body weight (kg)/(Height (m) x Height (m)) or (kg/m2= [lb/in2x 703])
Change from baseline to week 26 and week 52 in 7-point SMPG profile:
!Mean 7-point profile; defined as the area under the profile, calculated using the trapezoidal 
method, divided by the measurement time
!Mean postprandial increment (over all meals)
The above continuous endpoints will be analysed separately using similar model approaches as for 
the primary endpoint with the associated baseline response as a covariate. Fasting lipid profile CONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 98 of 125
endpoints will be log-transformed prior to analysis with the associated log-transformed baseline 
value as a covariate.
For evaluation of the primary estimand, the analysis will be performed separately for week 26 and 
week 52. For the analysis at week 52, the imputation of missing data will be further differentiated 
by whether subjects have discontinued trial product or initiated rescue medication prior to week 26 
or at or after week 26. This will result in imputation of missing data within 8 groups of subjects 
instead of the 4 groups as described for the week 26 evaluation in Section 17.3.1 . If less than 5 
subjects have available data in one of the 8 groups, the imputation will be made within the 4 groups 
specified for the primary evaluation. The frequency of missing data is expected to be slightly larger 
at week 52 compared to week 26. The rate of missing data is expected to decline over time. 
For evaluation of the secondary estimand, the MMRM based primary analysis will include all 
scheduled post-baseline measurement up to and including week 52. From this model the estimated 
treatment differences (ratios) will be presented at week 26 (except for HbA 1cand body weight), and 
week 52 with 95% confidence intervals and two-sided p-values for test of no difference.
Binary efficacy endpoints
If a subject after week 26 achieves (yes/no):
!HbA 1c< 7.0% (53 mmol/mol) (ADA) target
!HbA 1c≤ 6.5% (48 mmol/mol) (AACE) target
!HbA 1creduction ≥ 1% (10.9 mmol/mol)
!Weight loss ≥ 3%
!Weight loss ≥ 5%
!Weight loss ≥ 10%
!HbA 1c< 7.0% (53 mmol/mol) without hypoglycaemia (treatment-emergent severe or 
BG-confirmed symptomatic hypoglycaemic episodes) and no weight gain
!HbA 1creduction ≥ 1% (10.9 mmol/mol) and weight loss ≥ 3%
The above eight endpoints will also be evaluated after week 52.
The above eight binary endpoints will be analysed using a logistic regression model with treatment 
and region as fixed effects and baseline response as covariate (i.e. baseline HbA1c for binary 
HbA1c endpoints, baseline weight for weight endpoints and both baseline HbA1c and baseline 
weight for the binary endpoint that combines both parameters). To account for missing data, the 
analysis will be made using a sequential multiple imputation approach as described below:CONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 99 of 125
!Multiple imputed data sets (100) will be created in which missing values for the underlying 
continuous assessments are imputed by treatment group and treatment adherence/rescue status 
assuming MAR and as described in section 17.3.1 for the primary estimand and by treatment 
group assuming MAR and as described in section 17.3.2 for the secondary estimand.
!The binary endpoint will be created for each of the 100 complete data sets
!Each of the created complete data set will be analysed with the logistic model and inference will 
be drawn using Rubin’s rule52.
Time to event endpoint
!Time to rescue medication
Subjects completing the study without need for rescue medication will be censored at the time point 
of the (actual) last date on trial product. The start time is the first date on trial product. Time to 
rescue medication will be described and compared for oral semaglutide versus empagliflozin using 
likelihood ratio tests obtained from a proportional Cox hazards model with treatment and region as 
categorical fixed effects, and baseline HbA 1cas covariate. From this analysis the estimated Hazard 
ratios between semaglutide versus empagliflozin will be presented together with 95% confidence 
intervals and two-sided p-values for test of no difference. 
Pharmacokinetic endpoints
!SNAC plasma concentrations 
!Semaglutide plasma concentrations for population PK analyses
The SNAC plasma concentrations and semaglutide plasma concentrations collected in this trial will 
be evaluated using relevant summary statistics. In addition, the semaglutide plasma concentration 
will be part of a meta-analysis across the oral semaglutide phase 3a trials, see Section 17.6.
17.4.2.2 Safety endpoints
The safety endpoints will be evaluated based on SAS using the on-treatment observation period and
the in-trial observation period unless otherwise stated. The following endpoints are used to support 
the safety objective:
Adverse events 
!Number of TEAEs during exposure to trial product, assessed up to approximately 57 weeks
All AEs will be coded using the most recent version of the Medical Dictionary for Regulatory 
Activities (MedDRA) coding. 
A treatment-emergent AE is defined as an AE with onset in the on-treatment observation period 
(see definition of observation periods in Section 17.2).CONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 100 of 125
TEAEs will be summarised in terms of the number of subjects with at least one event (N), the 
percentage of subjects with at least one event (%), the number of events (E) and the event rate per 
100 patient years of observation time (R) for the on-treatment observation period. Supportive 
summaries of AEs will be made for the in-trial observation period. The development over time in 
gastrointestinal AEs will be presented graphically.
Other safety endpoints
Change from baseline to week 26 and week 52 in:
!Amylase
!Lipase
!Pulse
!Systolic blood pressure
!Diastolic blood pressure
The above safety endpoints will be evaluated using the primary analysis for the primary estimand 
based on SAS using the in-trial observation period and using the primary analysis for the secondary 
estimand based on SAS using the on-treatment observation period. Endpoints will be analysed 
separately as described above for continuous efficacy endpoints. Results will be presented at week 
26 and at week 52. Amylase and lipase endpoints will be log-transformed prior to analysis with the 
associated log-transformed baseline value as a covariate.
Change from baseline to week 26 and week 52 in:
!Haematology 
!Biochemistry (except for amylase and lipase)
!Calcitonin
!ECG evaluation
!Physical examination (week 52 only)
Change from pre-dose to post-dose (25 and 40 min) at week 4, 26, and 52 in: 
!Lactate
Any occurrence of anti-semaglutide antibodies (yes/no) up to approximately 57 weeks:
!Anti-semaglutide binding antibodies
!Anti-semaglutide neutralising antibodies 
!Anti-semaglutide binding antibodies cross reacting with native GLP-1
!Anti-semaglutide neutralising antibodies cross reacting with native GLP-1
Anti-semaglutide binding antibodies up to approximately 57 weeks:
!Anti-semaglutide binding antibody levelsCONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 101 of 125
The above safety endpoints will be summarised descriptively by treatment arm and visit. The binary
safety endpoints will be summarised as counts and relative frequencies. Calcitonin will also be 
presented by gender. 
Hypoglycaemia
!Number of treatment-emergent severe or BG-confirmed symptomatic hypoglycaemic episodes 
during exposure to trial product, assessed up to approximately 57 weeks
!Treatment-emergent severe or BG-confirmed symptomatic hypoglycaemic episodes during 
exposure to trial product, assessed up to approximately 57 weeks (yes/no) 
Classification of hypoglycaemia:
Hypoglycaemic episodes will be summarised for the SAS and the on-treatment observation period 
only.
Treatment-emergent: hypoglycaemic episodes will be defined as treatment-emergent if the onset of 
the episode occurs within the on-treatment observation period (see definition of observation periods 
in Section 17.2).
Nocturnal hypoglycaemic episodes: episodes occ urring between 00:01 and 05.59 both inclusive.
Hypoglycaemic episodes are classified according to the Novo Nordisk classification of 
hypoglycaemia and the ADA classification of hypoglycaemia (see Figure 17–2 ).
Novo Nordisk classification of hypoglycaemia
In normal physiology, symptoms of hypoglycaemia occur below a PG level of 3.1 mmol/L 
(56 mg/dL)56. Therefore, Novo Nordisk has included hypoglycaemia with PG levels below this cut-
off point in the definition of BG-confirmed hypoglycaemia.
Novo Nordisk uses the following classification in addition to the ADA classification:
Severe or BG-confirmed symptomatic hypoglycaemia: An episode that is severe according to the 
ADA classification42or BG-confirmed by a PG value < 3.1 mmol/L (56 mg/dL) with symptoms 
consistent with hypoglycaemia. CONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 102 of 125
ADA classification of hypoglycaemia42
!Severe hypoglycaemia: An episode requiring assistance of another person to actively administer 
carbohydrate, glucagon, or take other corrective actions. PG concentrations may not be 
available during an event, but neurological recovery following the return of PG to normal is 
considered sufficient evidence that the event was induced by a low PG concentration.
!Asymptomatic hypoglycaemia: An episode not accompanied by typical symptoms of 
hypoglycaemia, but with a measured PG concentration ≤ 3.9 mmol/L (70 mg/dL).
!Documented symptomatic hypoglycaemia: An episode during which typical symptoms of 
hypoglycaemia are accompanied by a measured PG concentration ≤ 3.9 mmol/L (70 mg/dL).
!Pseudo-hypoglycaemia: An episode during which the person with diabetes reports any of the 
typical symptoms of hypoglycaemia with a measured PG concentration > 3.9 mmol/L 
(70 mg/dL) but approaching that level.
!Probable symptomatic hypoglycaemia: An episode during which symptoms of hypoglycaemia 
are not accompanied by a PG determination but that was presumably caused by a PG concentration ≤ 3.9 mmol/L (70 mg/dL).
Hypoglycaemic 
episode PG ≤ 3.9 mmol/L 
(70 mg/dL) 
or 
Alleviation of 
symptoms 
or
Seizure, coma or 
fatal 
SMPG
measurementAsymptomatic 
hypoglycaemia
Documented 
symptomatic 
hypoglycaemia
Pseudo-
hypoglycaemia
Probable 
symptomatic 
hypoglycaemiaNo
Yes
No measurement 
with symptomsPG > 3.9 mmol/L 
(70 mg/dL)
with symptomsPG ≤3.9 mmol/L 
(70 mg/dL)
with symptomsPG ≤3.9 mmol/L 
(70 mg/dL)
without symptoms
NoYes
Note: Glucose measurements are performed with capillary blood calibrated to plasma equivalent glucose valuesSubject 
able to 
treat him/
herselfSevere 
hypoglycaemia
(ADA 2013)
Figure 17–2 ADA classification of hypoglycaemia
PG: plasma glucose. SMPG: Self-measured plasma glucoseCONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 103 of 125
Data on treatment-emergent hypoglycaemic episodes will be presented in terms of the number of 
subjects with at least one episode, the percentage of subjects with at least one episode (%), the total 
number of episodes and the episode rate per 100 patient years of observation time.
Analysis of severe or BG-confirmed symptomatic hypoglycaemic endpoints
The number of treatment-emergent severe or BG-confirmed symptomatic hypoglycaemic episodes 
will be evaluated for the on-treatment period using a negative binomial regression model with a log-
link function and the logarithm of the duration of the subject’s on-treatment observation period as 
offset. The model will include treatment and region as fixed factors and baseline HbA 1cas 
covariate.
The binary endpoint showing whether a subject has at least one treatment-emergent severe or 
BG-confirmed symptomatic hypoglycaemic episode will be analysed using a logistic regression 
model with treatment and region as fixed factors and baseline HbA 1cas covariate.
17.5 Interim analysis 
No interim analyses will be performed before the database is locked.
17.6 Pharmacokinetic and/or pharmacodynamic modelling
Data from this trial will be evaluated using population pharmacokinetic analysis and exposure-
response for semaglutide. The purpose of the population pharmacokinetic analysis will be 1) to 
describe the covariate factors (such as weight, age, gender, race and ethnicity) that influence 
semaglutide exposure, 2) to estimate a steady-state exposure level for each subject with 
pharmacokinetic data in order to facilitate subsequent exposure-response analyses. The purpose of 
the exposure-response analyses will be to support the recommended doses by investigating response 
and potentially side effects across the exposure range. 
The population pharmacokinetic and exposure-response analyses will be conducted as a meta-
analysis, including all relevant Phase 3a trials with PK assessment relevant oral semaglutide phase 3 
trials. A separate modelling analysis plan will be prepared before database lock, outlining details of 
the analyses. The modelling will be performed by Quantitative Clinical Pharmacology at Novo 
Nordisk A/S and will be reported separately from the CTR.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 104 of 125
17.7 Patient reported outcomes
Change from baseline to week 26 and week 52 in:
!SF-36v2™ (acute version) health survey: Scores from the 8 domains and the physical 
component score and mental component score summary scores
!CoEQ: Scores from the 4 domains and scores from 19 individual items
The PRO endpoints will be evaluated using the primary analysis for the primary estimand based on 
FAS using the in-trial observation period and using the primary analysis for the secondary estimand 
based on FAS using the on-treatment without rescue medication period. All of the above scores will 
be analysed separately as the other continuous efficacy endpoints with the associated baseline 
response as a covariate.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 105 of 125
18 Ethics
18.1 Benefit-risk assessment of the trial
18.1.1 Risks and precautions
The nonclinical safety programme of oral semaglutide has not revealed any safety issues precluding 
use in humans. 
The sections below describe the important identified and potential risks and precautions associated 
with oral semaglutide treatment. These are based on findings in nonclinical studies and clinical 
trials with oral semaglutide as well as other GLP-1 RAs. For each of these risks and precautions, 
mitigating actions have been implemented to minimise the risks for subjects enrolled in this trial.
Identified risks
Gastrointestinal adverse events
Consistent with findings with other GLP-1 RAs, the most frequently reported AEs in clinical trials 
with oral semaglutide have been gastrointestinal disorders (nausea, vomiting, diarrhoea, dyspepsia 
and constipation). Clinical trials have indicated that a low starting dose and gradual dose escalation 
mitigates the risk of gastrointestinal AEs. Consequently, a low starting dose and dose escalation 
with 4 week dose-escalation steps have been implemented in the trial.
Potential risks
Medullary thyroid cancer
The human relevance of the proliferative C-cell changes found in rodents treated with GLP-1 RAs 
is unknown, but data suggest that rodents are more sensitive to the mode of action of GLP-1 RAs 
for induction of C-cell tumours. However, as a precaution, subjects with a family or personal 
history of MEN 2 or MTC will not be enrolled in the trial. During the trial, calcitonin will be 
measured on a regular basis, and the guidance for investigators on further evaluation and action on 
elevated calcitonin concentrations is included in appendix A . 
Acute pancreatitis
Acute pancreatitis has been reported in subjects treated with GLP-1 RAs including oral 
semaglutide. As a precaution, subjects with a history of acute or chronic pancreatitis will not be 
enrolled in the trial. Also, subjects will be informed about the symptoms of acute pancreatitis and 
serum levels of lipase and amylase will be monitored throughout the trial.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 106 of 125
Pancreatic cancer
Patients with T2DM have an increased risk of certain types of cancer such as pancreatic cancer. 
There is currently no support from nonclinical studies or clinical trials or post marketing data that 
GLP-1-based therapies increase the risk of pancreatic cancer. However, pancreatic cancer has been 
included as a separate potential risk due to the scientific debate surrounding a potential association 
to GLP-1-based therapies and the unknown long-term effects of stimulation of β-cells and 
suppression of α-cells. Pancreatic cancer has been classified as a potential class risk of GLP-1 RAs 
by European Medicines Agency.
Allergic reactions
As in the case with all protein-based pharmaceuticals, treatment with oral semaglutide may evoke 
allergic reactions. These may include urticaria, rash, pruritus as well as anaphylactic reactions. As a 
precaution, subjects with known or suspected hypersensitivity to trial product(s) or related products 
will not be enrolled in the trial. In addition, subjects will be instructed to contact the site staff as 
soon as possible for further guidance if suspicion of a hypersensitivity reaction to the trial product 
occurs.
Hypoglycaemia
Based on current knowledge about the GLP-1 RA drug class, there is a risk of hypoglycaemic 
episodes. Hypoglycaemic episodes have mainly been observed when a GLP-1 RA is combined with 
sulphonylurea or insulin. The risk for development of hypoglycaemia with oral semaglutide in 
combination with sulphonylurea and insulin is currently unknown. 
Acute renal impairment
In subjects treated with GLP-1 RAs, including oral semaglutide, gastrointestinal AEs such as 
nausea, vomiting and diarrhoea may lead to significant dehydration and secondary acute renal 
impairment. Subjects with gastrointestinal AEs are recommended to drink plenty of fluids to avoid 
volume depletion. Also, serum creatinine and other markers of kidney function will be monitored 
throughout the trial.
Impaired renal function may increase the risk of metformin associated lactic acidosis when GLP-1 
RAs are co-administered with metformin. As a precaution, serum creatinine will be measured regularly. In subjects treated with metformin who experience prolonged or severe nausea and 
vomiting, the investigator should monitor serum creatinine, and if clinically indicated, withhold 
metformin until resolution of renal dysfunction.
The use of the background medication should be in accordance with the current approved labels.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 107 of 125
Other safety considerations
Teratogenicity (embryo-foetal development toxicity)
Semaglutide caused embryo-foetal malformations in the rat through a GLP-1 receptor mediated 
effect on the inverted yolk sac placenta leading to impaired nutrient supply to the developing 
embryo. Primates do not have an inverted yolk sac placenta which makes this mechanism unlikely 
to be of relevance to humans. However, as a precaution, females who are pregnant, breast-feeding
or intend to become pregnant or are of childbearing potential and not using an adequate 
contraceptive method will not be enrolled in the trial. In addition, pregnancy tests will be performed 
at all visits, including screening and follow-up and at any time during the trial if a menstrual period 
is missed, or as required by local law.
General precautions 
All subjects will be included after a thorough evaluation in regards to in- and exclusion criteria 
defined in order to ensure that subjects are eligible for trial treatment.
There are also strict glyacemic rescue criteria in place to ensure acceptable glycaemic control 
during the trial. If rescue medication is required, it should be in accordance with ADA/European 
Association for the Study of Diabetes27, 28(excluding GLP-1 RAs, DPP-4 inhibitors, amylin 
analogues and SGLT-2 inhibitors). 
It is the responsibility of the investigator to ensure the best possible care according to the principles 
outlined in Diabetes Care 2014 Standards of Medical Care in Diabetes57.
Further details with regards to safety of trial product are described in the current edition of the IB for oral semaglutide (NN9924)
24, or any updates thereto.
18.1.1.1 Empagliflozin
Subjects should be considered suitable for treatment with empagliflozin and the use of 
empagliflozin should be in accordance with the current, approved label. It is important to monitor 
renal function and for signs and symptoms of volume depletion during therapy. Serum creatinine 
will be measured regularly for monitoring of renal function.
The most common adverse reactions reported with empagliflozin are hypoglycaemia (when used 
with sulphonylurea or insulin), genital infections, pruritus (generalised) and increased urination. 
Uncommon adverse reactions are volume depletion and dysuria25. SGLT-2 inhibitors have recently 
been associated with a risk of ketoacidosis and urinary tract infections58. Symptoms of ketoacidosis 
include nausea, vomiting, abdominal pain, tiredness, general malaise and shortness of breath. Ketoacidosis associated with the use of SGLT-2 inhibitors can occur even if the blood sugar level is 
not elevated. If ketoacidosis is suspected, the SGLT-2 inhibitor should be discontinued and 
treatment instituted promptly.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 108 of 125
18.1.2 Benefits 
In this trial, subjects will be randomised to one of two treatment arms involving an active add-on 
treatment regimen anticipated to be more efficacious than the treatment they receive at the time of 
entry into the trial (metformin only). 
Based on the results of the phase 2 dose-finding trial, oral semaglutide is expected to provide 
clinically relevant improvements in glycaemic control and body weight in subjects with T2DM.
Similarly, treatment with empagliflozin is expected to provide clinically relevant improvements in 
glycaemic control25. In addition, it is expected that all subjects will benefit from participation 
through close contact with the study site, with close follow-up of their T2DM and a careful medical 
examination, all of which will most likely result in an intensified management of their T2DM.
All subjects in this trial will receive trial products and auxiliary supplies free of charge. 
18.1.3 Risk and benefit conclusion 
The safety profile for oral semaglutide generated from the clinical and nonclinical development 
programme has not revealed any safety issues that would prohibit administration of oral 
semaglutide in accordance with the planned clinical trial. The phase 2 results indicate that oral 
semaglutide will provide clinically relevant improvements in glycaemic control and body weight. 
Empagliflozin is already a marketed drug approved for the use in subjects with T2DM. 
Safety and efficacy will be monitored regularly and acceptable glycaemic control will be reinforced 
at all times during the trial.
In conclusion, the potential risk to the subjects in this trial is considered low and acceptable in view 
of the anticipated benefits oral semaglutide/empagliflozin will provide to subjects with T2DM.  
18.2 Informed consent
In seeking and documenting informed consent, the investigator must comply with applicable 
regulatory requirement(s) and adhere to ICH GCP1and the requirements in the Declaration of 
Helsinki2.
Before any trial-related activity, the investigator must give the subject verbal and written 
information about the trial and the procedures involved in a form that the subject can read and 
understand.
The subjects must be fully informed of their rights and responsibilities while participating in the 
trial as well as possible disadvantages of being treated with the trial products.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 109 of 125
The investigator must ensure the subject ample time to come to a decision whether or not to 
participate in the trial.
A voluntary, signed and personally dated informed consent must be obtained from the subject 
before any trial-related activity.
The responsibility for seeking informed consent must remain with the investigator, but the 
investigator may delegate the task to a medically qualified person, in accordance with local 
requirements. The written informed consent must be signed and personally dated by the person who
seeks the informed consent before any trial-related activity.
If information becomes available that may be relevant to the subject’s willingness to continue 
participating in the trial, the investigator must inform the subject in a timely manner and a revised 
written subject information must be provided and a new informed consent must be obtained.
In order to avoid missing data, the subjects will be informed about the importance of completing the 
trial also if the subjects discontinue from trial product.
18.3 Data handling
If the subject withdraws from the trial or is lost to follow-up, then the subject’s data will be handled 
as follows:
!Data already collected and any data collected at the end of trial visit including follow-up visit 
will be retained by Novo Nordisk, entered into the database and used for the clinical trial report. 
!Safety events will be reported to Novo Nordisk and regulatory authorities according to 
local/national requirements.
If data is used, it will always be in accordance with local regulations and IRBs/IECs.
18.4 Information to subjects during trial
All written information to subjects must be sent to IRB/IEC for approval/favourable opinion and to 
regulatory authorities for approval or notification according to local regulations.
18.5 Premature termination of the trial and/or trial site
Novo Nordisk, the IRBs/IECs or a regulatory authority may decide to stop the trial, part of the trial 
or a trial site at any time, but agreement on procedures to be followed must be obtained.
If the trial is suspended or prematurely terminated, the investigator must inform the subjects 
promptly and ensure appropriate therapy and follow-up. The investigator and/or Novo Nordisk must 
also promptly inform the regulatory authorities and IRBs/IECs and provide a detailed written 
explanation. CONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 110 of 125
If, after the termination of the trial, the benefit-risk analysis changes, the new evaluation must be 
provided to the IRBs/IECs in case it has an impact on the planned follow-up of subjects who have 
participated in the trial. If it has an impact, the actions needed to inform and protect the subjects 
should be described.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 111 of 125
19 Protocol compliance
19.1 Protocol deviations
Deviations from the protocol should be avoided.
If deviations do occur, the investigator must inform the monitor and the implications of the 
deviation must be reviewed and discussed.
Deviations must be documented and explained in a protocol deviation by stating the reason, date, 
and the action(s) taken. Some deviations, for which corrections are not possible, can be 
acknowledged and confirmed via edit checks in the eCRF or via listings from the trial database. 
Documentation on protocol deviations must be kept in the investigator trial master file and sponsor
trial master file.
19.2 Prevention of missing data
The importance of subject retention will be addressed by Novo Nordisk in the training and 
communication with the trial sites. 
The subjects will be carefully informed about the trial procedures before signing informed consent, 
so that they know the implications of participating in the trial.  
Close surveillance of subject retention will be performed throughout the trial by Novo Nordisk with 
focus on reasons for premature discontinuation of trial product or withdrawal of consent to secure 
early mitigations in collaboration with the trial sites. 
The investigator will make every effort to ensure that all assessments are performed and data is 
collected. If missing data does occur the reason will be collected via the protocol deviation process, 
see Section 19.1. Novo Nordisk will monitor protocol deviations on an on-going basis throughout 
the trial followed by appropriate actions (e.g. re-training of site staff).CONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 112 of 125
20 Audits and inspections
Any aspect of the clinical trial may be subject to audits conducted by Novo Nordisk or inspections 
from domestic or foreign regulatory authorities or from IRBs/IECs. Audits and inspections may 
take place during or after the trial. The investigator and the site staff as well as Novo Nordisk staff 
have an obligation to cooperate and assist in audits and inspections. This includes giving auditors 
and inspectors direct access to all source documents and other documents at the trial site relevant to 
the clinical trial. This includes permission to examine, analyse, verify and reproduce any record(s) 
and report(s) that are relevant to the evaluation of the trial.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 113 of 125
21 Critical documents
Before a trial site is allowed to start screening subjects, written notification from Novo Nordisk 
must be received and the following documents must be available to Novo Nordisk:
!Regulatory approval and/or acknowledgement of notification as required 
!Approval/favourable opinion from IRBs/IECs clearly identifying the documents reviewed as 
follows: protocol, any protocol amendments, subject information/informed consent form, any 
other written information to be provided to the subject and subject recruitment materials
!List of IRB/IEC members and/or constitution (or a general assurance number/statement of 
compliance)
!Curricula vitae of investigator and sub-investigator(s) (current, dated and signed - must include 
documented GCP training or a certificate)
!Signed receipt of IB for oral semaglutide and summary of product characteristics (SmPC) or 
similar product information for Jardiance®(empagliflozin)
!Signed and dated Agreement on Protocol
!Signed and dated Agreement on Protocol Amendment, if applicable
!Contract, signed by the investigator and/or appropriate parties on behalf of the investigator’s site 
and Novo Nordisk
!Source document agreement
!Central laboratory certification and normal ranges
!Insurance statement, if applicable
!Financial disclosure form from investigator and sub-investigator(s)
!For US trial sites: verification under disclosures per Code of Federal Regulations (CFR) of 
Financial Conflict of Interest
!For US trial sites: FDA form 1572 must be completed and signed by the investigator at each site
FDA form 1572:
For US sites:
!Intended for US sites
!Conducted under the IND
!All US investigators, as described above, will sign FDA Form 1572
For sites outside the US:
!Intended for participating sites outside of the US
!Not conducted under the IND
!All investigators outside of the US will not sign FDA form 1572
Novo Nordisk will analyse and report data from all sites together if more than one site is involved in 
the trial.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 114 of 125
By signing the protocol agreement, each investigator agrees to comply fully with ICH GCP1, 
applicable regulatory requirements and the Declaration of Helsinki2. 
By signing the protocol agreement, each investigator also agrees to allow Novo Nordisk to make
investigator’s name and information about site name and address publically available if this is 
required by national or international regulations.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 115 of 125
22 Responsibilities
The investigator is accountable for the conduct of the trial at his/her site and must ensure adequate 
supervision of the conduct of the trial at the trial site. If any tasks are delegated, the investigator 
must maintain a log of appropriately qualified persons to whom he/she has delegated specified trial-
related duties. The investigator must ensure that there is adequate and documented training for all 
staff participating in the conduct of the trial. It is the investigator’s responsibility to supervise the 
conduct of the trial and to protect the rights, safety, and well-being of the subjects.
A qualified physician, who is an investigator or a sub-investigator for the trial, must be responsible 
for all trial-related medical decisions.
The investigator will follow instructions from Novo Nordisk when processing data.
The investigator is responsible for filing essential documents (i.e. those documents which 
individually and collectively permit evaluation of the conduct of a trial and the quality of the data
produced) in the investigator trial master file. The documents including the subject identification 
code list must be kept in a secure locked facility, so no unauthorized persons can get access to the 
data. 
The investigator will take all necessary technical and organisational safety measures to prevent 
accidental or wrongful destruction, loss or deterioration of data. The investigator will prevent any 
unauthorised access to data or any other processing of data against applicable law. The investigator 
must be able to provide the necessary information or otherwise demonstrate to Novo Nordisk that 
such technical and organisational safety measures have been taken.
During any period of unavailability, the investigator must delegate responsibility for medical care of 
subjects to a specific qualified physician who will be readily available to subjects during that time.
If the investigator is no longer able to fulfil the role as investigator (e.g. if he/she moves or retires), 
a new investigator will be appointed in consultation with Novo Nordisk. 
The investigator and other site personnel must have sufficient English skills according to their 
assigned task(s).CONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 116 of 125
23 Reports and publications
The information obtained during the conduct of this trial is considered confidential, and may be 
used by or on behalf of Novo Nordisk for regulatory purposes as well as for the general 
development of the trial product. All information supplied by Novo Nordisk in connection with this 
trial shall remain the sole property of Novo Nordisk and is to be considered confidential 
information. 
No confidential information shall be disclosed to others without prior written consent from Novo 
Nordisk. Such information shall not be used except in the performance of this trial. The information 
obtained during this trial may be made available to other physicians who are conducting other 
clinical trials with the trial product, if deemed necessary by Novo Nordisk. Provided that certain 
conditions are fulfilled, Novo Nordisk may grant access to information obtained during this trial to 
researchers who require access for research projects studying the same disease and/or trial product 
studied in this trial.
Novo Nordisk may publish on its clinical trials website a redacted clinical trial report for this trial.
One or two investigators will be appointed by Novo Nordisk to review and sign the clinical trial 
report (signatory investigator) on behalf of all participating investigators. The signatory investigator 
will be appointed based upon the criteria defined by the International Committee of Medical Journal 
Editors for research publications59. 
23.1 Communication of results
Novo Nordisk commits to communicating, and otherwise making available for public disclosure, 
results of trials regardless of outcome. Public disclosure includes publication of a paper in a 
scientific journal, abstract submission with a poster or oral presentation at a scientific meeting, or 
disclosure by other means.
The results of this trial will be subject to public disclosure on external web sites according to 
international and national regulations, as reflected in the Novo Nordisk Code of Conduct for 
Clinical Trial Disclosure4.
Novo Nordisk reserves the right to defer the release of data until specified milestones are reached, for example when the clinical trial report is available. This includes the right not to release the 
results of interim analyses, because the release of such information may influence the results of the 
entire trial.
At the end of the trial, one or more scientific publications may be prepared collaboratively by the 
investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or 
communication for up to 60 days to protect intellectual property.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 117 of 125
In all cases the trial results will be reported in an objective, accurate, balanced and complete 
manner, with a discussion of the strengths and limitations. All authors will be given the relevant 
statistical tables, figures, and reports needed to evaluate the planned publication. In the event of any 
disagreement on the content of any publication, both the investigators’ and Novo Nordisk opinions 
will be fairly and sufficiently represented in the publication.
Where required by the journal, the investigator from each trial site will be named in an 
acknowledgement or in the supplementary material, as specified by the journal. 
Novo Nordisk maintains the right to be informed of plans by any investigator to publish and to 
review any scientific paper, presentation, communication or other information concerning the 
investigation described in this protocol. Any such communication must be submitted in writing to 
Novo Nordisk before submission for comments. Comments will be given within four weeks from 
receipt of the planned communication. 
23.1.1 Authorship
Authorship of publications should be in accordance with the Uniform Requirements of the 
International Committee of Medical Journal Editors59(sometimes referred to as the Vancouver 
Criteria). Novo Nordisk will appoint investigator(s) to prepare publications in collaboration with Novo Nordisk.
23.1.2 Site-specific publication(s) by investigator(s)
For a multi-centre clinical trial, analyses based on single-site data usually have significant statistical 
limitations and frequently do not provide meaningful information for healthcare professionals or 
subjects, and therefore may not be supported by Novo Nordisk. It is a Novo Nordisk policy that 
such individual reports do not precede the primary manuscript and should always reference the 
primary manuscript of the trial.
Novo Nordisk reserves the right to prior review of such publications. Further to allow for the 
primary manuscript to be published as the first, Novo Nordisk asks for deferment of publication of 
individual site results until the primary manuscript is accepted for publication. As Novo Nordisk 
wants to live up to the industry publication policy, submission of a primary publication will take 
place no later than 18 months after trial completion. 
23.2 Investigator access to data and review of results
As owner of the trial database, Novo Nordisk has the discretion to determine who will have access 
to the database. 
Individual investigators will have their own research subjects' data, and will be provided with the 
randomisation code after results are available.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 118 of 125
24 Retention of clinical trial documentation and human biosamples
24.1 Retention of clinical trial documentation
Subject’s medical records must be kept for the maximum period permitted by the hospital, 
institution or private practice.
The investigator must agree to archive the documentation (this includes both electronic and paper-
based records) pertaining to the trial in an archive after completion or discontinuation of the trial if 
not otherwise notified. The investigator should not destroy any documents without prior permission 
from Novo Nordisk. If the investigator cannot archive the documents at the trial site, Novo Nordisk 
can refer the investigator to an independent archive provider that has a system in place to allow only 
the investigator to access the files.
The investigator must be able to access his/her trial documents without involving Novo Nordisk in 
any way. Site-specific CRFs and other subject data (in an electronic readable format or as paper 
copies or prints) will be provided to the investigator before access is revoked to the systems and/or 
electronic devices supplied by Novo Nordisk. These data must be retained by the trial site. If the 
provided data (e.g. the CD-ROM) is not readable during the entire storage period, the investigator 
can request a new copy. A copy of all data will be stored by Novo Nordisk.
Novo Nordisk will maintain Novo Nordisk documentation pertaining to the trial for at least 20 years 
after discontinuation of the marketing authorisation, termination of the trial or cancellation of the 
research project, whichever is longest.
The files from the trial site/institution must be retained for 15 years after end of trial as defined in 
Section 7, or longer if required by local regulations or Novo Nordisk. In any case trial files cannot 
be destroyed until the trial site/institution is notified by Novo Nordisk. The deletion process must ensure confidentiality of data and must be done in accordance with local regulatory requirements.
24.2 Retention of human biosamples
Antibody samples may be retained for later analysis for further characterisation of antibody 
responses towards drug if required by health authorities or for safety reasons.
The samples will be stored at a central bio-repository after end of trial and until marketing 
authorisation approval or until the research project terminates, but no longer than 15 years from end 
of trial after which they will be destroyed.
The subject’s identity will remain confidential and the antibody samples will be identified
only by subject number, visit number and trial identification number. No direct identification of the 
subject will be stored together with the samples. CONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 119 of 125
Only Novo Nordisk staff and bio-repository personnel will have access to the stored antibody 
samples. 
Subjects can contact the investigator if they wish to be informed about results derived from stored 
antibody samples obtained from their own body.
For Brazil only: Biological samples from Brazil will be destroyed at the end of the trial.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 120 of 125
25 Institutional Review Boards/Independent Ethics Committees and 
regulatory authorities
IRB/IEC:
Written approval or favourable opinion must be obtained from IRB/IEC prior to commencement of 
the trial.
During the trial, the investigator or Novo Nordisk, as applicable, must promptly report the 
following to the IRB/IEC, in accordance with local requirements: updates to IB, unexpected SAEs 
where a causal relationship cannot be ruled out, protocol amendments according to local 
requirements, deviations to the protocol implemented to eliminate immediate hazards to the 
subjects, new information that may affect adversely the safety of the subjects or the conduct of the 
trial (including new benefit-risk analysis in case it will have an impact on the planned follow-up of 
the subjects), annually written summaries of the trial status, and other documents as required by the 
local IRB/IEC.
The investigator must ensure submission of the CTR synopsis to the IRB/IEC.
Protocol amendments must not be implemented before approval or favourable opinion according to 
local regulations, unless necessary to eliminate immediate hazards to the subjects.
The investigator must maintain an accurate and complete record of all submissions made to the 
IRB/IEC. The records must be filed in the investigator trial master file and copies must be sent to 
Novo Nordisk.
Regulatory Authorities:
Regulatory authorities will receive the clinical trial application, protocol amendments, reports on 
SAEs, and the clinical trial report according to national requirements.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 121 of 125
26 Indemnity statement
Novo Nordisk carries product liability for its products, and liability as assumed under the special 
laws, acts and/or guidelines for conducting clinical trials in any country, unless others have shown 
negligence.
Novo Nordisk assumes no liability in the event of negligence, or any other liability of the sites or 
investigators conducting the trial, or by persons for whom the said site or investigator are 
responsible.
Novo Nordisk accepts liability in accordance with:
For Poland only: Novo Nordisk carries liability for the trial exclusively in the scope defined by the 
applicable laws and in particular by the Civil Code and the Pharmaceutical Law dated 6 September 
2001 (uniform version Journal of Laws of 2008 No. 45 item 271 with amendments). In order to 
support potential claims for liability attributable to the trial, Novo Nordisk and the investigators 
are covered by the insurance policy issued according to applicable Polish law.
For Russia only: Federal law of 12 April 2010 No. 61-FZ ‘On Medicinal Drugs’ Circulation.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 122 of 125
27 References
1. International Conference on Harmonisation. ICH Harmonised Tripartite Guideline. 
Guideline for Good Clinical Practice E6(R1), Step 4. 10 June 1996.
2. World Medical Association. Declaration of Helsinki. Ethical Principles for Medical 
Research Involving Human Subjects. Last amended by the 64th WMA General Assembly, Fortaleza, Brazil. October 2013.
3. DeFronzo RA. Pathogenesis of type 2 diabetes mellitus. Med Clin North Am. 
2004;88(4):787-835, ix.
4. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional 
treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):837-53.
5. Chuang LM, Tsai ST, Huang BY, Tai TY, Diabcare-Asia Study G. The status of diabetes 
control in Asia--a cross-sectional survey of 24 317 patients with diabetes mellitus in 1998. Diabet Med. 2002;19(12):978-85.
6. Ford ES, Li C, Little RR, Mokdad AH. Trends in A1C concentrations among U.S. adults 
with diagnosed diabetes from 1999 to 2004. Diabetes Care. 2008;31(1):102-4.
7. Holst JJ, Vilsboll T, Deacon CF. The incretin system and its role in type 2 diabetes mellitus. 
Mol Cell Endocrinol. 2009;297(1-2):127-36.
8. Kieffer TJ, Habener JF. The glucagon-like peptides. Endocr Rev. 1999;20(6):876-913.9. Bagger JI, Knop FK, Lund A, Vestergaard H, Holst JJ, Vilsboll T. Impaired regulation of 
the incretin effect in patients with type 2 diabetes. J Clin Endocrinol Metab. 2011;96(3):737-45.
10. Nauck M, Stockmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-
insulin-dependent) diabetes. Diabetologia. 1986;29(1):46-52.
11. Nauck MA, Vardarli I, Deacon CF, Holst JJ, Meier JJ. Secretion of glucagon-like peptide-1 
(GLP-1) in type 2 diabetes: what is up, what is down? Diabetologia. 2011;54:10-8.
12. Perley MJ, Kipnis DM. Plasma Insulin Responses to Oral and Intravenous Glucose - Studies 
in Normal and Diabetic Subjects. Journal of Clinical Investigation. 1967;46(12):1954-&.
13. Hojberg PV, Vilsboll T, Rabol R, Knop FK, Bache M, Krarup T, et al. Four weeks of near-
normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes. Diabetologia. 2009;52(2):199-207.
14. Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. 
Nat Rev Endocrinol. 2012;8(12):728-42.
15. Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 promotes satiety and 
suppresses energy intake in humans. J Clin Invest. 1998;101(3):515-20.
16. Nauck MA, Niedereichholz U, Ettler R, Holst JJ, Orskov C, Ritzel R, et al. Glucagon-like 
peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol. 1997;273(5 Pt 1):E981-8.
17. Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W. Normalization of 
fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia. 1993;36(8):741-4.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 123 of 125
18. Nauck MA. Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and 
clinical implications. Am J Med. 2011;124(1 Suppl):S3-18.
19. Toft-Nielsen MB, Damholt MB, Madsbad S, Hilsted LM, Hughes TE, Michelsen BK, et al. 
Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab. 2001;86(8):3717-23.
20. Buse JB, Nauck M, Forst T, Sheu WH, Shenouda SK, Heilmann CR, et al. Exenatide once 
weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet. 2013;381(9861):117-24.
21. European Medicines Agency. ICH Topic M 3 (R2): Non-Clinical Safety Studies for the 
Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals, Step 3. July 2008.
22. Waser B, Blank A, Karamitopoulou E, Perren A, Reubi JC. Glucagon-like-peptide-1 
receptor expression in normal and diseased human thyroid and pancreas. Mod Pathol. 2015;28(3):391-402.
23. Novo Nordisk A/S. Investigators Brochure for s.c. Semaglutide (NN9535), Edition 10 or 
any updates hereof. 2015.
24. Novo Nordisk A/S. Investigators Brochure for oral Semaglutide (NN9924), Edition 6 or any 
updates hereof. 2015.
25. Jardiance - Summary of Product Characteristics. 2015.26. Jardiance - US Prescribing Information. 2015.27. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. 
Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35(6):1364-79.
28. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. 
Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2015;58(3):429-42.
29. Novo Nordisk Code of Conduct for Clinical Trial Disclosure http:/novonordisk-
trial.com/website/content/how-we-disclose-trial-information.aspx. 1/11/2015 2015.
30. De Angelis C, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R, et al. Clinical trial 
registration: a statement from the International Committee of Medical Journal Editors. N 
Engl J Med. 2004;351(12):1250-1.
31. U.S. Department of Health and Human Services, Food and Drug Administration. Food and 
Drug Administration Amendments Act of 2007. 27 September 2007.
32. The European Parliament and the Council of the European Council. Directive 2001/20/EC 
of the European Parliament and of the Councill of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use, article 11. Official Journal of the European Communities. 1 May 2001.
33. The European Parliament and the Council of the European Council. Regulation (EC) No 
726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for CONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 124 of 125
human and veterinary use and establishing a European Medicines Agency, article 57. 
Official Journal of the European Communities. 2004.
34. Ware JE, Jr., Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. 
Conceptual framework and item selection. Med Care. 1992;30(6):473-83.
35. Ware JE, Kosinski M, Dewey JE. How to Score Version Two of the SF-36 Health Survey. 
Edition 3 ed: Lincoln RI: QualityMetric, Incorporated. 2000.
36. Turner-Bowker DM, Bartley PJ, Ware JE. SF-36® Health Survey & "SF" Bibliography. 
Lincoln, RI: QualityMetric Incorporated; 2002 Third Edition (1988-2000). 2002.
37. Hill AJ. The psychology of food craving. Proc Nutr Soc. 2007;66(2):277-85.38. Hill AJ, Heaton-Brown L. The experience of food craving: a prospective investigation in 
healthy women. J Psychosom Res. 1994;38(8):801-14.
39. Hill AJ, Weaver CF, Blundell JE. Food craving, dietary restraint and mood. Appetite. 
1991;17(3):187-97.
40. Hill AJ, Rogers PJ, Blundell JE. Techniques for the experimental measurement of human 
eating behaviour and food intake: a practical guide. Int J Obes Relat Metab Disord. 1995;19(6):361-75.
41. National Kidney F. KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 
Update. Am J Kidney Dis. 2012;60(5):850-86.
42. Seaquist ER, Anderson J, Childs B, Cryer P, Dagogo-Jack S, Fish L, et al. Hypoglycemia 
and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care. 2013;36(5):1384-95.
43. McAulay V, Deary IJ, Frier BM. Symptoms of hypoglycaemia in people with diabetes. 
Diabet Med. 2001;18(9):690-705.
44. U.S. Department of Health and Human Services, Food and Drug Administration. Guidance 
for Industry. Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. December 2009.
45. Stull DE, Leidy NK, Parasuraman B, Chassany O. Optimal recall periods for patient-
reported outcomes: challenges and potential solutions. Curr Med Res Opin. 2009;25(4):929-42.
46. Commission E. The Rules Governing Medicinal Products in the European Union, Volume 4, 
Annex 13, Investigational Medicinal Products. Brussels, February 2010.
47. Hicks KA, Hung HMJ, Mahaffey KW, Mehran R, Nissen SE, Strockbridge NL, et al. 
Standardized Definitions for Cardiovascular and Stroke End Point Events in Clinical Trials (Draft). 20 Aug 2014.
48. KDIGO. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney international 
supplements. 2012;2(1):1-138.
49. European Medicines Agency. Assessment report for Jardiance (INN name: empagliflozin). 
EMA/CHMP/137741/2014. 20 March 2014.
50. Bretz F, Posch M, Glimm E, Klinglmueller F, Maurer W, Rohmeyer K. Graphical 
approaches for multiple comparison procedures using weighted Bonferroni, Simes, or parametric tests. Biometrical Journal. 2011;53(6):894-913.
51. Rohmeyer K, Klinglmueller F. gMCP: Graph Based Multiple Test Procedures. R package 
version 0.8-8. 3 Oct 2014.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 125 of 125
52. Little RJA, Rubin DB. Statistical analysis with missing data: New York: John Wiley & 
Sons. 1987.
53. Koch GG. Comments on 'Current issues in non-inferiority trials' by Thomas R. Fleming, 
Statistics in Medicine, DOI: 10.1002/sim.2855. Stat Med. 2008;27(3):333-42.
54. Committee for Medicinal Products for Human Use (CHMP). Guideline on Missing Data in 
Confirmatory Clinical Trials. EMA/CPMP/EWP/1776/99 Rev. 1. 2 Jul 2010.
55. National Academy of Sciences (NAS). The Prevention and Treatment of Missing Data in 
Clinical Trials. Washington D.C.: The National Academies Press. 2010.
56. Schwartz NS, Clutter WE, Shah SD, Cryer PE. Glycemic thresholds for activation of 
glucose counterregulatory systems are higher than the threshold for symptoms. J Clin Invest. 1987;79(3):777-81.
57. Standards of medical care in diabetes--2015: summary of revisions. Diabetes Care. 2015;38 
Suppl:S4.
58. U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA revises labels 
of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. 07-Jan-2016.
59. International Committee of Medical Journal Editors. Recommendations for the Conduct, 
Reporting, Editing, and Publication of Scholarly Work in Medical Journals. 12/16/2014 
2014.CONFIDENTIAL
Protocol - Appendix A
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 1 of 6
Appendix A
Monitoring of Calcitonin
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
partiesCONFIDENTIAL
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.
Protocol - Appendix A
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 2 of 6
1 Background
Treatment with GLP-1 receptor agonists has shown to be associated with thyroid C-cell changes in 
rodents but not in non-human primates. The human relevance of this finding is unknown. However, 
based on the findings in rodents, monitoring of serum calcitonin (a sensitive biomarker for C-cell 
activation) is currently being performed in clinical trials with semaglutide.
While there is general agreement on the clinical interpretation of substantially elevated calcitonin 
levels (greater than 100 ng/L) as likely indicative of C-cell neoplasia, the interpretation of values 
between upper normal range (5.0 and 8.4 ng/L for women and men, respectively) and 100 ng/L is 
less clear with regards to indication of disease.
There are several known confounding factors affecting calcitonin levels, e.g.:
!renal dysfunction
!smoking
!autoimmune thyroiditis
!several drug classes (e.g. proton pump inhibitors, beta-blockers, H 2-blockers and 
glucocorticoids)
Physiology of C-cell activation in various clinical conditions and in different patient populations 
(i.e. with various co-morbidities) is poorly understood. There may be various clinical conditions not 
identified so far which mildly or moderately affect calcitonin secretion by C-cells.CONFIDENTIAL
Protocol - Appendix A
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 3 of 6
2 Calcitonin monitoring
A blood sample will be drawn at pre-specified trial visits for measurement of calcitonin.
In case a subject has a calcitonin value ≥ 10 ng/L the algorithm outlined in Figure 1 and described 
below should be followed. The algorithm applies for all calcitonin values in the trial.
Calcitonin < 10ng/L
Calcitonin  ≥ 10 ng/L and 
< 50 ng/L
Calcitonin  ≥ 50 ng/L and 
< 100 ng/L
Calcitonin  ≥ 100 ng/LEvaluation of 
calcitonin results
Calcitonin  ≥ 10 ng/L and 
last measurement in the 
trialNo action
●Investigate potential confounding 
factors
●Continue sampling of calcitonin 
according to protocol
●Refer to thyroid specialist
●Discontinue trial product
●Refer to thyroid specialist
●Refer to thyroid specialist
Figure 1 Flow of calcitonin monitoring
2.1 Calcitonin ≥ 100 ng/L  
Action: The subject must immediately be referred to a thyroid specialist for further evaluation and 
the trial product must be discontinued (see protocol Section 6.5premature discontinuation of trial CONFIDENTIAL
Protocol - Appendix A
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 4 of 6
product). The subject should remain in the trial, however, all medications suspected to relate to this 
condition must be discontinued until diagnosis has been established.
Background: These values were found in 9 (0.15%) of a population of 5817 patients with thyroid 
nodular disease1.All of these patients were diagnosed with MTC resulting in a positive predictive 
value of 100 %.
Diagnostic evaluation should include:
!thyroid ultrasound examination
!fine needle aspiration of any nodules > 1 cm 
!potentially surgery with neck dissection
In case a subject is diagnosed with MTC, it is common clinical practice to explore the family 
history of MTC or MEN2 and perform a genetic test for RET proto-oncogene mutation.
2.2 Calcitonin ≥ 50 and < 100 ng/L
Action: The subject should be referred to a thyroid specialist for further evaluation. The subject 
should remain in the trial and continuation on trial product should be based on the evaluation done 
by the thyroid specialist. 
Background: These values were found in 8 (0.14%) of the population of 5817 patients with thyroid 
nodular disease1. Two of these subjects were diagnosed with MTC and two were diagnosed with 
C-cell hyperplasia, resulting in a positive predictive value of a C-cell anomaly of 50%.
Diagnostic evaluation should include: 
!thyroid ultrasound examination 
!if available and there are no contraindication, a pentagastrin stimulation test should be done. For 
subjects with positive pentagastrin stimulation test, surgery should be considered.
!if pentagastrin stimulation test is not available, thyroid ultrasound and fine needle aspiration 
biopsy may add important clinical information about the need for surgery.
2.3 Calcitonin ≥ 10 and < 50 ng/L
Action: The subject can continue in the trial on trial product. Continue sampling of calcitonin 
according to the protocol.
If the value is from the last sample taken in the trial, the subject should be referred to a thyroid 
specialist for further evaluation.CONFIDENTIAL
Protocol - Appendix A
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 5 of 6
Background: Calcitonin values from 20-50 ng/L were found in up to 1% of subjects of the 
population of 5817 patients with thyroid nodular disease1. The predictive value of a C-cell anomaly 
for this calcitonin level was 8.3%. However, the likelihood of having a medullary carcinoma >1 cm with calcitonin in this range is extremely low.
For calcitonin values between 10-20 ng/L Costante et al
1identified 216 (3.7%) patients. One patient 
out of the 216 had a subsequent basal (unstimulated) calcitonin of 33 ng/L, and had C-cell 
hyperplasia at surgery. Two other studies used a cut-off of calcitonin > 10 ng/L to screen for C-cell 
disease, but they do not provide sufficient information on patients with basal calcitonin > 10 and <
20 ng/L to allow conclusions2,3.CONFIDENTIAL
Protocol - Appendix A
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 6 of 6
3 References
1 Costante G, Meringolo D, Durante C, Bianchi D, Nocera M, Tumino S et al. Predictive value of serum calcitonin 
levels for preoperative diagnosis of medullary thyroid carcinoma in a cohort of 5817 consecutive patients with thyroid nodules. J Clin Endocrinol Metab 2007; 92(2):450-455.
2 Scheuba C, Kaserer K, moritz A, drosten R. Sporadic hypercalcitoninemia: clinica and therapeutic consequences. 
Endocrine Related Cancer 2009; 16(1):243-253.
3 Verga U, Ferrero S, Vicentini L, Brambilla T, Cirello V, Muzza M et al. Histopathological and molecular studies in 
patients with goiter and hypercalcitoninemia: reactive or neoplastic C-cell hyperplasia? Endocr Relat Cancer 2007; 
14(2):393-403.CONFIDENTIAL
Protocol - Appendix B
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 1 of 9
Appendix B
Adverse events requiring additional data collection
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
partiesCONFIDENTIAL
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.
Protocol - Appendix B
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 2 of 9
Adverse events requiring additional data collection 
For the following AEs additional data collection is required and specific event forms must be 
completed in the eCRF in addition to the AE form:
!Acute coronary syndrome (myocardial infarction or hospitalisation for unstable angina)
!Cerebrovascular event (stroke or transient ischaemic attack [TIA])
!Heart failure
!Pancreatitis
!Neoplasm (excluding thyroid neoplasm)
!Thyroid disease (including thyroid neoplasm)
!Renal event
!Hypersensitivity reaction
!Acute gallstone disease
!Medication error (concerning trial products):
oAdministration of wrong drug. 
oNote: Use of wrong DUN is not considered a medication error unless it results in 
administration of wrong drug.
oWrong route of administration.
oAdministration of an overdose with the intention to cause harm (e.g. suicide attempt), 
misuse or abuse of trial product.
oAccidental administration of a higher dose than intended. A higher dose is a dose of at least 
one tablet more than the intended dose; however the administered dose must deviate from 
the intended dose to an extent where clinical consequences for the trial subject were likely to happen as judged by the investigator, although they did not necessarily occur.
!Lactic acidosis
!Creatine kinase (CK) > 10x UNL
!Hepatic event:
oALT or AST > 5x UNL and total bilirubin ≤ 2x UNL
oALT or AST > 3x UNL and total bilirubin > 2x UNL*
oHepatic event leading to trial product discontinuation 
*Please note that in case of a hepatic event defined as aminotransferase (ALT) or aspartate 
aminotransferase (AST) >3 x UNL and total bilirubin >2 x UNL, where no alternative aetiology 
exists (Hy's law), this must be reported as an SAE using the important medical event criterion if no 
other seriousness criteria are applicable.
In case any of these events fulfil the criteria for an SAE, please report accordingly, see Section 
12.1.2 .CONFIDENTIAL
Protocol - Appendix B
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 3 of 9
Some of these events will undergo event adjudication by the Event Adjudication Committee (EAC), 
see protocol Section 12.7.2 and Table 12-1 .
Acute coronary syndrome
If an event of acute coronary syndrome (ranging from unstable angina pectoris to myocardial 
infarction) is observed during the trial, the following additional information must be reported if 
available: 
!Duration of symptoms
!Changes in ECG
!Collection of cardiac biomarkers
!Cardiac imaging
!Cardiac stress testing
!Angiography
!Use of thrombolytic drugs
!Revascularisation procedures 
Cerebrovascular event
If a cerebrovascular event (e.g. TIA, stroke) is observed during the trial, the following additional 
information must be reported if available: 
!Type of event (e.g. TIA, Stroke)
!Contributing condition
!Neurologic signs and symptoms
!History of neurologic disease
!Imaging supporting the condition
!Treatment given for the condition
Heart failure
If an event of heart failure is observed during the trial, the following additional information must be 
reported if available: 
!Signs and symptoms of heart failure
!NYHA Class
!Supportive imaging
!Supportive laboratory measurements
!Initiation or intensification of treatment for this conditionCONFIDENTIAL
Protocol - Appendix B
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 4 of 9
Pancreatitis
For all confirmed events of pancreatitis the following additional information must be reported if 
available:
!Signs and symptoms of pancreatitis
!Specific laboratory test supporting a diagnosis of pancreatitis:
!Imaging performed and consistency with pancreatic disease
!Treatment for and complications of the event
!Relevant risk factors for pancreatic disease
!Family history of pancreatic disease
Assessments in case of suspicion of acute pancreatitis
Most patients with acute pancreatitis experience severe abdominal pain that is located generally in 
the epigastrium and radiates to the back. The onset of the pain may be swift reaching maximum 
intensity within 30 min, it is frequently unbearable and characteristically persists for more than 
24 hours without relief1.The pain is often associated with nausea and vomiting. Physical 
examination usually reveals severe upper abdominal tenderness at times associated with guarding. 
In general, both amylase and lipase are elevated during the course of acute pancreatitis. The serum 
lipase may remain elevated slightly longer than amylase. The level of the serum amylase and/or 
lipase does not correlate with the severity of acute pancreatitis1. In general, serum lipase is thought 
to be more sensitive and specific than serum amylase in the diagnosis of acute pancreatitis. 
In case of suspicion of acute pancreatitis, the trial product should promptly be interrupted (no 
treatment discontinuation call should be made in IWRS before diagnosis of acute pancreatitis is 
confirmed). Appropriate additional examinations must be performed, including local measurement 
of amylase and lipase. 
The diagnosis of acute pancreatitis requires two of the following three features2: 
!abdominal pain consistent with acute pancreatitis (acute onset of a persistent, severe, epigastric
pain often radiating to the back)
!serum lipase activity (and/or amylase activity) at least three times greater than the upper limit of 
normal
!characteristic findings of acute pancreatitis on imaging.
If acute pancreatitis is ruled out, trial product should be re-initiated.
If acute pancreatitis is confirmed, appropriate treatment and careful monitoring of the subject 
should be initiated. The subject must be discontinued from trial product (treatment discontinuation 
call), but should remain in the trial (see protocol Section 6.5 and8.1.5 ).CONFIDENTIAL
Protocol - Appendix B
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 5 of 9
Neoplasm
All events of neoplasms (excluding thyroid neoplasms, which will be reported under thyroid 
disease) must be reported during the trial and the following additional information must be reported 
if available:
!Type of neoplasm
!Symptoms leading to identification of event
!Diagnostic imaging
!Pathological examination results
!Treatment for the event
!Participation in screening programs
!Risk factors associated to the event
Thyroid disease
If an event of thyroid disease, including any thyroid neoplasms, is observed during the trial, the 
following additional information must be reported if available:
!History of thyroid disease
!Signs and symptoms leading to investigations of thyroid disease
!Specific laboratory tests describing thyroid function
!Diagnostic imaging performed and any prior imaging supporting the disease history 
!Pathologic examinations
!Treatment given for the condition
!Risk factors identified
!Family history of thyroid disease
Renal event 
If a renal event is observed during the trial, the following additional information must be reported if 
available:
!Signs and symptoms of renal failure
!Specific laboratory tests supporting the diagnosis 
!Imaging performed supporting the diagnosis
!Kidney biopsy results
!Risk or confounding factors identified including exposure to nephrotoxic agentsCONFIDENTIAL
Protocol - Appendix B
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 6 of 9
Hypersensitivity reaction
All events of hypersensitivity reactions must be reported and the following additional information
must be reported if available:
!Signs and symptoms associated to the event
!Time of appearance after administration of trial drug
!Relevant immunological tests performed
!Treatment given for the reaction
!Previous history of similar reaction
!Risk or confounding factors identified
Assessments in case of suspicion of hypersensitivity reaction
In case of suspicion of a severe immediate systemic hypersensitivity reaction3to the trial product, 
the subject must be discontinued from trial product but should remain in the trial (see protocol 
Section 6.5 and 8.1.5 ).
If suspicion of a hypersensitivity reaction occurs, the subjects should be instructed to contact the 
site staff as soon as possible for further guidance.
To assist in the diagnostic evaluation it is recommended to draw a blood sample for measurement of 
tryptase (total and/or mature tryptase, local assessment) within 3 hours of onset of the 
hypersensitivity reaction, and if this is achieved, a tryptase sample should also be drawn at V13A. 
Furthermore, a blood sample for assessment of anti-semaglutide IgE antibodies should be drawn as 
soon as possible after the event and at V13A and sent to central laboratory. Tryptase concentrations, 
if available, should be included in the specific event form when reporting the AE.
In case of suspicion of immune complex disease3, the subject must be discontinued from trial 
product but should remain in the trial (see protocol Section 6.5 and 8.1.5). It is recommended to 
draw a blood sample for local assessment of complement levels (C3 and C4) to assist in the 
diagnostic evaluation. Complement level results should be included in the specific event form when 
reporting the AE.CONFIDENTIAL
Protocol - Appendix B
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 7 of 9
Acute gallstone disease
If an event of acute gallstone disease or clinical suspicion of this is observed during the trial, the 
following additional information must be reported if available: 
!Signs and symptoms of acute gallstone disease
!Specific laboratory tests supporting a diagnosis of gallstone
!Imaging performed and consistency with gallstone disease
!Treatment given for the condition
!Relevant risk factors for acute gallstone disease
!Family history of gallstones
Medication error 
If a medication error is observed during the trial, the following additional information is required 
and must be reported: 
!Trial product(s) involved 
!Classification of medication error
oWrong drug(s) administered
oAdministration of an overdose
!Whether the subject experienced any hypoglycaemic episode and/or AE(s) as a result of the 
medication error 
!Suspected primary reason for the medication error 
For definition of medication error, see protocol Section 12.1.4.
Lactic acidosis
If an event of lactic acidosis is observed during the trial, the following additional information must 
be reported if available:
!Signs and symptoms of lactic acidosis
!Specific laboratory tests describing the event 
!Possible cause(s) of the event
Creatine kinase > 10x UNL
If an event of CK > 10x UNL is observed during the trial, the following additional information must 
be reported if available:
!Signs and symptoms associated to the event 
!Recent physical activity
!Possible cause(s) of the eventCONFIDENTIAL
Protocol - Appendix B
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 8 of 9
Assessments in case of increased levels of creatine kinase
In case of CK > 10x upper limit of normal (UNL), prompt repeat testing (at central laboratory) of 
CK should be done. Repeat testing (at central laboratory) should be done regularly until CK levels 
return to normal or baseline state. Additional clinical information should be gathered to seek the 
possible cause of the observed CK elevation. 
Hepatic event
!ALT or AST > 5x UNL and total bilirubin ≤ 2x UNL
!ALT or AST > 3x UNL and total bilirubin > 2x UNL*
!Hepatic event leading to trial product discontinuation 
If one of the above events is observed during the trial, the following additional information must be 
reported if available:
!Signs and symptoms associated to the event 
!Risk factors
!Relevant laboratory test results 
!Diagnostic imaging performed 
!Possible cause(s) of the event 
Assessments in case of increased levels of aminotransferases
Both events should prompt repeat testing (at central laboratory) including ALT, AST, ALP and total 
bilirubin and discontinuation of trial product should be considered. Thereafter, repeat testing (at 
central laboratory) of ALT, AST, alkaline phosphatase and total bilirubin should be done regularly 
until the abnormalities return to normal or baseline state. Additional clinical information such as related symptoms, risk factors and contributing conditions (e.g. viral hepatitis, autoimmune 
hepatitis, alcoholic hepatitis, hepatobiliary or pancreatic disorders) should be gathered to seek a 
possible cause of the observed laboratory test abnormalities.
*Please note that risk of liver injury defined as ALT or AST > 3x UNL and total bilirubin > 2x 
UNL, where no alternative aetiology exits (Hy’s law), should also be reported as a SAE (important 
medical event, according to section 12.1.2 ).CONFIDENTIAL
Protocol - Appendix B
CONFIDENTIALDate: 14 March 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 2.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 9 of 9
References: 
1. Banks PA, Freeman ML, Practice Parameters Committee of the American College of G. 
Practice guidelines in acute pancreatitis. Am J Gastroenterol. 2006;101(10):2379-400.
2. Banks PA, Bollen TL, Dervenis C, Gooszen HG, Johnson CD, Sarr MG, et al. Classification 
of acute pancreatitis-2012: revision of the Atlanta classification and definitions by international consensus. Gut. 2013;62(1):102-11.
3. Food and Drug Administration. Guidance for Industry: Immunogenicity Assessment for 
Therapeutic Protein Products. August 2015.CONFIDENTIAL
Global and country key Novo Nordisk staff
Attachments I and II (if applicable) to the protocol are located in the Trial Master File.
Content: Global key staff and Country key staffCONFIDENTIALDate: Novo Nordisk
Version:
Status:Oral Semaglutide
Trial ID: NN9924-4223Clinical Trial Report
Appendix 16.1.12FWREHU 2018

)LQDOCONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 15 November 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 1.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 1 of 16
Protocol Amendment
no 1
to Protocol, final version 2.0
dated 14 March 2016
NN9924-4223
Efficacy and Safety of Oral Semaglutide versus Empagliflozin
in Subjects with Type 2 Diabetes Mellitus
Trial phase: 3a
Applicable to all countries
Amendment originator:
, 
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.CONFIDENTIAL
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.
Protocol Amendment
CONFIDENTIALDate: 15 November 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 1.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 2 of 16
Table of Contents   
Page
Table of Contents.............................................................................................................. ................................2
1 Introduction including rationale for the protocol  amendment .............................................................3
1.1 Additional eye examinations and additional data collection on diabetic retinopathy....................3
1.2 Investigator’s responsibility in ensuring evaluation and management of certain risk factors 
and complications .............................................................................................................. ............3
1.3 Clarification of the criteria for completion, w ithdrawal and lost to follow-up..............................4
1.4 Clarification of criteria for premature discontinuation of trial product .........................................4
1.5 Risks and Precauti ons for empag liflozin ..................................................................................... ..4
1.6 Other minor adjustments, clarifications  and correction of typographical errors............................4
1.6.1 Laboratory analysis......................................................................................................41.6.2 Lactate................................................................................................................... .......4
1.6.3 Statistical considerations..............................................................................................5
1.6.4 Adverse events for Adjudication .................................................................................5
2 Changes ....................................................................................................................... ...............................6
2.1 Section 2 Flow chart ........................................................................................................ ..............6
2.2 Section 4.2.2.2 Supportive seconda ry safety endpoints.................................................................7
2.3 Section 6.5  Criteria for premature discontinuation of trial product..............................................7
2.4 Section 6.6 Withdrawal from trial ........................................................................................... ......7
2.5 Section 8.1.4 End-of-treatment (visit 12) and Follow-up (visit 13 )..............................................8
2.6 Section 8.1.5 Premature discontinuation of trial product and follow-up (visits 12A  and 
13A) ........................................................................................................................... ....................8
2.7 8.1.6.1 Lost to follow-up ................................................................................................................9
2.8 Section 8.4.1.2 Adverse events requi ring additional data collection.............................................9
2.9 Section 8.4.2  Physical examination ......................................................................................... ...10
2.10 Section 8.4.4  Eye examination............................................................................................. .......10
2.11 Section 8.4.8 Anti-semaglutide antibodies .................................................................................. 10
2.12 Section 8.6.1 Lactate...................................................................................................... ..............10
2.13 Section 12.1.5 Adverse events requi ring additional data collection ............................................11
2.14 Section 12.2 Reporting of adverse events................................................................................... .11
2.15 Section 12.7.2 Event ad judication committee..............................................................................11
2.16 Section 17.2 Definitio n of analysis sets.................................................................................... ...11
2.17 Section 17.3.1 Primary analysis for the primary estimand ..........................................................11
2.18 Section 17.4.2.1 Efficacy endpoints ........................................................................................ ....12
2.19 Section 17.4.2.2 Safety endpoints.......................................................................................... ......12
2.20 Section 18.1 Benefit-risk assessment of the trial .........................................................................1 3
2.21 Section 27 References...................................................................................................... ............14
2.22 Appendix B, Adverse events re quiring additional data collection...............................................15
2.23 Appendix B, new section.................................................................................................... .........16CONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 15 November 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 1.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 3 of 16
1 Introduction including rationale for the protocol amendment
This protocol amendment introduces:
1. Additional eye examinations and additional data collection on diabetic retinopathy 
2. Investigator’s responsibility in ensuring evaluation and management of certain risk factors and 
complications
3. Clarification of the criteria for completion, withdrawal and lost to follow-up
4. Other minor corrections and clarifications
1.1 Additional eye examinations and additional data collection on diabetic retinopathy 
Updated protocol Sections: 2, 4.2.2.2, 8.4.1.2, 8.4.4, 12.1.5, 17.2, 17.4.2.2, 18.1 and Appendix B.
Transient worsening of diabetic retinopathy is a recognised complication in selected patients with 
diabetes after initiation of intensive antidiabetic treatmentref x1,x2,x3. Risk factors for these events 
include long-standing poor glycaemic control and presence of proliferative retinopathy, and initial 
large improvements in blood glucose may be an additional aggravating factor. In a recently 
completed cardiovascular outcomes trial with s.c. semaglutide, results indicate an increased risk of 
events related to diabetic retinopathy in subjects treated with semaglutide compared to placeboRef x4. 
The majority of the related adverse events were moderate in severity and did not lead to premature 
discontinuation of trial product.  additional eye examinations 
have been implemented in all trials in the PIONEER programme. Also, to further understand this 
safety signal, additional information will be collected and for all diabetic retinopathy events 
reported during the trial. The information will be collected not only from new subjects enrolled by 
the time of this amendment, but also from already enrolled subjects to the extent that the 
information is available. Furthermore, information to the investigators and subjects related to 
diabetic retinopathy has been added to the protocol (see Section 18) and the subject information. 
1.2 Investigator’s responsibility in ensuring evaluation and management of certain risk 
factors and complications
Updated protocol Section: 8.4.2, 8.4.4. and 18.1
, text is added to highlight the investigator’s responsibility in 
relation to further evaluation of potential incidental thyroid nodules discovered at the physical 
examination.
In addition, text is added to highlight the investigator’s responsibility in ensuring evaluation and 
management of cardiovascular risk factors and microvascular complications such as diabetic kidney 
disease and diabetic retinopathy.CONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 15 November 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 1.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 4 of 16
1.3 Clarification of the criteria for completion, withdrawal and lost to follow-up
Updated protocol Sections: 6.6, 8.1.4, 8.1.5 and 8.1.6.1.
The criteria for subject completion, -withdrawal and -lost to follow-up respectively are clarified and 
have been made consistent across sections. Lost to follow-up is considered a subcategory to 
withdrawal from trial. In addition, it is emphasised that as soon as contact to a subject is lost, efforts 
must be made to regain contact and the efforts must continue until the subjects last planned visit. 
Only if contact is not regained at that time point can the subject be considered lost to follow up. 
Because this trial is not an outcome trial the terminology ‘health status’ is replaced with “relevant 
safety information” - the purpose of which is to follow up on any adverse events or pregnancy, and 
not to determine if a subject completes the trial or not.
1.4 Clarification of criteria for premature discontinuation of trial product
Updated protocol Section 6.5
For subjects randomised to emplagliflozin, it has been emphasized that trial product should be 
prematurely discontinued if the eGFR falls persistently < 45 mL/min/1.73 m2 (confirmed by re-test 
at central laboratory), for subjects randomised to empagliflozin. This was only stated in Section 5.3 
previously.
1.5 Risks and Precautions for empagliflozin
Updated protocol Section 18.1.1
Empagliflozin’s label has been updated why additional information has been added to section 
18.1.1 to reflect this update and to guide investigators.
1.6 Other minor adjustments, clarifications and correction of typographical errors
1.6.1 Laboratory analysis
Updated protocol Section: 8.5
The protocol currently specifies that the in vitro neutralising antibody assays will be performed by 
Novo Nordisk, however it may be decided by Novo Nordisk that the laboratory currently 
responsible for antibody binding analysis (Celerion) will perform the assay.
1.6.2 Lactate
Updated protocol Section: 8.6.1.
The protocol has been updated to specify the importance of remaining resting throughout the lactate 
assessments, as this was not obvious from the previous protocol text.CONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 15 November 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 1.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 5 of 16
1.6.3 Statistical considerations
Updated protocol Sections: 17.3.1, 17.4.2.1 and 17.4.2.2.
For the pattern mixture model using multiple imputation, the number of imputations will be 
increased from 100 to 1000 data sets, to ensure a greater precision of the estimates. In addition, an 
error in the number of groups used for imputation is corrected.
1.6.4 Adverse events for Adjudication
Updated protocol Section: 12.7.2 and Appendix B
Table 12-2 has been aligned with Table 12-1 reflecting that unstable angina pectoris (UAP) requires
hospitalisation to qualify for event adjudication.CONFIDENTIAL
Protocol Amendment UTN: U1111-1176-6006 Date: 15 November 2016 Status: Final Novo Nordisk
Trial ID: NN9924-4223 EudraCT No.: 2015-005209-36 Version: 1.0 Page: 6 of 16
2 Changes
In this protocol amendment:
!Any new text is written in italics.
!Any text deleted from the protocol is written using strike through.
2.1 Section 2 Flow chart 
Trial Periods ScreeningaRandomi-
sation TreatmentEnd-of-
treatment 
(EoT)Follow-
upbEoT premature 
discontinuationcFollow-up 
premature 
discontinuationc
Visit (V), Phone (P) V1 V2 P3 V4 V5 V6 V7 V8 V9 V10 V11 V12 V13 V12A V13A
Timing of visit
(Weeks)Up to -2 
weeks0 2 4 8 14 20 26 32 38 45 52 57Day of
discontinuation
of trial
product5 weeks after
discontinuation
of trial product
(Days)±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 +3 +3 +3
SAFETY
Eye examinationfx x x
Footer Description
xfDilated fundoscopy/fundus photography performed within 90 days prior to randomisation is acceptable if results are available fo r
evaluation at V2, unless worsening of visual function since last examination.
Fundus photography or dilated fundoscopy must be performed again:
!at V12 or within 5 weeks thereafter for subjects completing treatment
!at V12A or within 5 weeks thereafter, and again within 5 weeks prior to V12, for subjects who have prematurely discontinued tria l 
product
Protocol Amendment
CONFIDENTIALDate: 15 November 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 1.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 7 of 16
2.2 Section 4.2.2.2 Supportive secondary safety endpoints
Change from baseline to week 26 and 52 in:
!Haematology
!Biochemistry
!Calcitonin
!Pulse
!Systolic blood pressure
!Diastolic blood pressure
!Electrocardiogram (ECG) category
!Physical examination (only week 52)
!Eye examination category (only week 52)
2.3 Section 6.5 Criteria for premature discontinuation of trial product 
All efforts should be made to keep the subject on trial product. However, the subject may be 
prematurely discontinued from trial product at the discretion of the investigator due to a safety 
concern. The subject must be prematurely discontinued from trial product if the following applies:
!Safety concern related to trial product or unacceptable intolerability
!Included in the trial in violation of the inclusion and/or exclusion criteria
!Pregnancy
!Intention of becoming pregnant
!Simultaneous participation in another clinical trial of an approved or non-approved  
investigational medicinal product
!Calcitonin ≥ 100 ng/L
!For subjects randomised to empagliflozin only: If the eGFR falls persistently < 45 mL/min/1.73 
m2(confirmed by re-test at central laboratory) (see Section 5.3)
2.4 Section 6.6 Withdrawal from trial
The subject may withdraw consent at will at any time. The subject’s request to withdraw from the 
trial must always be respected. Only subjects who withdraw consent should be considered as 
withdrawn from trial. A subject who does not complete the trial is also considered withdrawn from 
the trial. Hence, a subject is considered withdrawn if the following applies:
!Subject withdrew consent
!Subject is lost to follow-up (only to be used if there is no contact with the subject by the time of 
the subject’s last scheduled visit, see Sections 8.1.4, 8.1.5, 8.1.6 and 8.1.6.1)
!Other (subject deceased or closure of trial site)CONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 15 November 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 1.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 8 of 16
2.5 Section 8.1.4 End-of-treatment (visit 12) and Follow-up (visit 13 )
At V12 the subject should be reminded about the importance of attending the follow-up visit (V13). 
If the subject, nonetheless, does not attend V13, the site should make efforts to obtain contact with 
the subject within the visit window. 
A trial completer is defined as a subject who attends, or is in contact with the site, at the subject’s 
last scheduled visit. For subjects who complete treatment, the last scheduled visit is V13. (For 
subjects who discontinued trial product, see Section 8.1 .5).
In case the subject cannot be reached (by clinic visit or phone contact) at the scheduled visit 19, the 
site should consult the contacts provided by the subject (e.g. close relatives), relevant physicians, 
medical records and locator agencies (if allowed according to local law) to collect health status. If 
no health status can be collected, the subject should be considered lost to follow up and this should 
be specified in the end-of-trial form.
2.6 Section 8.1.5 Premature discontinuation of trial product and follow-up (visits 12A  
and 13A)
Subjects, who only agree to attend or provide health status at the planned V12, should not be 
considered withdrawn from the trial. In case the subject cannot be reached (by clinic visit or phone 
contact) at the scheduled V12, the site should consult the contacts provided by the subject (e.g. 
close relatives), relevant physicians, medical records and locator agencies (if allowed according to 
local law) to collect health status. If no health status can be collected, the subject should be
considered lost to follow-up and this should be specified in the end-of-trial form.
A subject who prematurely discontinued trial product is still considered a trial completer if the 
subject attends or is in contact with the site, at the subject’s last scheduled visit. For subjects who 
prematurely discontinue trial product, the last scheduled visit is V12 (or V13A if it is scheduled 
after V12). The site should in due time prepare for establishing contact with the subject within the 
visit window of the scheduled V8 and V12 respectively, if the subject has agreed to attend these 
visits.
In summary, subjects should stay in the trial irrespective of lack of adherence to randomised 
treatment, lack of adherence to visit schedule, missing assessments or trial product discontinuation 
for any reason. Only subjects who decline any further contact with the site in relation to the trial 
should be considered as having withdrawn consent from the trial (for withdrawal procedures, see 
Section 8.1.6). CONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 15 November 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 1.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 9 of 16
2.7 8.1.6.1 Lost to follow-up
In case contact to the subject is lost during the trial, the site should immediately undertake efforts to
re-establish contact. If the subject cannot be reached (by clinic visit or phone contact) and the 
subject has consented to it, the site should consult the contacts provided by the subject (e.g. close 
relatives), relevant physicians, medical records and locator agencies (if allowed according to local 
law) in an attempt to regain contact with the subject or to obtain relevant safety information from 
other sources. Efforts to regain contact should continue until the end of the subject’s last scheduled 
visit: V13 for subjects who have completed treatment, whereas for subjects who have discontinued 
trial product prematurely the last visit is V12 (or V13A if it is scheduled after V12). Only if contact 
with the subject is not regained by the end of the visit window of the last scheduled visit window,
can the subject be considered lost to follow-up (see Section 6.6). 
2.8 Section 8.4.1.2 Adverse events requiring additional data collection 
For the following AEs additional data collection is required and specific event forms must be 
completed in the eCRF in addition to the AE form:
!Acute coronary syndrome (myocardial infarction or unstable angina)
!Cerebrovascular event (stroke or transient ischaemic attack)
!Heart failure 
!Pancreatitis
!Neoplasm (excluding thyroid neoplasm)
!Thyroid disease (including thyroid neoplasm)
!Renal event
!Hypersensitivity reaction
!Acute gallstone disease
!Medication error
!Lactic acidosis
!Creatine kinase (CK) > 10x UNL
!Hepatic event defined as:
- ALT or AST > 5x UNL and total bilirubin ≤ 2x UNL
- ALT or AST > 3x UNL and total bilirubin > 2x UNL*
- Hepatic event leading to trial product discontinuation
!Diabetic retinopathy and related complications
*Please note that in case of a hepatic event defined as aminotransferase (ALT) or aspartate 
aminotransferase (AST) >3 x UNL and total bilirubin >2 x UNL, where no alternative aetiology 
exists (Hy's law), this must be reported as an SAE using the important medical event criterion if no 
other seriousness criteria are applicable.CONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 15 November 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 1.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 10 of 16
2.9 Section 8.4.2 Physical examination
A physical examination will be performed by the investigator according to local procedure (see 
Section 2 and 8.1.7). A physical examination must include:
!General appearance
!Head, ears, eyes, nose, throat, neck
!Thyroid gland*
!Respiratory system
!Cardiovascular system
!Gastrointestinal system including mouth
!Musculoskeletal system
!Central and peripheral nervous system
!Skin
!Lymph node palpation
*Please note that the diagnostic evaluation of thyroid nodules should be in accordance with the 
American Thyroid Association Management Guidelines or any updates hereof Ref x5, and adapted to 
local treatment guidelines if applicable
2.10 Section 8.4.4 Eye examination 
Fundus photography or dilated fundoscopy will be performed as per flow chart (see Section 2) by 
the investigator or according to local practice. Fundoscopy requires pharmacological dilation of 
both pupils. Results of the fundus photography or dilated fundoscopy will be interpreted by the 
investigator (see Section 8.1.7).
2.11 Section 8.4.8 Anti-semaglutide antibodies
Furthermore, samples drawn at randomisation may be used for calculations of the neutralising effect 
in the in vitro neutralising antibody assays. The in vitro neutralising assays will be performed by 
Novo Nordisk or the special laboratory responsible for antibody binding analysis .
2.12 Section 8.6.1 Lactate
The subject must be fasting for the assessment and remain fasting until the last sample has been 
taken, that is, at least 40 minutes after dosing. Also, the subject should have rested for at least 30 
minutes in a sitting position prior to sampling, and should remain resting until the last sample has 
been taken.CONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 15 November 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 1.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 11 of 16
2.13 Section 12.1.5 Adverse events requiring additional data collection
Table 12-1 Adverse events requiring completion of specific event forms and/or are subject to 
event adjudication [Note: In this document only the additional event is shown, all other events are 
unchanged]
Event Specific event form Event adjudication
Diabetic retinopathy and related complications Yes No
2.14 Section 12.2 Reporting of adverse events
Novo Nordisk assessment of AE expectedness: 
Novo Nordisk assessment of expectedness is performed according to the following reference 
documents: IB for oral semaglutide (NN9924)24and Jardiance® (empagliflozin) SmPC and 
prescribing information25,26; current version and any updates thereto.
2.15 Section 12.7.2 Event adjudication committee
Table 12-2 Adverse events for adjudication [Note: Only shown is the event with updated event 
description, all other events are unchanged]
Events Description Adjudication outcome
Acute Coronary Syndrome Acute Coronary Syndrome conditions include: 
!ST-elevation acute myocardial infarction 
(STEMI)
!Non-ST elevation acute myocardial infarction 
(NSTEMI)
!Silent MI 
!Unstable angina pectoris (UAP ) requiring 
hospitalisation!Acute myocardial 
infarction (STEMI or 
NSTEMI), silent MI
!Unstable angina pectoris 
requiring hospitalisation
2.16 Section 17.2 Definition of analysis sets
For adjudicated events, ECGs, eye examination category, anti-semaglutide antibodies, and AEs 
including hypoglycaemic episodes, th e observation period ends at the first date of any of the 
follwing:
2.17 Section 17.3.1 Primary analysis for the primary estimand
Missing values for each group will be imputed as follows:
An analysis of covariance (ANCOVA) with region as a categorical fixed effect and baseline HbA 1c
measurement as a covariate will be fitted to observed values of the change from baseline in HbA 1c
at week 26.CONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 15 November 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 1.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 12 of 16
The estimated parameters for location and dispersion will be used to impute 100 1000 values for 
each subject with missing week 26 data based on region and baseline HbA 1c. Thus, 100 1000
complete data sets will be generated including observed and imputed values.
Analysis used for confirming superiority versus empagliflozin at week 26:
For each of the 100 1000 (now complete) imputed data sets, the change in HbA 1cfrom baseline to 
week 26 will be analysed using an ANCOVA with treatment and region as categorical fixed effects, 
and baseline HbA 1cas covariate. The results obtained from analysing the datasets will be combined 
using Rubin’s rule52to draw inference. 
2.18 Section 17.4.2.1 Efficacy endpoints
For evaluation of the primary estimand, the analysis will be performed separately for week 26 and 
week 52. For the analysis at week 52, the imputation of missing data will be further differentiated 
by whether subjects have discontinued trial product or initiated rescue medication prior to week 26 
or ator /after week 26. This will result in imputation of missing data within 8 6groups of subjects 
instead of the 4 groups as described for the week 26 evaluation in Section 17.3.1. If less than 5 
subjects have available data in one of the 8 6groups, the imputation will be made within the 4 
groups specified for the primary evaluation. The frequency of missing data is expected to be slightly 
larger at week 52 compared to week 26. The rate of missing data is expected to decline over time. 
Binary efficacy endpoints
!Multiple imputed data sets (100 1000 ) will be created in which missing values for the 
underlying continuous assessments are imputed by treatment group and treatment 
adherence/rescue status assuming MAR and as described in section 17.3.1 for the primary 
estimand and by treatment group assuming MAR and as described in section 17.3.2 for the 
secondary estimand.
!The binary endpoint will be created for each of the 100 1000 complete data sets
!Each of the created complete data set will be analysed with the logistic model and inference will 
be drawn using Rubin’s rule52.
2.19 Section 17.4.2.2 Safety endpoints
Other safety endpoints
Change from baseline to week 26 and week 52 in:
!Haematology 
!Biochemistry (except for amylase and lipase)
!Calcitonin
!ECG evaluation
!Physical examination (week 52 only) CONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 15 November 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 1.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 13 of 16
!Eye examination category (week 52 only)
2.20 Section 18.1 Benefit-risk assessment of the trial
Other safety considerations
Diabetic retinopathy complications
A transient worsening of diabetic retinopathy is a recognised complication in selected patients with 
diabetes after initiation of intensive antidiabetic treatmentRef x1, x2, x3. Risk factors for these events 
include long-standing poor glycaemic control and presence of proliferative retinopathy, and initial 
large improvements in blood glucose may be an additional aggravating factor. Several studies 
have, however, documented long-term beneficial effects of intensive glycaemic treatment in 
reducing retinopathy progressionRef x6, x7even in intensively treated patients who experienced early 
worseningRef x2. In a cardiovascular outcomes trial with s.c. semaglutide, results indicate an 
increased risk of events related to diabetic retinopathy in subjects treated with semaglutide 
compared to placeboRef x4. As a precaution in this trial, all subjects are required to have a fundus 
photography or dilated fundoscopy performed before enrolment into the trial; moreover, subjects 
with proliferative retinopathy or maculopathy requiring acute treatment will be excluded. As part of 
good diabetes management the investigator is encouraged to ensure adequate monitoring and 
treatment of diabetic retinopathy in subjects enrolled into the trial57.
General precautions 
There are also strict glyacemic rescue criteria in place to ensure acceptable glycaemic control 
during the trial. If rescue medication is required, it should be in accordance with ADA/European
Association for the Study of Diabetes27, 28(excluding GLP-1 RAs, DPP-4 inhibitors, amylin 
analogues and SGLT-2 inhibitors).
It is the responsibility of the investigator to ensure the best possible care of the subject. This 
includes adequate glycaemic control, appropriate risk factor modification such as optimal 
treatment of hypertension, dyslipidaemia and other cardiovascular risk factors, as well as regular 
monitoring and treatment of diabetic kidney disease and diabetic retinopathy57according to the
principles outlined in Diabetes Care 2014 Standards of Medical Care in Diabetes57.
Section 18.1.1.1 Empagliflozin
Subjects should be considered suitable for treatment with empagliflozin and the use of
empagliflozin should be in accordance with the current, approved label25,26. It is important to 
monitor
renal function and for signs and symptoms of volume depletion during therapy. Serum creatinine
will be measured regularly for monitoring of renal function.
The most common adverse reactions reported w ith empagliflozin ar e hypoglycaemia (when used
with sulphonylurea or insulin), genital infections, pruritus (generalised) and increased urination.CONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 15 November 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 1.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 14 of 16
Uncommon adverse reactions are volume depletion and dysuria25. SGLT-2 inhibitors have recently
been associated with a risk of ketoacidosis and urinary tract infections58. Symptoms of ketoacidosis
include nausea, vomiting, abdominal pain, tiredness, general malaise and shortness of breath.
Ketoacidosis associated with the use of SGLT-2 inhibitors can occur even if the blood sugar level is
not elevated. If ketoacidosis is suspected, the SGLT-2 inhibitor should be discontinued and
treatment instituted promptly. Treatment should always be interrupted in patients who are 
hospitalised for major surgical procedures or acute serious medical illnesses .
2.21 Section 27 References 
Reference numbers will change throughout the updated protocol when new references in the 
amendment are inserted.
New references in this amendment are marked with an x, i.e. Ref x1. The following references are 
new references:
1. Ref x1; Dahl-Jørgensen K, Brinchmann-Hansen O, Hanssen KF, Sandvik L, Aagenaes O. Rapid tightening of 
blood glucose control leads to transient deterioration of retinopathy in insulin dependent diabetes mellitus: the 
Oslo study. Br Med J (Clin Res Ed). 1985;290(6471):811-5.
2. Ref x2; The Diabetes Control and Complications Trial Research Group. Early worsening of diabetic 
retinopathy in the Diabetes Control and Complications Trial. Arch Ophthalmol. 1998;116(7):874-86.
3. Ref x3; Varadhan L, Humphreys T, Walker AB, Varughese GI. The impact of improved glycaemic control with 
GLP-1 receptor agonist therapy on diabetic retinopathy. Diabetes Res Clin Pract. 2014;103(3):e37-9.
4. Ref x4; Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al. Semaglutide and 
Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016.
5. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid 
Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid 
Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated 
Thyroid Cancer. Thyroid. 2016;26(1):1-133
6. Ref x5; 53 in PIONEER 8
7.Ref x6; 54 in PIONEER 8
Ref26will be deleted from protocol Section 12.2: Jardiance: US Prescribing Information. 2015.
Reference57in protocol version 2.0 will be updated:
Diabetes Care 2014, Standards of Medical Care in Diabetes.
American Diabetes Association. Standards of medical care in diabetes - 2016.Diabetes Care. 2016;39 (Suppl. 1):S1-S109.CONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 15 November 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 1.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 15 of 16
2.22 Appendix B, Adverse events requiring additional data collection
For the following AEs additional data collection is required and specific event forms must be
completed in the eCRF in addition to the AE form:
!Acute coronary syndrome (myocardial infarction or hospitalisation for unstable angina)
!Cerebrovascular event (stroke or transient ischaemic attack [TIA])
!Heart failure
!Pancreatitis
!Neoplasm (excluding thyroid neoplasm)
!Thyroid disease (including thyroid neoplasm)
!Renal event
!Hypersensitivity reaction
!Acute gallstone disease
!Medication error (concerning trial products):
- Administration of wrong drug.
- Note: Use of wrong DUN is not considered a medication error unless it results in 
administration of wrong drug.
- Wrong route of administration.
- Administration of an overdose with the intention to cause harm (e.g. suicide attempt), 
misuse or abuse of trial product.
- Accidental administration of a higher dose than intended. A higher dose is a dose of at least 
one tablet more than the intended dose; however the administered dose must deviate from 
the intended dose to an extent where clinical consequences for the trial subject were likely to 
happen as judged by the investigator, although they did not necessarily occur.
!Lactic acidosis
!Creatine kinase (CK) > 10x UNL
!Hepatic event:
- ALT or AST > 5x UNL and total bilirubin ≤ 2x UNL
- ALT or AST > 3x UNL and total bilirubin > 2x UNL*
- Hepatic event leading to trial product discontinuation
!Diabetic retinopathy and related complications
*Please note that in case of a hepatic event defined as aminotransferase (ALT) or aspartate
aminotransferase (AST) >3 x UNL and total bilirubin >2 x UNL, where no alternative aetiology
exists (Hy's law), this must be reported as an SAE using the important medical event criterion if no
other seriousness criteria are applicable.CONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 15 November 2016 Novo Nordisk
Trial ID: NN9924-4223 Version: 1.0
UTN: U1111-1176-6006 Status: Final
EudraCT No.: 2015-005209-36 Page: 16 of 16
2.23 Appendix B, new section
Diabetic retinopathy and related complications
If an event of diabetic retinopathy or related complications, is observed during the trial the 
following additional information must be reported, if available:
!Signs and symptoms associated with the event
!Results of the eye examination 
!Treatment for and complications of the event
!Contributing conditionsCONFIDENTIAL